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General Introduction 
For centuries opiates have been the mainstay in the f i e l d of analgesia. 
In addit ion they were widely used as ant i tussives, antidiarrhoeal and as 
psychotropic agents. I t has been the analgetic effectiveness of these drugs 
which has contributed to the i r use in the treatment of pain and in anesthesio-
logie pract ice. 
Marçy studies to elucidate the mechanisms and si tes of action of the 
opioid drugs have been carr ied out, and, especially during the las t ten 
years, knowledge of the basic mechanisms of the i r effectiveness has tremen-
dously increased. Furthermore, the increased understanding of these mech-
anisms has borne f r u i t i n allowing the introduct ion of new and more sophis-
t icated measures in the c l i n i c , including the use of opiates In unconven-
t ional routes namely the i r in jec t ion in to epidural and intrathecal spaces. 
An important landmark was the i den t i f i ca t i on of receptor s i tes which were 
shown to bind radioactive label led opiates and the i r antagonists in a stereo-
select ive fashion (Pert 1973, Simon 1973, Terenius 1973). This raised the 
question of whether a natural l igand would ex is t , as the alkaloids do not 
occur natural ly in the physiological systan of manmals. A morphine-like 
factor was extracted from brain t issue In 1974 (Hughes 1975 1 , Terenius 1975 
1) , and extension of these studi es revealed the two pentapeptides leucine-
enkephalin (leu-enkephalin) and methionine-enkephalin (met-enkephalin), which 
had such morphine-like action (Hughes 1975 2 ) . Various other 'endorphins' 
(endorphin = endogenous morphine) were to be i den t i f i ed , as was the i r d i s t r i -
bution in tissues and the i r organization in anatomically and/or funct ional ly 
d i s t i n c t endorphin subsystems. These, in addit ion to increased knowledge of 
the effectuator mechanisms linked to receptor-ligand in te rac t ion , provided 
the basic elenents of a complex and widely d is t r ibuted new neurotransmitter 
or neuromodulator system. 
The importance of the receptor s i tes i s not only indicated by the Impulse 
which the i r i den t i f i ca t ion gave to subsequent research, but also in the fact 
that the receptor si tes are actually the most accessible elements of the sys-
tem. This was because functional changes in the natural system may be i n s t i -
tuted by the administration of drugs which mimic (endorphlncmimetlcs) or re-
verse (antagonists) the effects of the natural ligands by a speci f ic in te r -
action with these receptor s i tes . 
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The d i f f e r e n t effects which may be observed af ter the administration of 
an opio id, do not only r e f l e c t the interact ion wi th in t h i s basic u n i t of the 
endorphin system, but also the sequence of events which involves the various 
endorphin subsystems, and the funct ional ly related systems. I t was presumed 
that especially the 'higher' neuronal c i r c u i t s mediated the analgetic e f f e c t ­
iveness of the opioid drugs, but reports on the involvement of spinal struc­
tures emerged. The results of experiments involving new techniques, including 
the technique of drug-inject ion i n the v i c i n i t y of spinal structures through 
indwell ing catheters (Yaksh 1976 2 ) , indicated that indeed spinal structures 
are important in the elaboration of a nociceptive signal p r i o r to i t s rostrad 
transmission. Moreover, the nociceptive signal could be modified so as to 
induce "analgesia", by selective drug-induced changes i n the various trans­
m i t t e r and modulator systems at a spinal l e v e l . 
I t was argued that to l i m i t the presence of a drug to a locus involved in 
mediating i t s e f f e c t , would allow the maximum use of the effectiveness and 
minimize other (undesirable) e f f e c t s . As to the spinal neuronal systems, 
analgesia might be achieved without the occurrence of various other e f f e c t s , 
as for example those supraspinally mediated ( l i k e respiratory depression and 
psychomimetic e f f e c t s ) , or those involving structures outside the neuraxis 
( l i k e gastrointest inal e f f e c t s ) . Therefore, when i t was known that no adverse 
effects were to be expected, the conventional c l i n i c a l methods of peridural 
or intrathecal i n j e c t i o n of drugs, were extended to include the i n j e c t i o n of 
opioid drugs for evaluation of the c l i n i c a l use of t h i s supposition. 
During c l i n i c a l t r i a l s on the effectiveness of per idural ly or i n t r a -
thecal ly injected opiates (endorphinomimetics) i t was noticed that not only 
antinociceptive e f f e c t s , but also (mild) cardiovascular ef fects were present. 
As i n analgesia, the endorphinergic mechanisms implicated in cardiovascular 
control thus far had indicated the involvement of 'higher' neuronal c i r c u i t s . 
Interest ingly enough, there exists an intimate functional and anatomical 
relat ionship between various supraspinally-located central nervous system 
centres which are involved both in cardiovascular and sensory homeostasis. 
The data to be presented below would indicate that a s imi lar overlap exists 
at a spinal l e v e l . As to the c l i n i c a l relevance of the endorphin receptors at 
a spinal l e v e l , both i t s involvement in cardiovascular control and i n 
nociceptive signal transmission may overlap. 
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Objective 
The objective of the theoretical considerations, the animal experiments, 
and the c l i n i ca l t r i a l s described in th is thesis is to answer the question: 
Do in t ra thecal ly - or epidural ly-administered opiates, by a sp ina l ly -
mediated effectiveness involving the endorphin receptors, i n s t i t u t e a modi f i -
cat ion of the transmission of nociceptive signals associated with an an t i -
nociceptive ef fect (which i s known by animal experiments and c l i n i ca l t r i a l s 
in patients with chronic pain) to such an extent, that the method provides a 
useful means to effectuate anti nociception in the anesthesiological 
practice? 
To answer th is question, the fol lowing was taken into consideration: 
1 . The organization of the system (the endorphin system), which i s 
presently thought to mediate opiate effectiveness. 
Therefore, the l i t e ra tu re was reviewed and to fur ther characterise 
functional aspects of endorphin mechanisms, my preliminary data on 
endorphinergic mechanisms in shock w i l l be included, as endorphin 
mechanisms in sensory and cardiovascular homeostasis prove to over-
lap. 
2. Various spinal mechanisms involved in nociceptive signal trans-
mission. 
To fur ther characterise these spinal mechanisms in nociceptive signal 
transmission, experiments to assess dose-effect relat ionships of i n t ra -
thecal ly - in jec ted opiates (morphine and nicomorphine), and the naloxone-
reve rs i b i l i t y of the spinally-mediated antinociceptive e f fec t , were 
perfomed. Furthermore, the involvement of an intraspinal muscarinic 
cholinergic system involved in nociceptive signal transmission and the 
importance of th is system to opiate effectiveness was established i n a 
preliminary study. 
During the c l i n i ca l t r i a l s , the 'analget ic ' effectiveness and the 
incidence of 'other ' effects of per idural ly or in t rathecal ly injected 
opiates were assessed for the perioperative period. 'Other' effects may be 
related to ei ther spinally-mediated effects (overlap of functional 
mechanisms, involvement of a l l i ed mechanisms), or non-spinally mediated 
e f fec ts . Therefore, the data on the k inet ics of in t rathecal ly or per idural ly 
injected opiates were evaluated by reviewing the available l i t e r a t u r e , as to 
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allow characterization of either mechanism. 
These factors together were considered to be essential for a critical 
answer to the question raised. 
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SECTION I 
THE ENDORPHIN SYSTEM 
Af ter i den t i f i ca t ion of natural ligands for the receptor s i tes which are 
thought to mediate opiate effects (see: General Int roduct ion), studies were 
performed as to fur ther characterize the organization of these elements, and 
the i r relationships to other parts of the central nervous system. 
The endorphin system is thought to have i t s basic un i ts , which are com-
posed of three elements: the receptor s i t es , the ligands and the ef fectu-
ator. The d is t r ibu t ion of the nerve terminals containing enkephalin-l ike 
immunoreactivity was shown to exhib i t a remarkable paral le l with the d i s t r i -
bution of the opiate receptors (Simantov 1977). Yet, regional differences 1n 
the d is t r ibu t ion of receptors and ligands were apparent (Lindberg 1979), 
which may relate to the existence of neurohumoral subsystems (Chapter I I I ; 
table I-A). Thus, binding of the ligand to i t s receptor s i te may be at a 
close or a distant s i t e . Af ter binding, a sequence of events w i l l resu l t , 
which may ( ind i rec t model) or may not (d i rec t model) involve the ef fectu-
ator. The endorphin system does seem to employ effectuator(s) (Chapter 
I . 3 . ) , and the ins t i tu ted functional change may be said to be related to : 
the s i te of the sequence of events and the involvement of a l l i ed mechanisms 
( fo r example: other transmitter systems). Eventually, an ef fect (the res-
ponse) resul ts . The complexity of the system is indicated by the occurrence 
of: various types of l igand-receptor in teract ions; various ligands and the i r 
prohormones; and, the involvement of various neurophysiological mechanisms 
related to effectuator mechanisms. These aspects w i l l be discussed in 
Chapter I : The elements of endorphin system ( I . 3 . ) . 
In terms of functional aspects, two important modes of interact ions can 
be distinguished: modulation and transmission. Although not conclusive, 
those data relevant for the i den t i f i ca t i on of a modulator or a transmitter 
substance w i l l be discussed. In an e f f o r t to define the difference of 
e i ther , one may arr ive at the question: 'what does an opiate do?' as we do 
introduce these substances in the system to create an ef fect (Chapter I I ) . 
F ina l l y , as was discussed (General Int roduct ion) , the i den t i f i ca t i on of 
dist inguishable effects relates to changed functioning of speci f ic nervous 
system structures. These speci f ic nervous system structures, employing endor-
phin mechanisms, are anatomically ( fo r example: the spinal system) and/or 
funct ional ly ( for example the "pain" modif icat ion system) d i s t i n c t , thus 
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allowing the introduction of the concept: 'subsystem i inapic i m , . 
The effects mediated by the endorphin receptor may prove to be separa­
b l e , i n that : a specif ic receptor (sub)type (or configuration) related to a 
desired e f f e c t is involved (Chapter 1.1.), which allows the introduct ion of 
specif ic ligands to induce such an e f f e c t ; or, a l t e r n a t i v e l y , separable 
effects in t h a t : a functional change is induced In an anatomically d i s t i n c t 
subsystem. As to the f i r s t p o s s i b i l i t y , analgesia has been related to the 
involvement of the so-called u-receptor ((sub)type) of the endorphin system. 
Unfortunately, specif ic μ-agonists induce respiratory depression and c i r c u l a ­
tory disturbance. Possibly, further refinement of subtype agonist, or the 
introduct ion of specif ic effectuator agents, may allow further separation of 
e f f e c t s . For the time being, the administration of a drug Into an 
anatomical ly-dist inct subsystem ( i . e . the spinal system) proves to be the 
most selective means at present (Section I I ) . 
I n recent reviews (Dirksen 1979 ( 1 , 2 ) , Dirksen 1980 1 , Dirksen 1981 1 ) , 
theoret ical aspects of the endorphin system were discussed. For more 
detai led information and additional references, the reader is referred to 
these. 
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CHAPTER I 
The Elements of the Endorphin System 
A. The endorphin receptors 
The hypothesis that opiates must bind to specif ic s i tes i n order to 
exert t h e i r effects has been put f o r t h f o r several decades. These binding 
s i tes have been termed receptors. Unfortunately, many d i f f e r e n t concepts to 
define a receptor have been proposed. Whereas Ehrl ich defined a receptor as: 
" that combining group of the protoplasmic molecules to which a foreign 
group, when introduced, attaches i t s e l f " , i t was more recently proposed that 
the concept of a receptor should include, i n addition to a binding s i t e , a 
transducing factor that allows binding to be translated i n t o physical or 
chemical sequelae that ult imately lead to an observable response (Simon 
1978). In addition to t h i s functional concept of a receptor, the concepts 
'receptor molecule' (the drug-binding component of the receptor) and 
'binding s i t e ' (a par t icu lar s i t e probably sensit ive to conformational 
changes) were introduced to account f o r the time-related events at a 
receptor level (Terem'us 1980). Noticeable differences i n pharmacological 
responses to d i f f e r e n t narcotic analgesics, including varying s u s c e p t i b i l i t y 
t o naloxone antagonism, d i f f e r e n t pharmacological p r o f i l e s , and t h e i r 
i n a b i l i t y to subst i tute for each other in suppression of withdrawal symptoms 
i n addicted chronic spinal dogs (Martin 1976, Gi lbert 1976), led to the 
proposit ion of the existence of three subclasses of opioid receptors 
designated у , к , and о af ter t h e i r prototypic agonists morphine, keto-
cyclazocine and SKF 10,047 (N-allyl-normetazocine). 
Evidence supporting mult ip le receptor s i t e theories has since accumula­
ted (see: Caruso 1980, Portoghese 1980, Squires 1978, Terenius 1978, 
Childers 1979, Knoll 1976, Kerecsen 1981, Lemaire 1978 1 , Lord 1977, Rônal 
1978, Schulz 1979, Schulz 1980, Koster l i tz 1978, Lesl ie 1980, Chang 1979 1) . 
Yet, the proposed heterogeneity may prove to have several possible or igins 
(Smith 1980), including: equi l ibrat ing disposit ions ( for example agonist-
antagonist d is t inct ions (Pasternak 1975, Simon 1975)); overlapping binding 
s i tes that overlap in a common port ion; or mul t ip le binding s i t es , which are 
completely separate and may exist on the same or d i f fe rent molecules. Only 
i f the molecules are d i f f e ren t , then mul t ip le receptors ex is t . For the time 
being, the structure (the molecular composition) of the endorphin 
receptor(s) and the or ig in of the heterogeneity remain to be elucidated. 
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Both proteins and l i p i d s were proven to be essential components of the 
opiate receptor, since both proteases (Pasternak 1974, Hitzeman 1975) and 
phospholipases (Pasternak 1974, Abood 1978, L in 1978) destroyed stereo-
speci f ic binding. I n i t i a l results with sol ubi l i zed membrane fract ions 
capable of stereospecif ical ly binding opiates, and also enriched in 'opiate' 
receptors, indicated that binding properties are s i m i l a r l y l o s t i f the 
enriched f r a c t i o n i s subjected to proteases (Riiegg 1980, Simonds 1980) or 
phospholipases (Bidlack 1980). These data and data which c o n f l i c t with the 
existence of mul t ip le receptor sites (Tepper 1978, H i l l e r 1980, DeLaBaume 
1981, Childers 1978, Waterfield 1976, Quirion 1981, Lee 1980 (1,2)) were 
recently reconciled i n the " l i p i d - p r o t e i n model" of the endorphin receptor 
(see: Smith 1981), as an a l ternat ive, or in addit ion, to the mult ip le confor­
mation model (Bowen 1981, Blume 1977, Chang 1978, Klee 1974, Blume 1980, 
Pfeuffer 1977)(for additional information the reader is referred to recent 
reviews on t h i s topic (Dirksen 1979 (1,2) , Dirksen 1981 1 , Smith 1981). 
As was indicated i n the general in t roduct ion, a functional change in the 
endorphin system may be I n s t i t u t e d by drugs which interact with the receptor 
s i t e s . As regards the m u l t i p l i c i t y of receptors which was indicated by the 
q u a l i t a t i v e l y distinguishable ways by which alkaloids, enkephalins and 
3-endorphin in teract with t h e i r binding s i t e s , pharmacological studies have 
indicated that the μ-receptor configurat ion may be involved i n the neuronal 
projections involved in nociceptive signal transmission (Hö l l t 1975, Yaksh 
1978 (1 ,4) , Székely 1978). However, i n some species mul t ip le conformations 
may prove to be involved (Székely 1978). This may indicate that e i ther a 
speci f ic configuration of the receptor i s confined to a function (Terenius 
1977 1 , Frenk 1978 (1,2)) or may be related to a specif ic transmitter 
involved in signal t ransfer (Kerecsen 1981). S ign i f i cant ly , a pentapeptide 
(LY 127623) has recently been shown to have a low a b i l i t y to produce 
physical dependence and a low capacity to substi tute for morphine in 
dependent mice, whereas i t retained i t s analgetic properties (Frederickson 
1980 2 ) . This indicates that indeed speci f ic agonists allow the (pa r t i a l ) 
separation of e f fec ts . 
Data supporting the concept that at a spinal level mul t ip le receptor 
configurations ex is t , were obtained (Fields 1980), indicat ing that the 
considerations described above may prove to be applicable for the spinal 
system (see: Section I I ) . 
5 
В. The ligands 
Soon af ter the disclosure of the amino acid sequence of leu-enkephalin 
and met-enkephalin (Tyr-Gly-Gly-Phe-Leu or -Met)(Graf 1976 ( 2 , 3 ) , Hughes 
1975 3 ) , i t was apparent that a s imi lar structure was contained i n P-LPH 
(Simantov 1976 2, Chang 1979 2, Teschemacher 1977). The absence of morphine-
l i k e effects of ß-LPH i t s e l f (Cox 1976, L i 1964, Lazarus 1976), the s t ruct -
ural analogy not only to the enkephalins but also to other endorphins ( i . e . 
ß-endorphin, γ-endorphin and α-endorphin), as well as data which showed that 
enzymatic cleavage of t h i s peptide y i e l d many active segments (Rónai 1976, 
Codd 1977, Pezalla 1978) have credited the notion that ß-LPH was the pro-
hormone (Lazarus 1976). 
However, el imination of a major source of ß-LPH, the p i t u i t a ry (Chapter 
I I I ) , did not s ign i f i can t l y change the brain endorphin content (Cheung 1976, 
Kobayashi 1978, Yang 1978). Moreover, incubation of exogenous and endogenous 
ß-LPH or ß-endorphin fa i l ed to cause an increase in the amount of detectable 
met-enkephalin (Clement-Jones 1980 1) . Therefore, local processing of en-
kephalin from a precursor other than pro-opiocort in is more l i k e l y (Hughes 
1978, Yang 1978, DiGui l io 1978). Recently an intermediate of the process 
which leads to the production of met-enkepalin was isolated (Mizuno 1980) 
and th is peptide (ВАМ 12P) is thought to be part of a large single gene 
mult ivalent enkephalin precursor molecule which was shown to y i e l d many 
ident ical active (enkephalin) segments (Rossier 1980 1 , Lewis 1980, Stern 
1981). This pro-met-enkephalin does not explain the presence of leu-
enkephalin, y e t , i t was proposed that a single base mutation (methionine: 
AUG, adenine, u r a c i l , guanine; leucine: CUG, cytosine, u r a c i l , guanine) may 
change the genetic code towards production of leucine instead of methionine 
and t h i s would lead to a dual releasing capacity (Stern 1981). However, pro-
leu-enkephalin is thought to be present as w e l l , and possible candidates f o r 
pro-leu-enkephalin include o-neoendorphin and dynorphin. Both peptides 
contain an N-terminal hexapeptide Tyr-Gly-Gly-Phe-Leu-Arg (Mizuno 1980, 
Kangawa 1980), which exists i n tissues and is thought to be an intermediate 
i n the processing of leu-enkephalin. Futhermore, the d i s t r i b u t i o n of 
dynorphin in the central nervous system has paral le ls to that of the 
enkephalins, i . e . : the extrapyramidal system, the gut, and the spinal cord 
(Tachibana 1982, Gramsch 1982, B o t t i c e l l i 1981). 
The potencies of both a-neoendorphin (Kangawa 1979, Matsuo 1980) and 
dynorphin (Lowney 1979) are high, indicat ing that these peptides may prove 
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to have additional funct ions. Also, the smaller segments, such as BAM 12P 
(Mizuno 1980) and dynorphin 1-8 (Minamino 1980, Tachibana 1982), proved to 
re ta in op io id- l i ke ac t i v i t i es in the guinea pig ileum, and the las t peptide 
i s thought to be present in the hypothalamus (Minamino 1980). The synthetic 
analog dynorphin 1-13 (Goldstein 1979), which proved to have potent actions 
i n guinea pig ileum, did not s ign i f i can t l y change t a i l - f l i c k response 
latencies in mice af ter intracerebroventr icular (ICV) in jec t ion (Herman 
1980, Friedman 1981), but did produce "analgesia" in the f l inch/jump 
response to footshock i n the rat af ter ICV in jec t ion (Pétr ie 1982). Further-
more, dynorphin may s ign i f i can t l y modulate opiate- and ß-endorphin-induced 
analgesia (Friedman 1981). 
In addition to the peptides described above ( f i g . 1-1), which may prove 
to be the main constituents of the endorphin-peptides, other peptides may 
have endorphin-like e f fec ts . Such e f fec ts , which are affected by naloxone, 
included increased response latencies af ter ICV in jec t ion , and were observed 
fo r Kyotorphin (Takagi 1979, Ueda 1980), androsterone sul fate (LaBella 
1978), somatostatin (Rezek 1978), CCK (Zet ler 1979), ACTH (Terenius 1976, 
Gispen 1976), and substance Ρ (Barclay 1980). The mechanisms involved are 
not f u l l y known for a l l substances. Interference with metabolic breakdown of 
M . E U H I 1 I I I 3 
Fig. 1-1. Various endorphins which have definite similarities in their 
structures in that they contain the leu- or met-enkephalin amino-acid 
sequence, have been shown to be present. 
1. pro-opiocortin 
2. pro-met-enkephalin 
3 . pro-leu-enkephalin-like peptide ( i . e . dynorphin and O-neoendorphin) 
M at these s i t e s cleavage of amino-acid bonds may occur. 
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enkephalins, as indicated by the a b i l i t y to i n h i b i t aninopeptidase-induced 
degradation of leu-enkephalin in r a t whole brain supernatant, as was shown 
to be a mode of action of substance Ρ and somatostatin (Barclay 1980); or 
release induction, as shown to be a feature with Kyotorphin (Takagi 1979; 
Rackham 1982); or possibly induction of a conformational change of receptor 
s i tes (see Dirksen 1981 1), could be involved. Whether opiates have an I n ­
d i r e c t e f f e c t due to such an interact ion with the endorphin system remains 
to be elucidated. What w i l l be apparent from the data presented above, is 
that ligand-receptor relationships should be considered as complex. Not only 
a m u l t i p l i c i t y of putative receptor (sub)types or configurations (see 1.1), 
but also various putative ligands are thought to be present. 
In the spinal cord, the local t ransmitter substance of the endorphin 
system is thought to be met-enkephalin (see: Section I I , Chapter I ) . 
Another endorphin i d e n t i f i e d at a spinal level is dynorphin ( B o t t i c e l l i 
1981). This peptide may prove to be a prohormone for leu-enkephalin (see 
above), y e t , i n other parts of the central nervous system, data supporting a 
genuine function have been obtained (Schulz 1981, Pétr ie 1982). In th i s 
respect i t may prove to be of considerable in terest that in binding to the 
receptor neither dynorphin 1-13 nor dynorphin 1-17 appeared to be select ive 
fo r any opiate receptor (sub)type (Quirion 1981), whereas the enkephalins 
pre ferent ia l ly in teract with the 6 or 'peptide' receptor conf igurat ion 
(Lesl ie 1980, Chang 1979 1 , Childers 1979). Furthenriore, the analgetic 
properties of B-endorphin and opiates are affected by dynorphin (Friedman 
1981), which indicates that the various peptides may moderate or amplify 
each others e f fects . F ina l l y , the pro-opiocort in peptides (see: Chapter 
I I I ) , including ß-endorphin, are present in the cerebrospinal f l u i d 
(McLoughlin 1981). 3-endorphin is very potent (Loh 1976), and i t s ef fects 
mediated by the receptor s i tes ( i t is not selective f o r u - or δ-receptors 
(Lee 1980 (1,2)) may prove to be d i f f e r e n t from those of the enkephalins 
(see Chapter I I : Receptor occupation as a function of t ime). Thus, various 
endorphins which have d e f i n i t e s i m i l a r i t i e s i n t h e i r s t ructure, are present 
at a spinal l e v e l ; and each of the ligands may serve i t s function (see 
Chapter I I ) ; furthermore, they may modify the function of one another. This 
would allow modif icat ion of the signal i n such a way, that ei ther the signal 
w i l l be rearranged as to be delivered as a message, or to be blocked from 
fur ther transmission. 
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С. The effectuator 
Eventually, the process of receptor-ligand interact ion involves mecha­
nisms leading to the observed e f f e c t . The receptor i t s e l f may be thought to 
mediate t h i s sequence of events (so c a l l e d : ' d i r e c t model ' ), which means 
that the change of the receptor molecule (secondary to the interact ion of 
the l igand with the receptor) d i r e c t l y changes neuronal transmission. 
However, experimental data of studies on the mechanisms of tolerance have 
indicated the presence of a lag-time between the s t a r t of receptor occupancy 
and the occurrence of tolerance, due to c e l l u l a r adaptation (Mushlin 1976). 
Furthermore, during tolerance, the receptor i t s e l f , as well as binding 
processes to the receptor, remain unchanged (Bläsig 1979, Dunn 1979). This 
would indicate that between receptor-l igand interact ion and the e f fec t , an 
intermediate is involved which w i l l be termed: the effectuator. Data on the 
nature and mechanisms involving th is effectuator are as yet not conclusive 
and the models which i l l u s t r a t e the concept are hypothetical. 
Some iden t i f i ed electrophysiological mechanisms include: 'system tuning' 
and modulation; membrane-associated processes and changes in the conductance 
of the ionphore; and, hyperpolarization. Which mechanism(s) apply to the 
spinal cord i s as yet not f u l l y known. 
a. 'Systen tuning' and modulation 
The concept 'system tuning' was introduced to acknowledge the a b i l i t y of 
some substances to change ( ' tune ' ) the neurophysiological system in a way 
that the syston i s more accessible to incoming signals (Barker 1978). Also 
the term 'modulation' (by peptides) has been introduced to describe those 
actions of peptides, which appeared d i f fe ren t from those of putat ive neuro-
humors. Thus, a neurotransmitter in i t s conventional sense has been defined 
as a substance that can produce a postsynaptic spike po ten t ia l , and deton-
at ion i s used to describe a propagated spike potent ia l . Some substances, 
however, have potent f a c i l i t a t o r y actions, without causing a change in 
spontaneous discharge. For the synapse, synaptic modulation describes an 
altered exc i t ab i l i t y of the synapse by a substance that does not ord inar i ly 
produce a propagated spike potential at the synapse. Synaptic transmission 
i s used to describe the process of conveying information across the synaptic 
c l e f t . Thus, detonation and modulation are dissociate concepts according to 
Fig. 1-2. Model illustrating the concept of recep-
tor modulation as a membrane-associated process. 
a. Without the co-release of a modulatory substance 
(END » endorphin) the transmitter (TR) will initi-
ate a sequence of events which alters ionic con-
ductance of the postsynaptic membrane. Summation 
of the altered membrane potentials at the axon 
hillock determines the genesis of action potentials 
(END.REC. » endorphin receptor; Ppi - pyrophos-
phate; ATP = adenosine triphosphate). 
Fig. 1-2 b. Co-release of endorphin induces a 
conformational change in the endorphin receptor and 
a secondary change in the conformation of the trans-
mitter receptor, which may involve a regulatory 
unit (GTP = guanosine triphosphate; reg = regula-
tory unit). Due to this change in transmitter 
receptor configuration a different effect results, 
because of a change in transmitter receptor-
effectuator coupling. Thus, the change of membrane 
potential is not equal to the initial one. This 
will reflect itself in the frequency of action 
potentials of the neuron, as the summation of 
membrane potentials (EPSP and/or IPSP) at the axon 
hillock is altered (from Dirksen 1981 1). 
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these def in i t ions (see: Krivoy 1980). These def in i t ions refer to the physio-
logical role and the capacity of a given substance at a given synapse and 
not to altered functioning due to a 'non-speci f ic ' functional change second-
a r i l y to a change of pH or temperature. 
Also, endorphin or endorphinomimetic action has been described as being 
modulatory (Koster l i tz 1977, Frederickson 1977). No specif ic change in 
synaptic functioning has been defined, which gives f u l l meaning to the 
concept 'modulation'. Extending the concept 'synaptic modulation' to 
inh ib i to ry effects may require the introduct ion of the deduced concepts 
' neuromodulati on' and 'receptor-modulation'. As w i l l be described below 
(Chapter I I : Receptor occupation as a function of t ime), neurcmodulation by 
endorphins may be defined as a sustained change of the synaptic membrane 
secondary to receptor-l igand in te rac t ion , and result ing in a changed f i r i n g 
pattern of the neuron involved, which prevails i f the cycle time of the 
receptor occupation by the ligand exceeds the cycle time of synaptic events. 
In addit ion to neurcmodulation, occupation of the receptor with an 
endorphin or an endorphinomimetic with i n t r i ns i c ac t i v i t y may resul t i n 
receptor modulation. Secondary to the conformational change in the endorphin 
receptor, a confonnational change in a transmitter receptor l inked to the 
endorphin receptor may occur, resul t ing in a modified receptor-effector 
coupling af ter the binding of the transmitter substance to the transmitter 
receptor ( f i g 1-2). Such mechanisms fo r a l los ter ic receptor modulation by 
endorphins was proposed for acetyl cholinergic transmission in the adrenal 
medulla (Kamakura 1980; see Section I I ) . 
b. Membrane-associated processes and changed ionic conductance 
The interact ion of a transmitter substance or a neuromodulator with i t s 
receptor may lead to a change in the conductance of the membrane of an ion , 
or of several ions, found on both sides of the membrane. I t is generally 
presumed that such a change in ionic conductance results from a confor-
mational change in membrane structural elements, which, in tu rn , leads to a 
functional change of the narrow hydrophylic channel that crosses the 
membrane, and th is w i l l permit the movement of ions of only a re la t i ve ly 
uni form size ( ionic se l ec t i v i t y ) . The transmitter recognition moiety of the 
receptor and ionophore moiety are considered as physic ia l ly d i s t i n c t , and, 
thus, a mul t i pie-receptor mediated change 1n a single Ionophore moiety is 
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thought possible (see: M i l l e r 1980). The coupling of the ligand (an endor-
phin) to the receptor (the endorphin receptor) w i l l induce a change of th is 
receptor (see: Dirksen 1981 1) . Several poss ib i l i t i es of a secondary change 
i n membrane-associated processes have been described (see: Smith 1981). Of 
signif icance may prove to be the involvement of the enzyme adenylate 
cyclase, as th is enzyme would i n i t i a t e changes in phosphorylation and ionic 
permeability (Greengard 1976, Nathanson 1977 (1 ,2 ) ) . Furthermore, opiate 
effectiveness has been related to the involvement of th is enzyme in vivo 
(Law 1980, Hosford 1981). Therefore, the mechanisms involved w i l l be 
discussed b r i e f l y . 
Due to secondary changes involving the enzyme adenylate cyclase, and 
resul t ing in a change of ac t i v i t y of th is enzyme, the i n t race l l u la r concen-
t r a t i on of cyc l ic 3'5'-adenosine monophosphate (cAMP, 3'5 '-adenyl ic acid) 
w i l l change. cAMP w i l l regulate the act ivat ion of cAMP-dependent protein-
kinase by binding to the regulatory un i t , and th is w i l l account for phospho-
ry la t ion of certain ce l l u la r proteins, including enzymes involved in i n t ra -
ce l l u l a r metabolism, or proteins in the membrane involved in membrane 
permeability (see: Nathanson 1977 (1 ,2 ) , M i l l e r 1980). Both endorphins and 
endorphinomimetics are thought to involve PGE.-stitnulated adenylate 
cyclase (PG = prostaglandin), and these membrane-associated effects are 
characterized by ( f i g . 1-3): (1) an i nh ib i t i on of PGE^stimulated 
adenylate cyclase (1*3, or 2*3), (2) a reduction of basal adenylate cyclase 
ac t i v i t y i n the absence of prostaglandins, and (3) a dose-dependent naloxone-
r e v e r s i b i l i t y (by competitive inh ib i t i on ) of these ef fects , which indicates 
that binding to the receptor si tes i s essential (Co l l ie r 1975, Klee 1975, 
Sharma 1975 1 , Klee 1976 (1 ,2) , Brandt 1976, Wahlström 1977, Bachrach 
1979). The ion channel funct ional ly related to the endorphin receptor may 
prove to be sodium select ive (Frank 1978). The inh ib i t i on of the increase in 
the levels of cAMP evoked by PGE. by various concentrations of opioid 
peptides (endorphins) Is preceded by an i n i t i a l increase in cAMP content 
(Wahlström 1977). This time course may be the resul t of (or may explain) 
the biphasic ef fect of the endorphins (and the endorphinomimetics), as was 
observed af ter low dose morphine in effectuating spinally-mediated anti noci-
ception (see: Section I I ) . Also, the course of the cardiovascular response 
to endorphins, and the mirror-image cardiovascular response of reversal of 
endorphin effects by naloxone was biphasic (see: Chapter I I I ) . 
Protracted i nh ib i t i on of adenylate cyclase ac t i v i t y as a resul t of 
endorphin receptor occupation by ei ther endorphins or endorphinomimetics 
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w i l l i n i t i a t e an "escape response" which is thought to involve the c e l l 
membrane ( M i l l e r 1980) and act ivat ion of the chronical ly inh ib i ted enzyme 
adenylate cyclase ( C o l l i e r 1975, Klee 1975, Traber 1975, Sharma 1975 2, Butt 
1979). Due to the secondary changes which counteract the i n h i b i t i o n by the 
endorphins or the endorphinomimetics ( i . e . the escape response), tolerance, 
and withdrawal may occur. Receptor-effectuator coupling rather than 
SIGNAL 
В 
prOtVin i
 l 
Fig 1-3. Model illustrating the concept of signal modulation by 
endorphins or endorphinomimetics. Transmission of a signal from 
neuron В to neuron A is modulated by neuron С Binding of either 
endorphin released by neuron C, or administration of an endor-
phinomimetic (opiate) will inhibit the activity of adenylate 
cyclase and, therefore, ionic conductance of the membrane of 
neuron В will be altered. Due to these secondary changes the 
release of the transmitter substance (TR) of neuron В will be 
diminished (PG = prostaglandin, Ppi = pyrophosphate, ATP -
adenosine triphosphate, R - receptor protein for the transmitter 
released by Neuron B)(from Dirksen 1979 1, 1981 1). 
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occupancy of the receptor s i tes proved to resul t i n reciprocal adenylate 
cyclase act ivat ion: concomitant administration of a ligand together with a 
high dose of an antagonist (naloxone) which w i l l f a i l to i n h i b i t adenylate 
cyclase, w i l l also f a i l to induce tolerance or dependence (Smith 1976, Yano 
1977, Jasinski 1967). Cross tolerance of endorphins and endorphinomimetics 
(Bläsig 1976, Waterfield 1976, Van Ree 1979, Elazar 1979, Miglécz 1977, 
Zieglgänsberger 1976 2) could resul t from a common mechanism in the 
sequence of events of receptor l igand-effectuator mechanisms, and i f so, 
three factors may govern the extent of reciprocal ac t iva t ion: receptor 
k ine t ic events, pharmacokinetic events, and the duration of the i nh ib i t i on 
of adenylate cyclase. 
c. Hyperpol ari zat i on 
In the myenteric plexus of the guinea pig ileum endorphinomimetics and 
endorphins hyperpol ar i zed the neuronal membrane in a dose-dependent naloxone-
reversible fashion (North 1976 (1 ,2 ,3) , Sastry 1978, Wouters 1978, Williams 
1979). The hyperpolarization is thought to be due to an action of the 
opiates (on receptor s i tes on the f ine varicose processes of the neuron), 
and has also been proposed as a mechanism for presynaptic i nh ib i t i on (North 
1979). Effects s imi lar to those in the myenteric plexus have been observed 
i n neurons in the guinea pig nucleus locus coeruleus (Pepper 1980) and 
lamina V ce l ls of the spinal cord (Zieglgänsberger 1976 1) . Withdrawal of 
the opiates resulted in hypopolarization associated with an increase in 
f i r i n g of the neurons (North 1976 2) . The mechanism of these effects is not 
presently known, but i t has been proposed that i t includes an act ivat ion in 
membrane potassium conduction (North 1980). 
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CHAPTER I I 
Functional Aspects of the Endorphins 
The accessible element of the endorphin systan i s , at present, the endor-
phin receptor and mostly the induced changes in functioning of the endorphin 
systen are a resul t of a l igand-receptor in te rac t ion . In the c l i n i c , endor-
phin adni ni s t r a t i on i s not a common pract ice. However, a change in funct ion-
ing of the system may also be achieved by the administration of a substance 
which mimics the effects of a natural l igand; in other words an endorphino-
mimetic. Such an endorphinomimetic w i l l have to meet structural demands to 
be able to in teract with the endorphin receptor and to actual ly involve 
effectuator mechanisms. Opiates do possess the structure to effectuate 
receptor-effectuator coupling; however, which functional aspect of the 
natural ligands do they mimic? To answer th is question, data on functional 
aspects of two kinds of natural ligands are considered, as are t ime-related 
events at a receptor l e v e l . 
The sequence of events of l igand-receptor-effectuator mechanisms w i l l 
express i t s e l f in a change of neuronal transmission, secondary to which the 
eventual ef fect may be observed. 
A. Structural requirements for in teract ion with the endorphin receptors 
As w i l l be discussed below ( I I . b . ) , enkephalins and fî-endorphin meet 
important c r i t e r i a proposed essential for the iden t i f i ca t ion of the i r 
functioning as a transmitter or modulator substance. The effects of these 
natural ligands involve the receptor s i tes . To establish 'endorphin' 
e f fec ts , alkaloids: the opioids, rather than the natural ligands are common-
l y used. 
The d ivers i ty in chemical const i tu t ion of the various opioids, as well 
as the endorphins, contrasts with the proposal that the i r high se lec t i v i t y 
of effects is mediated by a single endorphin receptor or a few subtypes (see 
Chapter I ) . This apparent paradox is solved by proposing structural and con-
formational s im i l a r i t i es in the three-dimensional structure of these various 
l igands; indeed. X-ray structures (Horn 1976, Horn 1977, Smith 1978), as 
well as the structures disclosed by nuclear magnetic resonance (Bleich 1979) 
or high f i e l d proton magnetic resonance (Roques 1976, Jones 1976, Gacel 
1979) confirmed th is proposal. 
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Early stereochenical Investigations of opioids outl ined the structural 
requirements of the receptor (Beckett 1954). However, the basic pr inc ip le of 
his model is a d i rec t f i t (single binding, ' lock and key' model), and th is 
model does not provide insight in to the m u l t i p l i c i t y of possible in ter -
act ions. The 'mul t ip le modality' model for interact ion (Portoghese 1965) 
extended the ear l ie r model to include the Interactions of ligands with 
e i ther a single type of opioid receptor, or a group of related but not 
ident ical opioid receptors. The possible modes of in teract ion in such a 
mul t ip le modality model include a ' lock and key' model for the r i g i d opioids 
as well as a 'z ipper ' mechanism for f l ex i b l e molecules. For ei ther of these 
modes of in terac t ion , the tyramine moiety of opioids and endorphins is 
considered crucial (Horn 1976, Bradbury 1976 2, Gacel 1979), as indicated by 
the absence of a f f i n i t y once the Tyr-Gly bond of the enkephalins was cleaved 
(Hambrook 1976, Rónai 1976, Knight 1978, Craves 197Θ). Either t h i s tyramine 
moiety or a conformationally s imi lar moeity may prove to be the s tar t ing 
point of a stepwise recognition and successive reor ientat ion towards other 
binding s i tes of the receptor molecule (Burgen 1975). Thus, the r i g i d opioid 
may be thought to ' f i t ' (or not at a l l ) , whereas a f l e x i b l e llgand w i l l , 
a f t e r a recognition of the tyramine binding s i t e , posit ion i t s e l f in a 
stepwise fashion over the remaining recognition s i tes (Horn 1976, Gacel 
1979). Methadone and related structures serve as examples of a molecule with 
high conformational m o b i l i t y (Horng 1976, Casy 1979, Portoghese 1978) and 
they display a mode of in teract ion with opioid receptor s i tes which is 
d iss imi lar to those molecules which are less f l e x i b l e or r i g i d . Methadone, 
and dextromoranide as w e l l , do not contain the tyramine moiety. However, in 
adjunct to a high conformational m o b i l i t y , a phenyl r ing and a basic 
nitrogen are constituents of the molecule, and i t is possible that 
reposit ioning of these structures w i l l consitute a functional equivalent 
(Horn 1977). The i n i t i a t i o n of a conformational change may prove to be part 
of the receptor i n t e r a c t i o n . The natural l igands, the enkephalins, also have 
a high degree of conformational m o b i l i t y . Depending on envirormental 
condit ions, they were shown to take d i f f e r e n t conformations (Han 1980 
( 1 , 2 ) ) . 
For the i n i t i a t i o n of an e f f e c t , structures i n addit ion to the tyramine 
moiety are necessary, as p-tyramine i t s e l f does not possess endorphinonn-
metic a c t i v i t i e s . Receptor-effector coupling requires additional occupation 
of recognition s i tes (Gorin 1978), and t h i s explains why in addit ion to the 
presence of structures i n t e r f e r i n g with the recognition s i t e s , functional 
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expression i s important (Fournie-Zaluski 1977). The tetrapeptide 
Tyr-Gly-Gly-Phe contains the tyramine moiety, yet the tetrapeptide had a 
very low IC50-value in competing for binding of e i ther radiolabelled 
D-Ala2-D-Leu5-enkephalin or naloxone in brain membrane (Chang 1979 1) . The 
three-dimensional structure proved to be d i f fe rent from active structures 
because of a change in the Gly-Gly bend (Fournie-Zaluski 1977). Another 
exanple of a substance which did not displace ef fec t ive ly radiolabelled 
naloxone, D-Ala2-D-Leu5-enkephalin, or ethylketocyclazone in in v i t r o opiate 
binding assays ( ra t membrane suspensions) is Kyotorphin (Rackham 1982), 
which had, however, an endorphin-like ef fect in that i t induced a dose-
related naloxone-preventable increase in the t a i l - p i neh or t a i l - f l i c k ref lex 
a f te r adnim'strati on in the cisterna magna of mice (Takagi 1979, Ueda 1980, 
Rackham 1982). 
The functional expression of those parts of the interact ing molecule 
which attach to the recognition si tes may be rest r ic ted because of s ter ic 
hindrance, due to the presence of additional groups in the molecule, or 
because of the energy barr ier which must be overcome to allow the molecule 
groups to at ta in the required posit ion ( l im i ted conformational mob i l i t y ) . 
Thus, as described above, a receptor-Induced conformational change of 
the ligand may contr ibute to a receptor-l igand binding. Furthermore, the 
l igand may induce a conformational change in the conformation of the 
receptor: 'induced f i t ' (Portoghese 1965, Balodis 1978). The conformational 
change of the receptor molecule may const i tute the i n i t i a l step for a 
secondary change in the enzyme adenylate cyclase or other structures which 
are funct ional ly related to the receptor s i tes (Chapter I : The ef fectuator ) . 
An additional in teract ion of a ligand with an accessory recognition s i te of 
the receptor molecule or a neighbouring structure may l i m i t a necessary 
receptor conformational change and thus receptor-effector coupling (competi-
t i ve antagonism). 
The to ta l sum of these dependent variables w i l l resul t i n a pharma-
cological response which may be defined at the receptor level i n terms of 
a f f i n i t y and i n t r i ns i c a c t i v i t y . The conformational mobi l i ty of the various 
interact ing structures w i l l make i t extremely d i f f i c u l t to out l ine s t r i c t 
structural requirements. The main l im i t i ng factors for in teract ion and 
subsequent ef fect are the thermodynamics of the binding process to the 
receptor si tes ( in teract ing energy) and the presence of s ter ic hindrance. 
Yet, at the receptor s i tes the various structures w i l l exhib i t a s t r i k ing 
s im i la r i t y in three-dimensional s t ructure, and as i t is crucial that the 
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opiates resemble the natural ligands (the endorphins), the opioids should be 
named endorphinomimetics (see Dirksen 1979 (1 ,2 ) , Dirksen 1981 1) . 
The short duration of enkephalin ac t i v i t y is at t r ibuted to the rapid 
enzymatic breakdown (Meek 1977, Von Voigtlander 1978, Hambrook 1976). As a 
resu l t of e f for ts to create 's tab le ' analogs, several hundred enkephalin-
l i k e molecules have been synthesized, some of which are potent ( for example 
i f the substituent part i s : Amidino-Tyrl-DMet2-Phe4-NH2) while others do not 
re ta in ac t i v i t y ( i . e . i f the substituent part is Pro5-NH2) (see Rónai 
1981). Recent research is directed to the development of pentapeptides as 
the short chain peptides prove to be easier and more economical to 
synthesize. The aim is to bypass pharmacokinetic problems (enzymatic 
breakdown, blood-brain barr ier permeation) and to l i m i t the e f f ec t i v i t y to 
speci f ic receptor configurations so as to reduce the l i a b i l i t y to induce 
tolerance, dependence and side-effects (see Chapter I ) . Whether the peptides 
have advantages over the opioids, ranains to be determined. 
B. Endorphins: neurotransmitters or neuromodulators? 
For the i den t i f i ca t i on of a new neurotransmitter substance several 
c r i t e r i a have to be f u l f i l l e d , and recently these were outl ined (Lembeck 
1980), i . e . : 
1 . presence of the transmitter candidate in the considered population of 
neurons, together with the fol lowing: 
2 . presence of an enzyme system for i t s synthesis and metabolism, 
3. evidence for axoplasmatic transport, and 
4 . evidence for storage in synaptic vesic les, 
5. demonstration of Ca -dependent release from nerve endings, 
6. de f in i t ion and characterization of postsynaptic receptors, 
7. knowledge of the manner in which synaptic transmission is terminated, 
8 . a b i l i t y to mimic the synaptic effects for which the candidate is 
considered to be responsible, 
9. pharmacological character izat ion, i . e . pharmacological modulation of 
synthesis, transport, release and action of the transmitter on 
receptors, and termination of synaptic transmission. 
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а. The enkephalins 
According to these c r i t e r i a enkephalins are indeed neurotransmitters, 
as: 
1 . immunocytochemical studies revealed the presence of enkephalin-
containing nerve c e l l s and f ibres i n the central nervous system, 
separate and morphologically d i s t i n c t from 3-endorphin-contain1ng 
structures (Bloom 1978 (1,2) , Watson 1978 ( 1 , 2 ) , Eide 1976), together 
with the fo l lowing: 
2. the presence of a specif ic local and nonspecific systanic enzyme systan 
involved i n the metabolic breakdown of enkephalins (Hambrook 1976, Marks 
1977, Knight 1978, Lane 1977). Specific enkephalinases proved to be 
present (Malfroy 1978, Malfroy 1979, Gorenstein 1979), and were shown to 
be associated with receptor sites (Schwartz 1980, DeLaBaume 1981). The 
enzyme system involved in synthesis has not been defined. The presence 
of local synthesis from the precursor amino-acids methionine, g lyc ine, 
and tyrosine in c e l l cultures (Neale 1980, Sosa 1978), and in the brain 
(Yang 1978, McKnight 1979, Hughes 1978) has been shown. 
3. evidence for local synthesis and intra-axonal transport in para­
sympathetic preganglionic neurons (Glazer 1980). 
4 . evidence for storage i n the synaptosomal f r a c t i o n , which represents 
nerve endings, of brain homogenates (Smith 1976). 
5. demonstration of Ca -dependent depol a r i s a t i on-induced release i n c e l l 
cultures (Neale 1980), brain s l ices (Osborne 1978, Henderson 1978, 
Iversen 1978, Hart 1980), the synaptosomal f r a c t i o n of brain homogenates 
(Smith 1976), and in vivo i n cat brain (Cesselin 1981). 
б. characterization of receptor s i tes (see Chapter I : The endorphin 
receptor). 
7. some knowledge of the manner i n which synaptic transmission is 
terminated, i . e . , recent ly, an energy-requiring re-uptake by synaptosome-
enriched f r a c t i o n of r a t striatum was described (George 1981). Further­
more, af ter dissociaton from the receptor s i t e s , which was shown to be 
regulated by GTP and Na+ i n NG 108-15 c e l l s in cul ture (Blume 1980), a 
rapid enzymatic breakdown of the enkephalins may occur (see above), f o r 
which receptor occupancy is not necessary (Hazum 1979). 
8. Endorphin effects are a feature of various endorphinomimetics, and 
various agonists f o r the d i f f e r e n t receptor configurations (see Chapter 
I ) have been outl ined (Martin 1976, Gi lbert 1976, Lord 1977). 
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b. g-Endorphin 
In contrast to the large number of widely-spread enkephalin ce l l groups 
and f i b res , ß-endorphin i s contained wi th in the single arcuate ce l l group 
which has a large f i b re system associated with those ce l l s (Watson 1978 
(1 ,2 ) ; see Chapter I I I ) (1 ) . As mentioned above, th is system is d i s t i nc t l y 
d i f fe ren t from the enkephalin system, indicat ing the presence of two d is-
t i n c t neuronal networks in addit ion to neurohumoral systems (see Chapter 
I I I ) . Furthermore, the presence of a precursor molecule (pro-opiocort in) in 
the soma of neurones and the release of ß-endorphin (Watson 1981)(2), 
indicates axonal transport associated with d i f fe ren t ia l processing (3 ) . The 
local processing of the pro-opiocort in precursor molecule was shown to occur 
i n arcuate nucleus neurons in culture (L io t ta 1979). Granules containing 
ß-LPH, ACTH and B-endorphin are present in the p i tu i ta ry (Bloom 1978 2, 
Weber 1980), and release may occur from these granules (4 ) . Ca -dependent 
potassiun-induced release from hypothalamic sl ices (Osborne 1979, Przewlocki 
1980) and the anter ior p i t u i t a r y (Przewlocki 1980) is known to occur (5 ) . 
B-endorphin is known to recognize binding si tes to which enkephalins and 
opiates bind as well (Aki l 1980; see: Chapter I ; The endorphin receptor); 
furthermore, B-endorphin interacts with a receptor configuration which could 
not be associated with e i ther t h e y - or δ-configurations (Schulz 1979) ( 6 ) . 
Knowledge of the manner i n which synaptic transmission is terminated is 
presently scarce. Synaptosomal membrane fract ions are known to convert 
B-endorphin to other peptides (Burbach 1979), and t h i s may abolish specif ic 
interact ions with the endorphin receptor. However, no rapid conversion or 
breakdown has been demonstrated. The slow dissociat ion of B-endorphin from 
binding sites (Aki l 1980) indicates that the processes involved in favouring 
dissociat ion are not e f f e c t i v e . Thus, even though several Important require­
ments for a transmitter function are met, other properties of B-endorphin 
indicate a d i f f e r e n t funct ion. As t h i s function is mediated by the receptor 
s i t e s , i t could be proposed t h a t , by interact ing with the receptor, 
B-endorphin serves as a modulator (see below: Receptor occupation as a 
funct ion of t ime). As B-endorphin proves to be more potent than the 
enkephalins, i t may be thought that occupation of the receptor by 
^-endorphin may overrule enkephalinergic transmission and may be associated 
with a sustained change of synaptic events. Endorphins released by the 
p i t u i t a r y into the c i r c u l a t i o n , or endorphin released into the CSF (see 
Chapter I I I ) may also i n s t i t u t e such a modulation by interact ing with the 
endorphin receptors. 
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с. Receptor occupation as a function of time 
To characterize a function of a substance as a modulatory, or rather as a 
transmitter one, two d i f f e r e n t time-dependent processes have to be taken 
i n t o consideration: the cycle time of the synapse (synaptic response time) 
together with the input frequency of the s i g n a l , and the cycle time of the 
receptor-ligand binding. The receptor occupation as a function of time 
(Qp'jrì can be calculated (see Colquhoun 1981) as: 
^ ft) , , t / f ) 
QRA = QRA ,„ · ( 1 - e (l) 
max (C ) 
A 
i n which Qittmawc i s t h e concentrati on-dependent maximum receptor 
occupation ( t = •> ), and 
τ = i / k 2 . ( l + с А / к д ) (2) 
which means that τ , a time constant, depends on the concentration of the 
drug and the processes of dissociation and association. In those conditions 
in which the concentration of the ligand is low (C << К ): 
Q D a/Q D = i/ (i + K./c.) = * „ _^A (3) 
К + С К, 
'RA' *R А' А 
А 
i n which condit ions: 
- /ϊ< 2 (4) 
and these conditions prevail during normal transmission. A low dissociat ion 
rate w i l l thus represent a long period (τ) of receptor binding (receptor 
residence t ime). I f t h i s time exceeds the cycle time of the synapse, a 
sustained change i n the postsynaptic membrane is present, and a new e f f e c t 
of a transmitter substance released w i l l superimpose I t s e l f on the former 
e f f e c t , or an in teract ion with the (already occupied) receptor w i l l be 
prevented. 
The dissociation of (J-endorphin from the binding sites (the Kn i s 
-9 in 
10 and 16 . 10 M) is slow and the dissociat ion h a l f - l i f e time has 
been proven to be ten times longer than f o r naloxone (Aki l 1980). This may 
serve as an explanation f o r the d i f f i c u l t y in reversing g-endorphin effects 
with naloxone, and, furthermore, i t indicates a neurcmodulatory r o l e . Yet, 
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as the cycle time at i n t r i n s i c B-endorphinergic synapses may prove to be 
low, (j-endorphin may s t i l l have a neurotransmitter funct ion. 
In the brain, exci tat ion that can summate with other excitatory post­
synaptic potentials lasts much longer than i n the spinal cord, and extensive 
sunriation of excitatory postsynaptic potentials is often required to f i r e a 
postsynaptic p o t e n t i a l . Therefore, the synaptic response time of a neuron in 
the brain can be quoted as var iable, and can take as long as 100 msec. , 
which is much longer than the response time at synapses of monosynaptic 
spinal ref lex paths (1 msec.)(Emmers 1981). I t is of considerable in terest 
that although β-endorphin neuronal pathways do not exist in the spinal cord 
(Watson 1978 2 ) , the l igand i t s e l f is present i n the CSF (McLoughlin 1981), 
and i t may be transported to the receptor sites by the CSF or the blood (see 
Chapter I I I ) . 
As to the opioid drugs, af ter administration and entering the receptor 
compartment, t h e i r receptor residence time may be said to exceed the synap­
t i c cycle time. I t i s hazardous to denominate them as modulators, as data on 
t ime-related events are wanting. However, the point to make i s : opiates w i l l 
not subst i tute for a d e f i c i t i n the natural transmitter funct ion. 
C. Functional changes in neuronal function as a consequence of endorphin 
receptor-effectuator coupling 
As a consequence of the endorphin-mediated effects of e i ther endorphins 
or endorphinomimetics, which involves the effectuator(s) (see Chapter I ) , a 
change i n f i r i n g pattern of the individual neurons w i l l r e s u l t . Both basal 
and stimulus-evoked f i r i n g was shown to be reduced and t h i s change proved to 
be naloxone-reversible. Cel lular recordings revealed such a change i n basal 
and stimulus-evoked f i r i n g i n : the central grey matter (Frederickson 1976 
( 1 , 2 ) , Gent 1976), the cerebral cortex (Palmer 1978, H i l l 1976, 
Ziegelgänsberger 1976 2, Frederickson 1976 2) , the locus coeruleus (Young 
1977), the re t icu la r formation (Bradley 1976, Nicol i 1977), the striatum 
(Frederickson 1976 (1 ,2 ) ) , the myenteric plexus of the guinea-pig ileum 
(North 1976 (1 ,2 ) ) , the vas deferens (Henderson 1976), and (s ign i f i can t l y ) 
the dorsal horn of the spinal cord (see Section I I ) . The effects of opiates 
(and endorphins) on the electrophysiology of the synapse are dependent on 
the concentrations used. Several studies have provided evidence that a s i te 
of action of opiates is presynaptic (LaMotte 1976, Atweh 1977 (1 ,2 ,3 ) ) . In 
23 
low doses morphine inh ib i ted the release of transmitter substances in an in 
v i t r o preparation (Henderson 1972), and at a higher dosage in ce l l cultures 
morphine was shown to impair transmission by presynaptic action (H i l l e r 
1978, MacDonald 1978, Grain 1978). An ef fect of an antagonist ( i . e . 
naloxone) w i l l prevail i f tonic release of i n t r i ns i c endorphins causes an 
e f fec t . Absence of an ef fect of receptor blockade by an antagonist indicates 
an endorphin (sub)systeni which functions only on demand. The mechanisms by 
which endorphins and endorphinomimetics presynaptically i n h i b i t the release 
of the neurotransmitter, or by which postsynaptic events are effectuated are 
not f u l l y known. As to the signal transfer in the central nervous system, i t 
may be described as a frequency-coded message (see Chapter I I I ) , and a 
change in basal, as well as stimulus-evoked ac t i v i t y would provide a 
mechanism by which modulation of information transfer could be achieved. 
Exogenous opiates or endogenous endorphin may i ns t i t u t e protracted changes 
i n these mechanisms and the expression of a result ing change w i l l depend on 
the systems l inked to the neuronal c i r c u i t . 
As to the spinal cord, the change in basal and stimulus-evoked f i r i n g of 
neurons in the dorsal horn and the secondary change in neuronal transmission 
presents i t s e l f : as an increase in response latencies in the hot-plate tes t 
and the t a i l - f l i c k ref lex (Section I I ) , as "analgesia" in pain conditions 
(Section I I , Chapter IV) , and as the various side-effects mediated at a 
spinal level (Section I I , Chapter IV) . 
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CHAPTER I I I 
Aspects of Sensory and Cardiovascular Homeostasis Involving 
Endorphlnerglc Mechanisms 
The term homeostasis, which is used to describe ' the various physio-
logical arrangements which serve to restore the normal s ta te , once i t has 
been disturbed' (Cannon 1932), has been introduced to acknowledge the 
presence of regulatory mechanisms which operate as to maintain the nomai 
equil ibrium ( ' s e t - p o i n t ' ) . Various pathophysiological conditions due to 
al tered functioning of endorphin subsystems or associated with a disturbance 
of normal endorphin subsystem funct ioning, and observations indicat ing funct-
ional relationships of endorphin ac t i v i t y to various homeostatic mechanisms 
(see Dirksen 1981 (1 ,3 ) ) , indicate the par t ic ipat ion of the endorphin system 
i n homeostatic regulatory processes. The unequal d i s t r ibu t ion of the elements 
of the endorphin system (Chapter I ) , the distinguishable functional aspects 
of the various natural ligands (Chapter I , Chapter I I ) , the effects of endor-
phins and endophinomimetics which resul t in measurable changes of ce l l u la r 
f i r i n g patterns of neurons of various si tes of the central nervous system 
(Chapter I I ) , and which f ind expression 1n a change in various bodily 
functions (see Dirksen 1981 (1 ,3 ) ) , as well as the presence of neuronal and 
neurohumoral endorphins (Table I-A), allowed the proposal of mul t ip le 
funct ional ly - and/or anatomical ly-dist inct subsystems. As the endorphin sub-
systems are on-demand subsystems rather than subsystems which show a tonic 
a c t i v i t y (as evidenced by the lack of ef fect of naloxone), a functional 
characterizat ion involves: effects of endorphins or endorphinomimetics which 
have been administered; observations of a functional change due to induced 
disturbances of e i ther synthesis or el iminat ion of the natural l igand; 
observations on pathophysiological conditions which resul t in dysfunctioning 
of one or mul t ip le endorphin subsystems, or which secondarily involve one or 
many endorphin subsystems. 
The spinal ly- located elanents of the endorphin systan (see Chapter I , 
Section I ; Chapter I , Section I I ) are part of mul t ip le endorphin subsystans 
which can be defined as to the i r functional aspects. The observations of the 
c l i n i c a l t r i a l s have indicated the involvement of the spinal subsystem (which 
i s anatomically d i s t i nc t ) in cardiovascular control mechanisms and noci-
ceptive signal transmission (see Section I I ) . Therefore, and because i n t ra -
thecal ly or epidural ly adninistered opioid drugs gain access to the "higher" 
Table I-A. Endorphin Subsystems 
The pro-op1ocortin subsystems 
A. Intracranial: 
Neurohunoral subsystem (pituitary) 
Neuronal subsystems: 
Arcuate Nucleus ( Nucleus 
Infundí bul ari s ) 
Non-Arcuate Nucleus 
Ventricular Releasing Subsystem 
(Arcuate Nucleus projections) 
B. Extracranial: 
Placentar 
Pancreatic 
I I . The 'enkephalinergic' subsystems 
A. Neuronal subsystems: 
Pituitary 
'Other' 
B. Neurohumoral subsystem: 
Adrenal 
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centrai nervous centres, the contr ibut ion of the spinal part to the overall 
system(s) w i l l be defined by characterization of the involvement of the 
endorphin systan in cardiovascular and/or sensory homeostasis (see below). 
The experimental characterisat ion of the endorphinergic mechanisms in 
cardiovascular homeostasis anploys observations on an induced patho-
physiological condit ion which results i n , or coincides w i t h , an altered 
functioning of the endorphin system (Dirksen 1980 4 , Dirksen 1981 (2 ,3 ) ) . 
A. Endorphin subsystems and cardiovascular homeostasis 
a. Introduction 
A function of endorphins in the modulation of cardiovascular mechanisms 
i s indicated by: 
1 . The presence of endorphin receptors as well as enke-
phalins in the cardiac muscle (Hughes 1977, Hughes 1981, 
Burm'e 1981) 
2 . The a b i l i t y of various endorphinomimetics to reduce myo-
cardial con t rac t i l i t y (Strauer 1972) 
3. Morphine intravenously injected causes naloxone-
reversible cutaneous d i l a ta t ion (Cohen 1980), and the 
enkephalin analogue FK 33-824 induced a s imi lar change 
(Stacher 1979) 
4 . Intravenous opiates cause a dose-dependent naloxone-
reversible cardiovascular depression (Fennessy 1971, 
Schweichel 1979, Hess 1981, Lind 1980, Lind 1981, 
Hutchinson 1981) 
5. In t rac is te rna l l y - in jec ted endorphinomimetics were shown 
to af fect baroreceptor sens i t i v i t y by an action which may 
be mediated by the ii-receptor configuration (Petty 1980; 
see Chapter I ) 
6. Perfusion with naloxone-containing solutions through the 
fourth vent r ic le reverses the c i rcu latory depressant and 
baroreceptor inh ib i to ry effects of fluothane (Arndt 
1979), and fluothane is thought to have endorphin-like 
effects (Finck 1977 1) . De- inhibi t ion of the baroreceptor 
sens i t i v i t y by naloxone may cause exaggerated c i rcu la tory 
27 
changes (Belenky 1979) 
7. Endorphinomimetics (opiates, see Chapter I I ) induce a 
centrally-mediated decrease in sympathetic tone and an 
increase in vagal tone leading to hypotension and brady-
cardia in dogs (Laubie 1977 (1 ,2 ) ) . The functional 
changes af ter intravenously injected opiates in blood 
pressure-dependent neurons in the tractus s o l i t a r i i and 
the nucleus ambiguus cardiovascular neurons (Laubie 1980) 
led to the proposition that these structures, which 
contain receptor s i tes (Atweh 1977 1) , as well as enke-
phalins (O'Donohue 1980, Hökfelt 1977, Katz 1979), 
mediate these cardiovascular changes 
8. The naloxone-reversi ble hypotension af ter systanic enke-
phalin (Moore 1980) and the naloxone-reversible hypo-
tension and bradycardia af ter appl icat ion of enkephalins 
to the ventral surface areas of the brainstem (Flórez 
1977) 
9. The naloxone-reversible hypotension af ter i ntraci s ternal -
l y (Laubie 1977 (1 ,2 ) , Feldberg 1978) or systenical ly-
in jected з-endorphin (Lemaire 1978 1) 
10. The int imate relat ionship between endorphins and the 
sympathetic nervous system, including: the sympathetic 
ganglia (Schultzberg 1978 1 , Schultzberg 1979, DiGiul io 
1978, Hervonen 1981) and the adrenal glands (Lundberg 
1979 ( 1 , 2 ) , Schultzberg 1978 ( 1 , 2 ) , Viveros 1979 2, 
Clement-Jones 1980 1 , Rossi er 1981, L i v e « 1980, L i v e t t 
1981, Stine 1980, Mizobe 1979, Boska 1982) 
1 1 . The regional d i s t r i b u t i o n of endorphins together with 
binding s i tes i n close association with brain nuclei 
involved i n cardiovascular regulation (Eide 1976, 
Simantov 1977, Atweh 1977 1 , Hbkfelt 1977). 
fj-endorphin or enkephalin have proved to be biphasic excitatory-
i n h i b i t o r y on the c i r c u l a t o r y system (Lemaire 1978 1 , Moore 1980), although 
single directed responses have been reported (Ykimura 1981, Voigt 1981). 
Analogous to the c i r c u l a t o r y effects of ß-endorphin, a biphasic change in 
hemodynamic variables in septicemia (Gi lber t 1960), or af ter morphine 5 
mg/kg have been observed (Hess 1981). The cardiovascular changes af ter high 
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dosages of endorphinomimetics are thought to involve 3-endorphin release, 
which can be prevented by corticosteroids (Rossier 1980 2 ) . 
The assumption that the cardiovascular changes of endorphins and endor­
phinomimetics summarized above contribute to the disturbance of the cir­
culation in conditions such as shock, was Indicated by data obtained in 
experimental hypovolemic (Faden 1979) and endotoxin-induced (Holaday 1978, 
Faden 1980 1) hypotension. The dose-dependent, stereospecific effectiveness 
of naloxone in reversing such hypotension is an indication of a specific 
(endorphin receptor-mediated) disturbance. 
The animal experiments to be described below anployed circulatory distur­
bance due to progressive occlusion of the l e f t anterior descending coronary 
artery (LAD) in pigs. The advantages of this experimental set-up include: 
experimental results with a cardiovascular system much l ike that of humans 
(Bertho 1964, Schaper 1971, Brooks 1975); recent research directs to the 
study of henodynamics in pigs (Brooks 1975, Skinner 1975, Verdouw 1978, 
Salerno 1981); and hypotension due to progressive occlusion of the LAD is a 
constant feature, in contrast with the phasic course which may de observed 
In endotoxemic or hypovolemic hypotension. In addition to the cardiovascular 
experiments in pigs, two experiments on monkeys previously subjected to an 
alcohol-induced adenolysls of the pituitary gland, were performed as to 
Inform on the importance of the pro-opiocortin systens (Table I-A) in these 
conditions of hypotension. 
b. Experiments 
b . l . Materials and methods 
Studies were performed on six pigs weighing between 22 and 25 kg, and 
two male Rhesus monkeys of 4.1 and 7.1 kg. The pigs were premedicated with 
ρ 
120 mg azaperone intranuscularly (Stresnil , Janssen Pharmaceutica, Beerse, 
Belgium). Half an hour after premedication, 150 mg metomidate was injected 
via the dorsal vein 1n the ear. In the monkeys, 1.2 mg/kg azaperone i.m. 
served as premedication and Induced anesthesia 1n 10 min. 
In all experiments, after catheterization, the heart was exposed via a 
midsternal split and,in pigs, a partial resection of the l e f t fourth and 
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f i f t h ribs. For ful l details and methods, the reader is referred to a pre­
vious publication of Verdouw (verdouw 1978). 
Acute alcohol-induced adenolysis of the pituitary gland was accomplished 
in two pigs, and to allow injection of IH - 24 ml absolute alcohol, a big 
bore needle with a length of 20 cm was introduced through the nose under 
constant X-ray surveillance through the corpus ossi s sphenoidal i s into the 
sella turcica. Both monkeys had been subjected to a similar procedure 10 
days before the experiments. 
b.2. Hemodynamic variables 
The electrocardiographic lead I I , l e f t ventricular pressures (measured 
by using catheters with a micromanometer at the tip introduced through the 
femoral artery in the pig and through the apex of the l e f t ventricle In the 
monkey), i ts f i r s t derivative (max LV dp/dt), central aortic pressure, and 
thermodilution curves were recorded on a Siemens Oscillomink В recorder. 
From these recordings the following variables were calculated: heart rates 
(HR, beats per minute), aortic pressures (BP: systolic, diastolic and mean; 
kPa), l e f t ventricular pressures (LVP, systolic, end-diastolic; kPa), LV 
dp/dt and in the pig also: cardiac output (CO, 1/min), stroke volume (SV, 
ml), and peripheral resistance calculated as " ^ . 
b.3. Experimental protocol 
Hemodynamic variables were recorded prior to any reduction of LAD flow. 
In four pigs and two monkeys the flow reduction started one hour after 
tennination of the surgical procedure, during which period nitrous oxide was 
washed out. The mean LAD-flow was reduced progressively by careful 
tightening of the J-shaped clamp in the pig, and by placing multiple 
stitches around the ramus descendens anterior of the l e f t coronary artery 
and the anastosmosing branches of the ramus circumflexus in the monkey, t i l l 
a clear reduction of mean aortic blood pressures (-20%), max LV dP/dt 
(-40*), and cardiac output (-20%) occurred. Due to this progressive 
obstruction of arterial blood supply to the l e f t ventricle, ischemia and 
functional disturbance occurred, as indicated by systolic bulging of the 
ventricular wall, colour changes of the cardiac muscle, and the afore-
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mentioned changes in c i rcu la tory var iables. After 45 minutes of ischemia (60 
minutes in the monkey) naloxone was intravenously injected (5 mg/kg body 
weight) , and for the remainder of the experiment the LAD-flow was maintained 
at the low l eve l . In two experiments with pigs s imi lar procedures, including 
catheter izat ion and median sternotomy, were fol lowed, but no reduction of 
LAD-flow was induced. Again one hour was allowed to elapse af ter the surgery 
before naloxone 5 mg/kg body weight was in jected, and during th is period 
nitrous oxide was washed out. 
c . Results 
c . l . Results of experiments in the pig 
The effects of naloxone 5 mg/kg body weight were evaluated in three 
groups of pigs. F i r s t , i n two pigs catheterizat ion procedures and median 
sternotomy were completed one hour pr ior to the in jec t ion of naloxone, 
however, i n these pigs the LAD-flow was not a r t i f i c i a l l y reduced. Second, in 
two pigs af ter catheter izat ion, sternotomy, and r ib resection, the LAD-flow 
was progressively reduced over a period of 45 minutes by carefu l ly t i gh t -
ening the J-shaped clamp. Th i rd , i n two pigs af ter catheter izat ion and pr ior 
to sternotomy, alcohol was injected in the sel la turcica to achieve an 
alcohol-induced adenolysis of the p i tu i ta ry gland. After the recording of 
henodynamic var iables, sternotomy and r i b resection were accomplished to 
allow a progressive occlusion of the LAD-flow, and naloxone was in jected. 
In the f i r s t group, in jec t ion of naloxone was associated with an instant-
aneous short- last ing reduction in heart rate ( f i g . 1-4). No changes in hemo-
dynanic variables occurred ( f i g . 1-5). Repeated in ject ions produced a repro-
ducible reduction i n heart ra te. In jec t ion of a s imi lar volume of saline was 
without e f fec t . B i la tera l surgical vagotomy in the neck did not af fect the 
naloxone-induced reduction in heart ra te. 
The changes in c i rcu la tory variables during the course of two 
experiments of the second group are shown in f i g . 1-6 and f i g . 1-7. The 
in jec t ion of naloxone resulted in an instantaneous and short - last ing 
reduction in heart rate associated with a s l igh t decrease in LV dP/dt and 
aort ic pressures. Following th is i n i t i a l reduction, a s ign i f i can t increase 
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• LAD OCCLUSION 
Δ HYPOPHYSECTOMIZED + 
LAD OCCLUSION 
Fig. 1-4. Relative changes 
(Δ%) in heart rates (HR) in 
each group of experiments 
after the injection of 
naloxone 5 mg/kg. The heart 
rate before injection is 
presented as 100% for each 
group (NAL = naloxone 5 
mg/kg intravenously in­
jected (arrow)). 
10 15 
TIME (MIN) 
i n heart rate occurred ( f i g . 1-4). The systol ic blood pressure returned to 
control values, the d i a s t o l i c blood pressure increased by 20% i n experiment 
one and remained unchanged i n experiment two. Both d i a s t o l i c and mean aort ic 
pressures remained below control value, but the values of LV dP/dt increased 
to 30% and 50% above control values. The experiments of group I I I included 
the evaluation of changes i n c i r c u l a t o r y variables due to the I n j e c t i o n of 
alcohol i n the sel la t u r c i c a , which causes an alcohol-induced adenolysis of 
the p i t u i t a r y gland (n = 3 ) . In two pigs no change occurred i n e i ther heart 
r a t e , aort ic pressures, LVP, LV dP/dt, LVEDP, cardiac output, carot id f low, 
stroke volume, or systemic peripheral resistance. However, i n one animal 
tachycardia, an increase i n aort ic pressures, cardiac output, LV dP/dt and 
carot id flow occurred. Ventricular f i b r i l l a t i o n at a l a t e r instance caused 
death, and post mortem examination revealed extensive subarachnoid bleeding 
due to mal placement of the needle. 
In the other two pigs sternotomy and r i b resection were accomplished, 
and the LAD-flow was progressively reduced by careful t ightening of the 
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J-shaped clamp. Thereafter, naloxone was in jected. After an I n i t i a l reduc­
t i o n i n heart rate, an increase of 11% occurred ( f i g . 1-4), and the mean 
aort ic pressure rose 6%, the LV dP/dt 15%, and the cardiac output 10% ( f i g . 
1-5). Changes i n the other hemodynamic variables were n e g l i g i b l e . The 
l i m i t e d number of experiments does not allow s t a t i s t i c a l analysis. 
t% 
ISOt 
100 
50 II 1 11 II 
HEART RATE MEAN Β Ρ LVdPMt CARDIAC PERIPHERAL 
OUTPUT RESISTANCE 
Fig. 1-5. Maximum relative increase (Δ%) of the cardio­
vascular variables heart rate, mean arterial blood 
pressure (mean BP, centrally measured), left ventricular 
dP/dt (LV dP/dt), cardiac output, and peripheral 
resistance, observed after Intravenous injection of 
naloxone 5 mg/kg, for groups I, II and III: 
I - control (n » 2), 
II » LAD occlusion (n = 2), 
III = hypophysectomized + LAD occlusion (n = 2). 
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't PROGfESSIVE OCCLUSION 
NAL. NAL. 
Fig. 1-6. Changes in circulatory variables due to 
progressive occlusion of the LAD in pigs, and the 
circulatory effects of naloxone (NAL.) injection 
(HR = heart rate, bpm = beats per minute; BP -
blood pressures, kPa; LV dP/dt » maximum left 
ventricular dP/dt, kPa/sec; CO = cardiac output, 
1/min). 
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• PROGBESSIVE OCCLUSION-
NAL. 
Fig. 1-7. Effect of naloxone (NAL.) injections 
on circulatory variables, in pigs (HR = heart 
rate, bpm » beats per minute; BP = blood pres-
sures, kPa; LV dp/dt = .jaximum left ventricular 
dP/dt, kPa/sec; CO - cardiac output, 1/min). 
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с.2. Results of the experiments in the monkey 
The changes in the circulatory variables are indicated in fig. 1-8 and 
fig. 1-9. Progressive occlusion of the arterial blood supply to the left 
ventricle was associated with an increase in the heart rates (17% and 5%), 
as well as a reduction in the aortic pressures and the LV dP/dt. The intra­
venous injection of naloxone in a dose of 5 mg/kg was associated with a 
reduction in heart rates, both after the first (14% and 3%) and the second 
administrations (16% and 5%), which lasted 5-10 minutes and thereafter 
m 120 
BP s 
i PROGRESSIVE OCCLUSION ( 70 mini 
Fig. 1-8. Effects of reduction of arterial blood 
supply to the left ventricle and subsequent 
naloxone injections (NAL.) on the circulatory 
variables, in hypophysectomized monkey (HR = 
heart rate, bpm = beats per minute; BP = blood 
pressures, kPa; LV dP/dt = maximum left ventri­
cular dP/dt, kPa/sec). 
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Fig. 1-9. Effects of reduction of arterial 
blood supply to the left ventricle and sub­
sequent naloxone injections (NAL.) on the cir­
culatory variables, in hypophysectomized 
monkey (HR • heart rate, bpm = beats per 
minute; BP = blood pressure, kPa; LV dP/dt = 
maximum left ventricular dP/dt, kPa/sec). 
returned to pre in ject ion values. The effects on aort ic pressures and LV 
dP/dt were negl ig ib le. In the f i r s t experiment a s l i g h t increase i n s y t o l i c , 
d i a s t o l i c , and mean pressure, as well as the LV dP/dt was observed; however, 
i n the second experiment the deter iorat ion in the c i r c u l a t o r y variables 
continued. A consistent f inding i n these experiments was the change in heart 
rate a f t e r the i n j e c t i o n of naloxone. Repeated in ject ions produced a repro­
ducible reduction i n heart rates, immediately af ter the i n j e c t i o n was 
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completed. An identical volume of saline did not change heart rate, while 
atropine in a dose of 0.25 mg/kg did not modify the response (data not 
shown). 
d. Discussion 
Hypotension induced by hemorrhage (Faden 1979, Vargish 1980, Feuerstein 
1980, Gurll 1981, Curtis 1981), endotoxemia (Holaday 1978, Reynolds 1980, 
Janssen 1980, Hess 1981, Raymond 1981), splanchnic artery occlusion (Curtis 
1981) or spinal cord in jury (Faden 1980 2, Holaday 1980, Faden 1981) was 
shown to be attenuated by pr ior in jec t ion of naloxone, and reversal of the 
induced hypotension may be achieved by naloxone in jec t ion . Only (-)-naloxone 
was shown to be ef fect ive (Faden 1979, Faden 1980 1) , whereas (+)-naloxone 
proved to be devoid of effects i n induced hypotension (Faden 1980 1 , Holaday 
1981). This may relate to the absence of measurable opiate receptor a f f i n i t y 
or narcotic antagonist effects of ( + )-naloxone ( l i j ima 1978). The minimum ef-
fect ive dose of intravenous naloxone on hanodynamic variables in hemorrhag-
ic shock was 0.5 mg/kg (Gurll 1981), and in spinal shock 0.1 mg/kg body 
weight (Faden 1980 2) . However, complete reversal of endorphin effects 
required high dosages (Laubie 1977 1) , and th is may relate to a low disso-
c ia t ion rate of 8-endorphin from receptor si tes (Akil 1980, see Chapter I I ) . 
Naloxone in concentrations which exceed estimated levels af ter a high 
dose intravenously in jec ted, was shown to d i rec t ly increase myocardial 
c o n t r a c t i l i t y i n isolated papi l lary muscle preparations (Curt is 1980), 
however, th is ef fect was minimal and w i l l not markedly influence cardiac 
performance in in tact animals. Explanations for th is f inding could be: a 
reversal of residual anesthetic effects on myocardial c o n t r a c t i l i t y , or a 
reversal of tonic endorphin effects mediated by the endorphin receptors in 
the heart (see Int roduct ion) . Intracerebroventricular perfusion with 
naloxone-contaim'ng solutions was shown to be associated with only minimal 
cardiovascular effects (Janssen 1980). 
The dose-dependency of the eff icacy of naloxone in attenuation of a 
hypotensive response (Gurll 1981) and the absence of observable c i rcu la tory 
ef fects of naloxone i t s e l f (Fol des 1963, Freye 1974, Schweichel 1979, 
Holaday 1981, Reynolds 1980, Belenky 1979, Raymond 1981; f i g . 1-5) may be 
regarded as a strong indicat ion of competitive antagonism of endorphinergic 
effects of a compound released during hypotension induced by hemorrhage, 
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endotoxemîa, splanchnic artery occlusion, or spinal transsection. The 
ef fects of naloxone are not l imi ted to posit ive effects on cardiovascular 
var iables; naloxone also proved to increase ( in a dose-dependent fashion) 
survival in various species, but not in rats (Reynolds 1980, Gurll 1981, 
Vargish 1980, Faden 1979, Curtis 1981). 
Although the nature of the compound which accounts for the naloxone-
reversible effects in shocked animals is not unequivocally determined, 
(ä-endorphin is most probably involved. Act ivat ion of release of ß-endorphin 
i s known to occur in stress (Guillemin 1977, Rossier 1977 2 ) , and shock 
states are characterized by profound stress. S ign i f i can t ly , endotoxemic 
shock is known to resul t i n secretion of ACTH (Moberg 1971), and ACTH is 
known to be released concomitant with 3-endorphin (Bloom 1978 2, Weber 1980, 
Przewlocki 1980). Adrenalectomy is known to increase suscept ib i l i t y to shock 
and ß-endorphin (Holaday 1977), and in the same instance the f a i l i n g feed-
back inh ib i t i on of c i rcu la t ing Cort isol on the hypothalamic-pituitary-
adrenal axis was shown to markedly increase the ACTH and ß-endorphin content 
i n the p i tu i ta ry (Guillemin 1977, Rossier 1977 (1,2) , Graf 1978) but may, 
however, also af fect enkephalin turnover (Hart 1980). Pr ior treatment with 
cort icosteroids diminished the storage as well as the release of fî-endorphin 
and ACTH (Sabol 1978, Sabol 1980, Rossier 1980 2, Sakakura 1981) from the 
p i t u i t a r y by means of feedback mechanisms. Therefore, i t reduces the plasma 
levels of ACTH and 0-endorphin, as was shown in humans (Krieger 1978). Due 
to t h i s , the effectiveness of naloxone in shock is markedly attenuated 
(Peters 1981). Surgical hypophysectomy w i l l eliminate the release of endor-
phins from the p i t u i t a ry and at the same time abolish the e f f e c t i v i t y of 
naloxone in shock (Holaday 1981). The experimental f indings c i ted above 
(see: f i g . 1-5, 1-8, 1-9) would indicate that the p i tu i ta ry is of prime 
importance. However, i t remains doubtful whether the endorphin content of 
the p i tu i ta ry is su f f i c ien t to account for a l l peripheral cardiovascular 
effects (Hess 1981, Lind 1980, Lind 1981). Thus, central mechanisms ( f i g . 
1-10; see below) may prove to be involved, which is fur ther indicated by the 
e f f e c t i v i t y of ventr iculocisternal administration of naloxone, which, in a 
dose not su f f i c ien t to give an ef fect ive plasma leve l , protected against 
severe hypotension during endotoxemic shock (Janssen 1980) and stereospeci-
f i c a l l y attenuated hypotension af ter spinal transsection (Holaday 1980). 
I t has been proposed that p i t u i t a ry peptides may gain access to central 
nervous system si tes (Bergland 1978, Bergland 1979, Mezey 1978, Rapoport 
1980), possible also by access to central nervous si tes not "protected" by 
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the blood-brain barr ier (Km'gge 1975, Weindl 1972; see Chapter I , Section 
I I ) . Sustained release may allow these peptides to gain access to areas 
sheltered by the blood-brain barr ier by a mechanism of accumulation, or due 
to a change in permeability of the blood-brain bar r ie r , as was shown to 
occur in hepatic fa i l u re (Schäfer 1982). The importance of the enkephalin-
l i k e peptides released by the adrenals ( f i g . 1-10; table I-A) remains to be 
determined. 
Naloxone was injected intravenously i n a dose of 5 mg per kilogram body 
weight i n three groups of pigs. In group one a thoracotomy was done as well 
as intravenous and i n t ra -a r te r i a l catheter izat ion, however, the c i rcu la t ion 
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Fig 1-10. During shock or severe stress a humoral factor is thought to be 
involved in the initiation of release of a releasing factor. Due to this, 
^-endorphin, ACTH, and ß-LPH will be liberated from a common precursor 
molecule. Target structures are present both in the central nervous system 
(CNS) and outside 
the blood-brain 
barrier. In the 
special circum-
stances of shock, 
0-endorphin releas-
ed from the pitui-
tary may gain ac-
cess to various 
central nervous 
system sites. 
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was not disturbed by progressive occlusion of the LAD. No drugs with known 
naloxone-reversi ble effects were used, or abolished pr ior to intravenous i n -
j ec t i on of naloxone. The change in cardiovascular variables was l imi ted to 
an instantaneous early reduction in the heart rate ( f i g . 1-4), and a return 
to base-line heart rate occurred wi th in 10 minutes. Bi lateral vagotomy f a i l -
ed to af fect th is ef fect of naloxone. Aspecific effects of naloxone are not 
l i k e l y to occur at th is dosage (Sawynok 1979, Dirksen 1980 1) , and in ter -
actions with etomidate anesthesia, d i rect effects on the heart, or a change 
i n sympathetic ac t i v i t y may account for the ef fect observed. At present, how-
ever, none of the poss ib i l i t i es can be disregarded. The other cardiovascu-
l a r variables remained at a constant l e v e l , thus confirming the observations 
of others (see above) on the absence of s ign i f icant effects by naloxone 
i t s e l f , and indicat ing the absence of cardiovascular effects of endorphins 
which have been released due to the surgical procedure (Finck 1977 2) . 
In group I I the LAD-flow was progressively reduced and th is caused d is-
turbance of the c i rcu la t ion as indicated by the cardiovascular var iables. 
Naloxone intravenously injected in a dose of 5 mg/kg body weight markedly 
affected the cardiovascular var iables. Ityocardial c o n t r a c t i l i t y quanti f ied 
by the maximum of the f i r s t der ivat ive of l e f t ventr icu lar pressures, the LV 
dP/dt, increased to above preocclusion values, and the cardiac output return-
ed to preocclusion values ( f i g s . 1-5, 1-6, and 1-7). These effects of 
naloxone are s imi lar to those observed in hypovolanic (Vargish 1980, Gurll 
1981) and endotoxemic hypotension (Reynolds 1980, Brückner 1981), but are 
at variance with the data on naloxone in hanorrhaged pigs (Salerno 1981). 
The main ef fect observed by these investigators include a substantial r ise 
i n blood pressures, no change in cardiac output and a substantial increase 
i n the peripheral resistance (Salerno 1981). The calculated peripheral resis-
tance in my experiments tended to decrease ( f i g . 1-5). An increase in the 
mean aort ic blood pressure was observed, and the systol ic blood pressure 
contributed to th is increase, as no change in the d ias to l ic blood pressure 
was measured. An instantaneous change in heart rate was observed af ter i n t ra -
venous in jec t ion of naloxone. An i n i t i a l decrease followed by a marked i n -
crease occurred. No naloxone-induced change i n heart rate was reported in 
e i ther endotoxanic or hemorrhagic hypotension (Reynolds 1980, Vargish 1980, 
Feuerstein 1981), however, methodological differences may explain th is d i f -
ference, as in these studies naloxone was injected pr ior to the induction of 
hypotension. Posit ive chronotropic effects of naloxone had been observed in 
endotoxin-shocked dogs subsequent to intracerebroventr icular adhii ni s t r a t i on 
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of the drug (Janssen 1980). Yet, the change proved to be transient and did 
not relate to the beneficial effects on other cardiovascular parameters. The 
substantial increase in heart rate may have increased the LV dP/dt, which is 
furthermore dependent on preload and af ter load. However, the l e f t ven t r i -
cular f i l l i n g pressure remained unchanged, the change i n calculated per i -
pheral resistance was minimal, and pacing studies had indicated that an 
increased heart frequency in ischanic hearts w i l l not contribute s ign i f i can t -
l y to an increase of dP/dt (Verdouw 1980), indicating that the observed i n -
crease in LV dP/dt re f lec ts an improved myocardial c o n t r a c t i l i t y , which 
secondarily improved the cardiac output and aort ic blood pressures. The time 
course of effects of naloxone indicates a biphasic mechanism, which is 
opposite to the biphasic response of cardiovascular variables af ter e i ther 
systemic (Lemaire 1978 1) or intracerebroventr icular endorphin (Laubie 1977 
1 , Feldberg 1978). 
In the th i rd group of pigs and in two monkeys an alcohol-induced adeno-
l ys is of the p i tu i ta ry gland preceded the progressive occlusions of the 
a r te r ia l blood supply to the l e f t ven t r i c le . After induction of a comparable 
disturbance in henodynamic var iables, naloxone was in jec ted. A biphasic 
change in heart rate occurred in pigs ( f i g . 1-4), but the changes were min i -
mal. S imi lar ly , the change in other hemodynamic variables was much less com-
pared to those of group I I , indicat ing that alcohol-induced adenolysis of 
the p i tu i ta ry gland, which did not cause s ign i f icant changes in the cardio-
vascular variables i t s e l f , markedly attenuated the naloxone-reversible 
component in cardiovascular changes. In monkeys in which alcohol-induced 
adenolysis of the p i t u i t a r y gland preceded the cardiovascular experiment by 
one week, the only observable change af ter naloxone in jec t ion was a reproduc-
able reduction in the heart rate which was not abolished by atropine. The 
observation that naloxone fa i led to i n s t i t u t e observable changes in hemo-
dynamic variables in shocked animals which had been hypophysectomized, 
substantiates the ear l ie r f indings by others (Holaday 1978). Whether the 
in jec t ion of th is amount of alcohol i n the sel la turcica caused a lesion or 
modif icat ion of functioning of the neuronal pro-opiocort in system (Nilaver 
1979, Bloom 1980, Osborne 1979, Rossier 1977 2; f i g . 1-10) remains to be 
detenni ned. 
Thus, the experimental results presented above indicate posi t ive effects 
of naloxone in disturbed c i rcu la t ion due to progressive occlusion of the 
LAD, and the substantial increase in l e f t ventr icu lar c o n t r a c t i l i t y was the 
one variable which may account for the improvement. The beneficial effects 
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depend on functional i n t e g r i t y of the hypothalaimc-pituitary-adrenal axis 
(Dirksen 1981 2; f i g . 1-11), as indicated by the attenuated effectiveness of 
naloxone af ter alcohol-induced adenolysis of the p i t u i t a r y gland. These 
f indings are i n accordance with e a r l i e r f indings of others (see above). 
Thus f a r , c l i n i c a l reports on the e f f e c t i v i t y of naloxone i n various 
forms of shock included observations on septicemic shock (Tiengo 1980, 
Dirksen 1980 4, Wright 1980, Peters 1981, Swinburn 1982), acute hepatic 
f a i l u r e (De Groot 1982), and cardiogenic shock (Dirksen 1980 4 ) . In the 
patients reported, naloxone i n j e c t i o n was associated with an instantaneous 
s i g n i f i c a n t improvement i n the c i r c u l a t i o n and c l i n i c a l condit ion of these 
pat ients. This indicates that the mechanisms discussed above apply to the 
human system, and th is means that a potential new approach to shock t reat­
ment may come f o r t h , but also that the mechanisms of withdrawal and over­
shoot may cause serious side effects (Dirksen 1981 3 ) . 
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В. Central nervous system structures involved in cardiovascular control and 
endorphins 
The central organization of cardiovascular regulation is complex and has 
not f u l l y been elucidated ( f o r a recent review see Galosy 1981). The endor­
phin mechanisms of cardiovascular control are even less well defined, how­
ever, an attempt w i l l be made to summarize some important recent f ind ings. 
An important system in cardiovascular control includes the baroreceptor 
r e f l e x , and endorphins may be thought to a f f e c t t h i s r e f l e x . 
The afferent f ibres ar is ing from the a r t e r i a l baroreceptors terminate i n 
a d i s t i n c t part of the nucleus tractus s o l i t a r i u s (NTS) (which is termed the 
cardiovascular nucleus tractus s o l i t a r i u s ) , and i n the paramedian r e t i c u l a r 
nucleus (Kerr 1962, Cottle 1975, Rhoton 1966, Miura 1972, Miura 1969, Berger 
1979, Katz 1979). A major putative transmitter substance of the baroreceptor 
afférents in the NTS is thought to be 1-glutamate (Taiman 1980, Perrone 
1980), and baclofen, which depresses the release of glutamate from tissue 
sl ices (Potaschner 1978), caused a consistent pressor response in conscious 
rats af ter local appl icat ion in to the region of the NTS (Persson 1981). How-
ever, intracerebroventr icular in jec t ion of baclofen led to marked hypo-
tension and bradycardia in cats anesthetized with pentothal (Bousquet 1981). 
Addi t ional ly , substance Ρ is thought to be involved i n f i r s t neuron 
transmission, and input mediated by substance Ρ neurons i s modulated by 
enkephalin (Fuxe 1980). Baroreceptor denervation was shown to increase the 
blood pressure and at the sane time enhanced the background a c t i v i t y of the 
white ramus (Danbowsky 1980). E lectr ica l st imulat ion of the NTS was shown to 
stimulate the baroreceptor ref lex and produced hypotension and bradycardia 
(Cri 11 1968). Bi latera l lesions in the NTS w i l l resul t in neurogenic hyper­
tension (Reis 1981) due to an intensive vasoconstriction secondary to 
augmented discharge of preganglionic sympathetic nerves (Doba 1973) and an 
increased release of adrenal catecholamine (Doba 1974). The expression of 
NTS lesion-induced hypertension was shown to be dependent on Intact long-
loop cardiovascular reflexes with higher brain levels (Doba 1973), as well 
as on descending noradrenergic t racts to the spinal cord (Doba 1974). 
In spontaneous hypertensive r a t s , naloxone blocked cloni di пе-induced 
hypotension and bradycardia 1n a dose-dependent fashion, although these 
drugs do not interact with the same receptor sites i n the brain (Farsang 
1979, Farsang 1980, Golembiowska-Nikitin 1980). The naloxone-reversible hypo­
tension due to a-adrenergic receptor st imulat ion in spontaneous hypertensive 
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rats indicated that the cardiovascular effects of central »-adrenergic 
receptor st imulat ion are mediated by endorphins. I t has been recently shown 
t h a t destruction of the NTS abolished the hypotensive and bradycardiogenic 
ef fects of Clonidine i n spontaneous hypertensive rats (Rockhold 1979), where­
as microin ject ion of Clonidine into the NTS resulted i n dose-dependent 
yohimbine-reversible hypotension and bradycardia (Rockhold 1980). This 
Clonidine e f f e c t was not observed i n nonnotensive rats (Farsang 1980). The 
d i f f e r e n t responses of these two strains of rats may prove to be related to 
d i f f e r e n t concentrations of vasopressin and somatostatin i n the bra in, or to 
a dopaminergic defect (Negro-Vil lar 1980, Hutchinson 1981). Stressed 
spontaneous hypertensive rats were found to have high concentrations of 
vasopressin and low concentrations of somatostatin i n various regions of the 
brain ( including the nucleus arcuatus); whereas basal levels did not d i f f e r 
s i g n i f i c a n t l y (Negro-Vil lar 1980), as was found in other areas related to 
cardiovascular control which were shown to contain s i g n i f i c a n t amounts of 
vasopressin including the neurohypophysial hormone synthesizing nuclei of 
the hypothalamus and the nucleus tractus s o l i t a r i u s (Dogterom 1980). The 
ef fects of vasopressin were shown to include regulation of ACTH (and thus 
ρro-opiocort in-related peptide) secretion (Przewlocki 1980) and changes i n 
catecholamine turnover (Van Wimersma-Greidanus 1980). The deta i ls on the 
organization of projections of vasopressin pathways and the relat ions 
towards other transmitter systems await fur ther evaluation (Zinmerman 1981). 
Intracerebroventr icular somatostatin was shown to cause a marked f a l l in 
blood pressure with a para l le l f a l l i n plasma catecholamines (Weitzman 
1979), and t h i s may indicate that somatostatin is involved i n primary neuron 
transmission, as somatostatin may be Involved in modulation of the excita­
tory glutamate response (Padjen 1977, l o f f e 1978). The involvement of 
endorphin mechanisms in the NTS is indicated by observations on cardio­
vascular changes observed a f t e r local i n j e c t i o n of endorphin and endorphino-
mimetics. S-endorphin Injected Into the NTS resulted in a biphasic change in 
blood pressures s imi lar to the changes observed af ter intravenous I n j e c t i o n 
of the peptide (Lanaire 1978 1, Petty 1981). Intracerebroventr icular 
infusion of naloxone-containing solutions (Janssen 1980, Arndt 1979) caused 
a s l i g h t increase i n blood pressures, which may indicate tonic a c t i v i t y of 
the endorphin subsystems. Local i n j e c t i o n of fentanyl decreased the f i r i n g 
of blood pressure-dependent neurons in the NTS (Laubie 1977 2 ) . 
The nucleus tractus s o l i t a r i u s appears to be a s i t e of action of 
α-methyl dopa (De Jong 1979), and α-methyl dopa was shown to cause naloxone-
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reversible hypotension in spontaneous hypertensive rats (Farsang 1980). This 
action may be thought to involve the release of endorphin, as both methyl-
adrenaline and Clonidine were shown to release 3-endorphin from superfused 
sl ices of the brain stem of spontaneous hypertensive ra ts , and th is action 
was blocked with yohimbine (Kunos 1981). The fa i l u re of yohimbine to anta-
gonize the hypotension and bradycardia of morphine indicated that the endor-
phinergic component is d is ta l to the adrenergic (Farsang 1980). 
The observation that endorphinomimetics induced bradycardia and hypoten-
sion in NTS-lesioned dogs (Laubie 1977 1) , indicated that although evidence 
had accumulated on the importance of the NTS in endorphinergic cardiovas-
cular cont ro l , other areas had to be important as we l l . These may include: 
1 . the nucleus ambiguus, which was shown to contain blood pressure-dependent 
neurons inhib i ted by fentanyl (Laubie 1977 1) , and proved to be extremely 
sensit ive to local in jec t ion of an enkephalin analog (Laubie 1979); 
2 . the nucleus re t i cu la r i s g igantocel lu lar is that , apart from d i rec t l y 
e l i c i t i n g card io- inh ib i t ion (Chan 1980, Kuo 1980, Kuo 1979), proved to 
have a modulatory role in the regulation of the c i rcu la t ion (Chen 1980, 
Chan 1980); and 
3. the dorsal and median raphe nucleus, stimulation of which caused an 
increase in blood pressures (Smits 1978) associated with act ivat ion of an 
ascending serotonergic neuronal system (including projections to the 
nucleus arcuatus, the median eminence, and the locus coeruleus (Smits 
1978, Palkovits 1977, Moore 1978)), and involved norepinephrine from 
postganglionic sympathetic nerve endings (Kuhn 1980, Coote 1981). In the 
v i c i n i t y of the c i rcu la tory excitatory si tes are the c i rcu la tory 
inh ib i to ry s i tes , which may explain d i f fe ren t ia l f indings regarding the 
effects of st imulat ion. Thus, st imulat ion in the nucleus raphe pal l idus 
and obscurus caused a reduction in sympathetic discharge (Gilbey 1981, 
Coote 1975). The function of serotonergic projections involves neuronal 
pathways, but may also involve a release of serotonin in to the CSF 
(Aghajanin 1975, Chan-Pal ay 1976), and the importance of both remains to 
be elucidated. 
A schematic representation of some of the important functional and 
anatomical relationships c i ted above (see also Aoki 1966, Chai 1962, Chen 
1976, Gunn 1968, Kerr 1969, Kirchheim 1976, Körner 1971, Kuo 1979, Kuo 1980, 
Lipski 1976, Loewy 1978, Munzner 1976, Putman 1977, Galosy 1981) w i l l be 
given in Section I I ( f i g . 11-27; Section I I , Chapter I V . C ) . 
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С. Nociceptive signal transmission and endorphins 
The o r i g i n of a nociceptive signal is thought to involve C-fibre and 
A j - f i b r e endings, which transduce a physical stimulus i n t o an action 
p o t e n t i a l , propagated along the C- and A^-fibres (C and A; f i g . 1-12, and 
f i g . I I - l ) . S imi lar ly , st imulation of these nerves may be associated with 
pain, indicat ing that no specialized organ i n i t i a t e s a code which is 
translated i n t o pain. After entering the spinal cord (SPC(8); f i g . 1-12), 
the signal is thought to be fed into an extensive integrat ive neuronal 
network, which involves various transmitter and modulator substances (see 
Chapter I , Section I I ) . From the spinal cord defined pathways ascend to 
higher centres of the central nervous system. 
During the transmission of the nociceptive s ignal , extensive elaboration 
occurs. Upon arr iva l at the integrat ive network, the spike potentials are 
rearranged into a frequency code which may serve as an input to p a r t i c u l a r 
thalamic neurons ( f o r additional information: see Enrners 1981). At the same 
t ime, the propagation of the nociceptive signal includes short as well as 
long feedback loops, which w i l l i n s t i t u t e a modulating e f f e c t on subsequent 
spike potentials arr iv ing at a spinal level (signal modulat ion)( f ig. I I - l ; 
see Dirksen 1981 1 , Dirksen 1982, Oirksen to be published). 
The s ignal , contained in the rearranged spike potential frequency and as­
cending i n the spinothalamic t r a c t , may (or may not) be able to act ivate a 
reverberating c i r c u i t which was shown to involve the somesthetic area of the 
thalamus (1) and the centrum median-parafasciculus nuclear complex (2) ( f i g . 
1-12). I f the result ing frequency-coded spike potentials of t h i s reverbera­
t i n g c i r c u i t are f i t f o r c o r t i c a l decoding, then noci-perception occurs (see 
Emmers 1981). 
Antinociceptive measures may be thought to aim at a l ter ing the sequence 
of events described above. Consequently, i t may be presumed that such 
measures w i l l e i ther prevent the act ivat ion of the reverberating c i r c u i t , 
o r , a l t e r n a t i v e l y , d isturb the cycl ic pattern i n such a manner that c o r t i c a l 
decoding is impossible. 
The physiological function of endorphin transmission or modulation at 
the various levels of t h i s putative "pain" system is presently unknown. 
Endorphin may pr imari ly be involved in the process of elaboration of the 
nociceptive s ignal . I n i t i a l l y , th is elaboration may include f a c i l i t a t i o n as 
to contribute to the délivrance of the message to the c i r cu i t s described 
above, whereas once the message is del ivered, a process involved in tenni na-
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Fig. 1-12. Relationships of important 
central nervous system structures involved 
in nociceptive signal transmission (see text). 
1, somesthetic region of the thalamus, the 
arrows indicate the presence of a rever­
berating circuit with the centrum medianum-
parafasciculus nuclear complex; 2, centrum 
medianum-parafasciculus nuclear complex; 
3, periaqueductal grey; 4, mesencephalic 
reticular formation; 5, nucleus locus coeruleus; 
6, nucleus raphe magnus; 7, nucleus reticularis 
gigantocellularis; 8, spinal cord: M = motor 
output, S = sympathetic outflow, С = C-fibre; 
A = Ag-fibre, DRG = dorsal root ganglion; 9, nucleus 
infundibularis (nucleus arcuatus); 10, corticomedlal 
nucleus amygdalae; 11, pituitary; END = 3-endorphin; 
arrow = cortical projection. 
(This figure has been drawn with the aid of: The Human 
Central Nervous System; Nieuwenhuys, Voogd, 
Van Huyzen; Springer-Verlag N.Y., 1978). 
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t i o n of the signal transmission may be i n i t i a t e d . As to the reverberating 
c i r c u i t , termination of the cycl ic discharge may prove to involve de-
i n h i b i t i o n of the periaqueductal grey neurons (PAG ( 3 ) ; f i g . 1-12 and f i g . 
I I - l ) , whereas prevention of unnecessary subsequent act ivat ion may prove to 
employ de- inh ib i t ion of the descending pathways to the spinal cord (see 
Section I I , Chapter I ) . The effects of opiates on the a c t i v i t y of the 
reverberating c i r c u i t are l imi ted to suppression of the secondary 
components, which occur af ter the i n i t i a l short-latency spike burst (Enrners 
1981). This may relate to the preferent ia l effects on C-fibre transmission 
and the e f f e c t i v i t y i n "hurt ing" (second) pain (see Section I I ) . 
Mapping of s i tes where micro-inject ions of endorphinomimetics e l i c i t e d 
analgesia (Yaksh 1978 5) or where naloxone attenuated analgesia by systemic 
endorphinomimetics, as well as studies involving lesioning which establ ish­
ed or attenuated analgesia, have contributed to knowledge on structures 
involved i n nociceptive signal transmission. Endorphin modulation of signal 
t ransfer is present at various levels (see f i g . 1-12, and f i g . I I - l ) and 
involves signal transfer to f i n a l decoding centres as well as the "loop 
system". At a spinal l e v e l , endorphins and endorphinomimetics w i l l suppress 
nociceptive signal transmission. Intrathecal in ject ion of endorphins or 
endorphinomimetics is associated with a dose-dependent naloxone-reversi ble 
analgesia (see Section I I ) , which recently proved to be of signif icance f o r 
c l i n i c a l appl icat ion (see Section I I , Chapter IV). A nociceptive stimulus i n 
the human i s characterized by the presence of an R-III response in the 
efferent signal (Kugelberg I960, Wi l ier 1976, Wil ier 1977). Naloxone, an 
endorphin antagonist, f a i l e d to af fect these nociceptive ref lexes, save for 
an exceptional s i t u a t i o n which is met in the rare syndrome of congenital 
i n s e n s i t i v i t y to pain (Dehen 1978 ( 1 , 2 ) , Dehen 1977). This i s a strong 
ind icat ion that normally the endorphin modulation of signal transmission is 
an on-demand process. Recently i t was shown that i n the human, inescapable 
footshocks and r e p e t i t i v e stress induced by the ant ic ipat ion of pain 
resulted i n a progressive increase i n heart rate and respiratory frequency, 
as well as f a c i l i t a t i o n of the Η-reflex, paral le l to an i n h i b i t i o n of the 
polysynaptic R-III ref lex (Wi l ier 1975). Naloxone resulted i n s i g n i f i c a n t 
exacerbation of the vegetative response (tachycardia, polypnea), indicat ing 
reversal of endorphin effects involving supraspinal centres. Furthermore, 
the f a c i l i t a t i o n of the Η-reflex was increased, while the R-III ref lex was 
dramatically f a c i l i t a t e d (Wi l ier 1980). This indicates that pain i t s e l f or 
stress act as an input to a naloxone-reversi ble (putat ive endorphinergic) 
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change of nociceptive ref lexes. 
Such naloxone-reversible (putat ive endorphinergic) mechanisms are 
thought to be involved in "stress-induced analgesia" (Amir 1979, Amir 1978) 
and analgesia af ter transcutaneous st imulat ion (Abram 1981). However, as 
naloxone does not f u l l y reverse analgesia secondary to ei ther stress or 
transcutaneous st imulat ion, and as the extent to which such analgesia is 
naloxone-reversible, d i f f e rs amongst various species (Aki l 1978 1 , Goldstein 
1976), i t may be thought that the "pain set-point" involves many transmitter 
systems (see f i g . I I - l ; see Section I I , Chapter I ) . As to the endorphinergic 
transmission and/or modulation, two kinds of peptides, the enkephalins and 
¡ä-endorphin, are involved (Chapter I ) . Enkephalinergic transmission is most 
abundant and present in various central nervous sytem s i tes , while the 
3-endorphinergic projections in the central nervous system or ig inate mainly 
i n the arcuate nucleus ( infundibular nucleus (9) , table I-A). 
Schematic representations of various nuclei and neuronal projections 
involved in nociceptive signal transmission and the modulatory endorphin-
ergic mechanisms are presented in f i g . 1-12 and f i g . I I - l . 0-endorphinergic 
projections or iginat ing in the arcuate nucleus project to the locus 
coeruleus (LC (5)) (Watson 1978 2 ) , which structure was shown to contain 
endorphin receptors (Snyder 1975). Morphine analgesia was attenuated by 
b i la te ra l lesioning of th is area (Sasa 1977). The cor t i comedi al nucleus of 
the amygdalae (CM Nucl Amygd (10)) was shown to receive projections from the 
locus coeruleus, the periaqueductal grey (Deakin 1978), and the nucleus 
arcuatus (Watson 1978 2) . Bi lateral in jec t ion of morphine in the CM Nucl 
Amygd resulted in analgesia (Rodgers 1977 1) which is thought to involve 
dopaminergic transmission (Rodgers 1978, Rodgers 1977 2) . Additional 
^-endorphinergic projections include f ibres which are thought to secrete 
in to the cerebrospinal f l u i d (CSF) (see table I-A) and f ibres to the PAG. 
Footshock stress was shown to cause a marked reduction in ß-endorphin immuno-
reac t iv i t y i n the PAG (Przewlocki 1980) and ß-endorphin is known to ex is t i n 
th i s area in nerve tenni nal s and f ibres (Bloom 1978 2) . In addit ion to the 
0-endorphinergic innervat ion, enkephalins are present as well (Simantov 1976 
1) . The effects of these two endorphinergic neurotransmitters or neuro-
modulators is mediated by the endorphin receptor which is loca l l y present 
(Kuhar 1973) (see Chapter I I ) . In ject ion of endorphinomimetics in to the PAG 
resulted in analgesia (Herz 1970, Deakin 1978). The PAG does not have 
s ign i f i can t project ion to the spinal neurons in the spinal cord, but is 
believed to exert i t s influence on spinal neurons in the spinal cord (8) v ia 
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a relay i n the more caudal midline nucleus raphe magnus (NRM (6)) (Basbaum 
1979, Basbaum 1978, Fields 1978, Bowsher 1978). Stimulation of the PAG (as 
well as st imulation i n 3-endorphinergic pathways) is known to i n s t i t u t e anal­
gesia (Richardson 1977 ( 1 , 2 ) , Richardson 1982), possibly secondary to a dis­
turbance of the cycl ic events i n the reverberating c i r c u i t of the centrum 
median-parafasciculus nuclear complex (2) and the somesthetic region of the 
thalamus (1) (Emmers 1981), as well as to an act ivat ion of descending path­
ways. Lateral ly the PAG is bordered by the mesencephalic r e t i c u l a r formation 
(4) and the l a t e r a l aspect of th is nucleus was shown to have endorphinomi-
metic-responsive sites (Pert 1974, Haigler 1978). The nucleus r e t i c u l a r i s 
g igantocel lu lar is (NRGC (7)) is activated by Ag-fibre st imulat ion (Casey 
1969), and, in general, input to spinoret icular f ibres was shown to or ig ina­
t e in the more deeply-lying intermediate grey matter (laminae V I , V I I , and 
V I I I ) of the spinal cord (Levante 1972, Fields 1975), at which s i t e the f i b ­
res of the more dorsal ly situated spinal neurons have converged. Act ivat ion 
of ascending transmission occurs af ter noxious st imulation (Fields 1977 2 ) . 
Micro-inject ion of morphine into the NRGC resulted i n a dose-dependent 
naloxone-reversible analgesia associated with a dose-dependent i n h i b i t i o n of 
noxious stimulus-induced a c t i v i t y of lamina V c e l l s , which are involved i n 
transmission of a nociceptive signal at a spinal level (Takagi 1976, Takagi 
1978). The descending f ibres to the spinal cord are thought to the catechol-
aminergic (Takagi 1975), and phenoxybenzamine was shown to antagonize anal­
gesic effects of microin ject ion of morphine into the NRGC (Kuraishi 1979). 
The a b i l i t y of microinjections of morphine into the NRGC to i n s t i t u t e 
analgesia required i n t e g r i t y of the NRM (Azani 1980 ( 1 , 2 , 3 ) ) . Thus, the NRM 
i s of Importance to morphine-induced analgesia and serves as an important 
relay for descending pathways which are de-inhibited by endorphinomimetics. 
Stimulation of the NRM caused a marked i n h i b i t i o n of noxious stimulus-
induced a c t i v i t y in dorsal horn c e l l s of the spinal cord (Beali 1976, 
Guilbaud 1977, Fields 1977 1 ) . The NRM is not thought to be a relay for 
coeruleospinal projections (Iggo 1981). Lesion of the NRM attenuated 
morphine analgesia (Proudf i t 1975). 
Systemically injected endorphinomimetics w i l l not l i m i t t h e i r action to 
a single endorphin receptor-containing s i t e but rather involve a l l struc­
tures. Access to these ( f i g . 1-12, f i g . I I - l ) w i l l depend on k inet ic v a r i ­
ables; presently i t i s not established with certainty whether β-endorphin 
released by the p i t u i t a r y (PIT (11)) w i l l also involve the various endorphin 
receptor-containing s i tes in i t s actions. 
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SECTION I I 
SPINAL MECHANISMS OF NOCICEPTIVE SIGNAL TRANSMISSION AND THEIR 
CLINICAL RELEVANCE 
In Section I , a general description of the endorphin system and i ts 
involvement in aspects of cardiovascular and sensory homeostasis was 
presented. In this section, the experimental data on the involvement of the 
anatomically-distinct spinally-located endorphin subsystem in nociceptive 
signal transmission and its relationships to the other systems, wil l be 
presented and discussed. Finally, the accessibility of this system allowed 
the clinical introduction of more sophisticated means for "analgesia". 
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CHAPTER I 
Transmitters and Modulators at a Spinal Level Involved In 
Nociceptive Signal Transmission 
A. Transmitters and/or modulators of the afferent neuronal circuit and the 
descending pathways 
a. Introduction 
As was described in Section I (Chapter I I I ; see f i g . 1-12, f i g . I I - l ) , 
the nociceptive signal is considered to or iginate in Ag- and C-f ibre 
endings. After the signal has entered the spinal cord, i t is thought to be 
fed in to an extensive integrat ive neuronal network. From the spinal cord, 
the signal ascends onto various defined centres of the central nervous 
system, and from several of these, descending pathways or ig inate. These 
descending pathways serve to feed the signal back on the spinal system. 
Consequently, the transmitters and/or modulators at a spinal level may be 
c lass i f ied as being involved in transmission and/or modulation of the 
afferent neuronal connections or as being involved in the feedback loops. 
b. Transmitters and/or modulators of the afferent neuronal c i r c u i t at a 
spinal level 
Probably, many transmitter or modulator substances are involved in the 
afferent limb of nociceptive signal transmission at a spinal l eve l . Recent-
l y , vasoactive in tes t ina l peptide (VIP), cholecystokinin (CCK), and panhibin 
have been local ized in dorsal root ganglia and primary afferent terminals in 
the dorsal horn (Hökfelt 1976, Fuxe 1977, Larsson 1976, Larsson 1979, Loren 
1979 (1 ,2 ) ) . Moreover, dopamine, which also proves to be a transmitter sub-
stance involved in the descending pathways (Hökfelt 1979 2 ) , was found to 
ex is t in an intraspinal dopaninergic system (Commissiong 197Θ, Karoum 1980). 
Unfortunately, the functional aspects of these transmitter systems has as 
y e t not been defined. 
Two transmitter and/or modulator substances found at a spinal l e v e l , 
I .e . endorphin and substance P, have been subject of many studies, and some 
functional aspects have been defined. 
A 
Fig. II-l. The transmitters and/or modulators at a 
spinal level may be classified as being involved in 
transmission and/or modulation of the afferent 
neuronal connections (I.e. substance Ρ and 
enkephalin) or as being involved in the feedback 
loops (i.e. serotonin and noradrenaline) (C -
C-fibre; A = A^-fibre; INT = integrative neuronal 
network, ENK. = enkephalin; SP = substance P, ser • 
serotonin; ne = noradrenaline; - • inhibitory; + " 
excitatory;! = inhibitory interneuron, PAG-PVG -
periaqueductal and periventricular grey. Mes. Ret. 
Form. = mesencephalic reticular formation; B.R.F. » 
bulbar reticular formation, Nucl. Raphe M. « 
nucleus raphe magnus (from Dirksen 1981 1, see also 
fig 11-27). 
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b . l . The endorphins at a spinal level 
At a spinal l eve l , two elements of the endorphin system (see Chapter I , 
Section I ) were i den t i f i ed : (1) The endorphin receptors, autoradiographi-
ca l l y i den t i f i ed , were shown to be associated with the primary afférents 
(Pert 1975, LaMotte 1976, Atweh 1977 1) . Furthermore, h igh-a f f in i t y binding 
s i tes of endorphins and endorphinomimetics were shown to be present (Fields 
1980, Kelly 1980); (2) High levels of enkephalin, one of the natural ligands 
fo r the endorphin receptor, were detected, and were found to be associated 
wi th ce l l bodies and nerve terminals in laminae I-V and lamina VII (Rexed 
1952)(Simantov 1976, Hökfelt 1977, Johansson 1978 1 , Neale 1978). More 
recent ly, enkephalin was shown to be located in peptidergic neurons (Neale 
1980). The a b i l i t y to release enkephalin from the spinal cord (Yaksh 1981 1) 
and the presence of spontaneous as well as Ca -dependent К -induced 
release of met-enkephalin by spinal cord c e l l i n culture (Neale 1980), would 
indicate a transmitter or modulator funct ion. Local processing of t h i s 
peptide is indicated by the a b i l i t y of spinal cord c e l l s to incorporate 
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S-L-methionine i n t o molecules with physicochemical properties of 
met-enkephalin (Neale 1980, Sosa 1978), and the a b i l i t y of i n h i b i t o r s of 
cytoribosomal protein synthesis to abolish such incorporation (Neale 1980). 
The effectuator has not been i d e n t i f i e d , although the effectiveness may 
be thought to relate to the a b i l i t y of local ly-appl ied morphine and 
enkephalin to reduce, in a naloxone-reversible fashion, the response of 
c e l l s in lamina I I and I I I (Duggan 1976, Davies 1978, Randic 1978) (see 
Chapter I I , Section I ; see Chapter I I , Section I I ) . 
In addition to the enkephalin(s), dynorphin ( B o t t i c e l l i 1981) and the 
pro-opiocort in peptides may prove to be involved in receptor-mediated 
events. Various reports on the presence of natural l igand i n the CSF have 
appeared (Terenius 1975 1 , Wahlström 1976, Aki l 1978 2, Same 1978), and 
although part of i t may prove to be enkephalin, ß-endorphin is most probably 
involved as well (McLoughlin 1980). The functional implications related to 
the presence of these various ligands fo r the endorphin receptor remain to 
be determined (see Section I , Chapter I I ) . 
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b.2. Substance Ρ 
A transmitter function of substance Ρ in the f i r s t sensory neuron was 
proposed i n 1953 (Lembeck 1953). Evidence supporting t h i s theory has since 
accumulated, i . e . : 
1. Substance Ρ was shown to be present in high concen­
t r a t i o n s in the Lissauer t r a c t , and laminae I , and I I , 
of the dorsal horn (Hbkfelt 1975, Kanazawa 1976, 
Takahashi 1975, Pernow 1980) 
2. Substance Ρ was shown to be located over synaptic 
vescicles in small-diameter afferent terminals 
(Chan-Palay 1977, Cuello 1977, Pickel 1977), and the 
highest concentration of substance Ρ was found i n nerve 
terminal regions (Kanazawa 1976) 
3. S igni f icant concentrations of substance Ρ were shown to 
be present in nerve endings of the spinal cord, higher 
i n the dorsal half than i n the ventral h a l f , and high-
3 
a f f i n i t y specif ic binding of ( Hjsubstance Ρ in the 
synaptic membrane suggested a transmitter ro le for sub­
stance Ρ (Nakata 1978) 
4 . Local production of substance Ρ was indicated as 
35 ( S)-methionine was found to be incorporated i n 
substance P-containing isolated sensory (dorsal root) 
ganglion (Harmar 1980) 
5. L igat ion of cat dorsal roots resulted i n accumulation 
of substance Ρ d i s t a l to the l igated horn, indicat ing 
synthesis in neuronal bodies i n the root ganglia and 
axonal transport to the nerve terminal regions 
(Takahashi 1975), where the concentration of substance 
Ρ was shown to be highest (Kanazawa 1976) 
6. Section of the s c i a t i c nerve produced a dramatic 
depletion of substance Ρ in the dorsal root ganglion 
and the dorsal horn, and t h i s ref lects degeneration of 
substance P-containing primary sensory neurons (Jessell 
1979) 
7. Two to three weeks af ter dorsal root sectioning, super­
s e n s i t i v i t y a t t r i b u t a b l e to an increase in receptor 
s i tes was shown to develop, and th is strongly supports 
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the notion that substance Ρ exerts a neurotransmitter 
ro le for primary afferent f ibres (Nakata 1979) 
8. The occurrence of potassium-induced Ca -dependent 
release of substance Ρ from sensory neurons i n ce l l 
cultures (Mudge 1979) and synaptosomes (Lanbeck 1977) 
9. Substance Ρ was shown to be released during st imulat ion 
of the dorsal roots (Otsuka 1976) 
10. lontophoret ical ly-appl ied substance Ρ in the cat spinal 
cord had excitatory effects (Henry 1974), and the c e l l s 
responding to chemical noxious st imulation were s imi lar­
l y responsive to application of substance P-analog 
(Wright 1980). 
1 1 . Single doses of capsicain, a substance which depletes 
substance Ρ from primary neurons (Jessell 1978, 
Yanagisawa 1980), induced last ing anti nociception to 
chemical, thermal, and pressure st imul i (Hayes 1980, 
Lembeck 1980) 
12. In dissociated mouse spinal neurons grown in t issue, 
substance Ρ was shown to have caused a fast-exci tatory 
t r a n s m i t t e r - l i k e response (Barker 1980). 
b.3. Functional relationships of substance Ρ and endorphin to the afferent 
neuronal c i r c u i t 
An Intimate relat ionship of substance Ρ transmission to endorphin trans­
mission is indicated by the l o c a l i z a t i o n of substance Ρ i n laminae I and I I 
of the dorsal horn, as s imi lar ly high concentrations of endorphins were 
shown to be present i n these layers. Moreover, the reduction of opiate 
receptor binding and the decrease in substance Ρ af ter s c i a t i c nerve section 
and dorsal rhizotomy provided evidence that opiate receptors may be pre-
synaptical ly-located on the terminals of substance P-containing primary 
afferent neurons in the substantia gelatinosa (Jessell 1979, Lembeck 1980). 
Enkephalin was shown to cause release-inhibi t ion of substance Ρ from sensory 
neurons in cul ture (Mudge 1979); substance Ρ antagonized morphine analgesia 
(Stern 1976); and, recently, intrathecal morphine was shown to i n h i b i t 
substance Ρ release from the mammalian spinal cord (Yaksh 1980). Yet, the 
mechanisms of nociceptive signal transmission may prove to be f a r more com-
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p l i c a t e d , as (see above) substance Ρ is one of the candidates of primary 
sensory neuron transmission, and other substances may be involved as w e l l . 
Another functional aspect to consider i s , that substance Ρ i t s e l f was 
reported to cause analgesia (Starr 1978, Stewart 1976). Further characteriza­
t i o n indicated a dose-dependent dual action of hypo- and hyperalgesia (Oehme 
1980). The naloxone-reversibi l i ty of substance P-induced analgesia has been 
reported (Frederickson 1978, Stewart 1976). This may re late to an endorphin 
mechanism of substance P-antinociception. Substance Ρ does not, however, 
i n t e r a c t with the endorphin receptor (Terenius 1975 2, Frederickson 1980). 
Mechanisms of substance P-induced analgesia may include: the involvement of 
serotonergic transmission (Szreniawski 1980; see below: The transmitters and 
modulators of the descending tracts and nociceptive signal transmission at a 
spinal l e v e l ) , enzyme i n h i b i t i o n by substance Ρ of aminopeptidases involved 
i n breakdown of enkephalins (Chrusciel 1980, Barclay 1980), and, possibly, 
the presence of a substance Ρ receptor at the enkephalin neurons ( f i g . 
I I - 2 ) . 
SIGNAL 
Fig. II-2. Schematic representation of functional relationships of sub­
stance Ρ (SP) and endorphin to the afferent neuronal circuit (- = 
enzyme inhibition, R - substance Ρ receptor, ENK • enkephalin). 
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с. The transmitters and/or modulators of the descending t racts and 
nociceptive signal transmission at a spinaT level 
Both serotonergic and noradrenergic pathways projecting from the brain 
to the spinal cord have been proposed (Dahlström 1965). Serotonin and 
substance Ρ or enkephalin are thought to co-exist i n c e l l bodies and nerve 
terminals of these descending systems (Hökfelt 1978, Chan-Palay 1978, 
Hökfelt 1979 1 , Bowker 1981), indicat ing that the existence of transmitters 
and/or modulators is ruled by the law of metabolic unity (Eccles 1957, 
Hökfelt 1980). However, these findings are mainly based on morphological 
studies and the functional implications of such a coexistence is presently 
hypothet ical . The serotonergic and noradrenergic descending projections are 
thought to be inh ib i to ry (centr i fugal pain-inhibit ing)(01eson 1978, Basbaum 
1977, Mayer 1976). Stimulation of the bulbospinal projections ( fo r example 
by periaqueductal grey st imulation) caused an increased a c t i v i t y , and 
induced analgesia which was antagonized by monoaminergic antagonists (Yaksh 
1978 2, Kuraishi 1979). Local in jec t ion of serotonin or adrenaline, ei ther 
in t ra thecal ly (Yaksh 1979 1 , Reddy 1980, Yaksh 1981 2) , or by iontophoretic 
appl icat ion (Engberg 1966, Headly 1978, Belcher 1978 1) , reduced the effects 
of noxious st imulat ion. Naloxone did not reduce these noradrenergic or 
serotonergic effects (Headly 1978), indicat ing that these effects are not 
mediated by endorphin transmission. I t was proposed that morphine induces an 
act ivat ion (de- inhib i t ion) of the noradrenergic descending pathways which is 
rapid in onset and short i n durat ion, and that the act ivat ion (de-
inh ib i t i on ) of serotonergic pathwôys is slow in onset and has a long 
duration (Shiorni 1978). 
c l . Serotoni η 
The periaqueductal grey proves to be essential f o r morphine a c t i v i t y , 
and involves de- inh ib i t ion of serotonergic descending pathways. Morphine i n ­
jected into the periaqueductal grey induced a dose-dependent and naloxone-
reversible increase in serotonin release or turnover at a spinal l e v e l , as a 
resu l t of an enhancement of nervous impulse flow (Yaksh 1979 (2,3) , Shiomi 
1978), and methysergide in t rathecal ly injected reduced the analgesic ef fect 
of such an i n j e c t i o n (Yaksh 1979 3 ) . These effects indicate a d i s i n h i b i t o r y 
influence of morphine i n these structures, associated with an increased re­
lease of the transmitter substance at a spinal l e v e l . E l e c t r o l y t i c destruc­
t i o n of the midbrain raphe nuclei (Samanin 1970, Yaksh 1977 3, Deakin 1978), 
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and the nucleus raphe magnus (Proudfit 1975), attenuated morphine-induced 
analgesia, and t h i s indicates that these structures serve as an i n t e r ­
mediate. In addition to the descending i n h i b i t o r y project ions, serotonergic 
innervation in ascending t racts proved to be important as well (York 1978). 
Interrupt ion of these f ibres was associated with an increase of a f fect ive 
threshold. 
Global interference with the serotonergic system result ing in a reduced 
concentration of serotonin (5-HT) in the CNS, induced hyperalgesia in 
animals (Lyt le 1975, Tenen 1967), and in man (Sicuter i 1973), and i t was 
shown to attenuate morphine-induced antinociception. Selective i n h i b i t i o n of 
5-HT reuptake produced hypoanalgesia, and potentiated morphine-induced a n t i ­
nociception (Sugrue 1976, Messing 1975, Johansson 197Θ 2, Van Loon 1978). 
Pethidine and methadone, proved to be exceptions i n regard to these effects 
(Sugrue 1979). Thus, a reduced 5-HT content was not associated with a re­
duced e f f e c t i v i t y (Tenen 1968), and i n h i b i t o r s of 5-HT reuptake did not 
increase the e f f e c t i v i t y (Sugrue 1979). The e f f e c t i v i t y of lower doses of 
pethidine were actually abolished by zimelidine (Gebhart 1980). 
с . 2 . Noradrenaline 
I n addition to these interact ions with functional aspects of the seroto­
nergic system, noradrenergic projections are involved. Thus, morphine in an 
analgesic dose increased the ponto-spinal i n h i b i t i o n of a nociceptive signal 
(Satoh 1970 ( 1 , 2 ) ) . The c e l l bodies wich give o r i g i n to these noradrenergic 
projections are thought to be situated in the A,, A^, and A,-, c e l l 
groups (Dahlström 1965, Satoh 1977). Noradrenaline released by nerve 
endings of the descending projections to lamina V, which were shown to 
or ig inate in the bulbar re t i cu la r formation (Takagi 1975, Kuraishi 1979),is 
thought to i n h i b i t the afferent nociceptive signal transmission (Anden 1963, 
Westman 1971). This explains the observations that intrathecal noradrenaline 
attenuated the response of spinal neurons to noxious peripheral st imulat ion 
(Belcher 1978 1 , Hicks 1978). As naloxone was shown not to reverse these 
spinally-mediated effects of noradrenaline (Headly 1978), endorphin trans-
mission i s not l i ke l y involved. However, as was indicated above, opiates did 
enhance nervous impulse flow of the noradrenergic project ions, and th is 
e f fec t was naloxone-reversible (Shiomi 1974). The loca l isa t ion of th is 
endorphin-modulation of catechol aminergic transmission was shown to include 
the PAG (Yaksh 1979 3) and the bulbar re t i cu la r formation ( f i g . I I - l ; see 
Section I , Chapter I I I ) . 
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d . Relationships of the endorphin subsystems to the spinal system 
As was described in Section I (Chapter I I I ) , the spinal system may be 
thought to be part of large functional subsystems. At various si tes of these 
functional subsystems endorphinergic mechanisms are present, and the natural 
l igand to the local receptor si tes w i l l be released in the i r v i c i n i t y . 
Furthermore, the (neurohumoral) subsystems may serve as a source for addi t io-
nal l igand. The ef fect and effectiveness of additional l igand, which depend 
on receptor k inet ic events and the ac t i v i t y of the local system (see Section 
I ; Chapter I I ) , may prove to include protracted unidirect ional changes (modu-
l a t i o n ) , or a reset of the set point (b id i rect ional control) by the effects 
of "anti-endorphins" . l i k e 3-MSH and ACTH-like peptides (see Dirksen 1981 
1) . The effects of the ligand released as to effectuate receptor-effectuator 
mechanisms at a d istant s i te is not l imi ted to the local changes, as they 
may also modify the ac t i v i t y of the descending t racts (see above; and see 
Section I , Chapter I I I ) . Either of these mechanisms requires the penetration 
of su f f i c ien t amount of l igand to the central nervous system, which i s , as 
was described above, l imi ted by the blood-brain barr ier . However, central 
nervous system structures without blood-brain barr ier are known to be 
present. These areas, the 'windows of the bra in ' (Knigge 1975), i . e . the 
median eminence, the neuronal lobe of the neurohypophysis, the Organum 
vasculosum of the lamina terminal is , the subfornical organ, the pineal gland 
and the area postrema, were shown to be permeable to proteins and peptides 
(Weindl 1973, Weindl 1972). Of special in terest may prove to be the area 
postrema, which i s located at the t rans i t ion from the fourth vent r ic le to 
the central canal, and thus l ies in the v i c i n i t y of the nucleus tractus 
s o l i t a r i i . Their relevance as to functional aspects of the spinal system 
remains to be determined. 
B. Materials and methods to study spinal mechanisms of nociception 
a. Introduction 
Non-surgical methods to prevent nociceptive signal transmission at a 
spinal level onto higher levels have thus far included the in jec t ion of 
local anesthetics in the peridural or intrathecal space. A more sophis t i -
cated mode may prove to be a combination of th is c l i n i c a l l y well-known 
method of epidural or intrathecal i n jec t i on , and drugs which are able to 
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selectively inhibit nociceptive signal transmission. As was discussed above, 
some functional aspects of a few transmitter and/or modulator substances 
have been identified. However, further revelation of systems involved in 
nociceptive transmission, as well as knowledge on drug interactions which 
may prove to be beneficial or undesirable, is necessary. 
Experimental models which enable us to test various drugs and which 
approach the clinical method of intrathecal injection have been described. 
These employ chronic catheterization of the spinal subarachnoid space (Yaksh 
1976 2). A modified technique is described below, and was used in the experi-
ments (Chapter II and III). The procedures and execution of the experiments 
was taught to the author by Prof. Yaksh in the Mayo Clinic. 
b. Materials and methods 
b.l. Method 
White Wistar rats of e i ther sex, weighing 250 - 300 grams, were anesthe-
p 
t i zed with fluothane admixed with a Forregger fluothane vaporizer to a mix-
ture of oxygen and a i r , and administered via a close f i t t i n g mask in an open 
breathing c i r c u i t . The head was shaved and the animal was mounted in a 
stereotaxic instrument. A midline inc is ion was made on the skul l extending 
from a l ine between the ears to a point approximately 2 cm caudally. The fas-
c ia was dissected, and the superf ic ia l neck muscles were blunt ly separated 
from the i r insert ion to the occip i ta l bone of the s k u l l . The occ ip i ta l crest 
served as an indicat ion of the midl ine pos i t ion. A retractor was used to 
expose the layer connecting the base of the skul l to the At las. Using the 
t i p of an 18 gauge sharp needle, a small inc is ion through the fascial layer 
and the underlying dura was made, t i l l a free flow of clear cerebrospinal 
f l u i d was obtained. The dura and the covering fascial layer were retracted 
upward with a small curved probe to f a c i l i t a t e the introduct ion of a special-
l y prepared polyethylene (PE-10) catheter ( f i g . 11-3) in to the subarachnoid 
space. At an angle para l le l to the dorsal surface of the brain stem, the 
catheter was carefu l ly advanced caudally. S l ight tension to the t a i l of the 
ra t ensured that the animal's spine remained s t ra ight . Occasionally i t 
proved d i f f i c u l t to advance the catheter. In some instances i t helped to 
deepen anesthesia and/or straighten the spine and/or to i n jec t a small 
volume of isotonic sal ine. Rotating the catheter was observed to cause 
damage to the spinal structures. After the catheter had been inserted to the 
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rost ra l aspect of the lumbar enlargement (8.5 cm caudally of the place where 
the catheter was introduced), the proximal end of the catheter was brought 
out the skin between the eyes with the aid of a 20 gauge sharp needle. 
Suturing the skin adequately f ixed the catheter in the pocket between the 
superf ic ia l neck muscles and the occip i ta l bone of the s k u l l . A small piece 
of t i g h t - f i t t i n g stainless steel wire was inserted into the proximal end of 
the PE-10 catheter, and prevented backflow of cerebrospinal f l u i d and pre-
PROXIMAL·, END 
DENTAL CEMENT— 
Fig. 11-3. Specially prepared PE-10 catheter for 
chronic catherization of the spinal subarachnoid 
space. 
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mature blocking of the catheter. The animals were allowed to recover and 
were observed for motor problems. Those animals with motor problems were 
expelled from the study. The animals were kept f o r a period of 7 - 14 days, 
with a 12-hourly day and night rhythm, and free access to water and food. 
After t h i s period, the animals were again observed for motor problems. Base­
l i n e response latencies to nociceptive st imulat ion were noted before the 
i n j e c t i o n of any drug. Those animals with a marked increase or reduction of 
base-line response latencies were expelled from the study. Approximately 20% 
of the animals subjected to subarachnoid insert ion of the catheter proved to 
have either motor problems or a marked change of base-line response laten­
c i e s . 
b.2. In ject ion procedures 
Solutions containing the drug to be injected were freshly prepared. 
Previous to i n j e c t i o n of the drug-containing so lut ion, the patency of the 
catheter was tested by i n j e c t i o n of 3 μ 1 of isotonic sal ine. This was 
delivered by a manually operated gear-driven microinjector syringe pump 
connected to a three-port valve, connected to PE-10 tubing. One PE-10 tube 
served as a drug reservoir, the other f o r the isotonic sal ine. Thus, only 
one syringe and drive system was needed to del iver drug and vehicle wash. To 
permit an accurate assessement of the i n j e c t i o n , a small a i r bubble was 
placed in each tube and the progression of the bubble served as a v i s i b l e 
indicat ion of the patency and the amount of the drug del ivered. Pr ior c a l i ­
brat ion of the bubble movement with a 10 u l Hamilton syringe permitted the 
tubing to be used as a measure of the actual volume of f l u i d del ivered. 
To allow intrathecal i n j e c t i o n of the drug-containing solut ion, the i n j e c t o r 
was connected to the catheter which had been implanted according to the 
method described above, with a 30 gauge stainless steel connecting tube. 
b.3. Measurement of the nociceptive threshold 
Two tests were employed to test changes i n nociceptive signal trans­
mission: the t a i l - f l i c k ref lex and the hot-plate response. The t a i l - f l i c k 
ref lex employed a 300 Watt focused halogen lamp (Splendor Halogen Floodl ight 
Lamp, double ended, 300 Watt, 220 -230 V, Holland) mounted 3 cm below a 
s l i t , over which the t a i l was l a i d . Thermal i s o l a t i o n prevented the surface 
on which the t a i ! was l a i d from becoming hot. The response to measure was 
the interval from the time the l i g h t was switched on u n t i l a v i s i b l e twitch 
was made. The mean response latency i n drug-naive animals was 7.0 seconds 
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η = 25; s.d. = 1.6 sec). The cut-off time in the absence of a visible 
response was 30 seconds. Earlier studies in the Department of Neurophanma-
cology of the Mayo Clinic employed a device inducing a t a i l f l ick within 2 
seconds, with a cut-off time of 6 seconds. The hot plate consisted of a 
metal surface (25 χ 25 cm) heated to 52.5° С by placing i t in a hot water 
bath maintained at a temperature of 52.5° С by a coil heater (Wilton and 
Co.). The metal surface was surrouded by a plexiglass wall 30 cm high. The 
water temperature was continuously measured with a temperature probe con­
nected to a measure device (Ellab a-s, Copenhagen). The response to measure 
was the interval between the time the rat was placed on the hot-plate and 
the licking response of either hind paw. In drug-naive rats licking behavior 
occurred after a mean response latency of 15.4 seconds (n = 25; s.d. 5.7 
sec). In most instances a change in the t a i l - f l i c k response latencies wil l 
parallel the change in response latencies in the hot-plate test. However, as 
i t may not, the relative change indicating the contribution to each of these 
tests may be assessed in the t a i l - f l i c k (TF) / hot-plate (HP) index, which 
wi l l be defined as: 
TF - TF max с 
the relative change in t a i l - f l i c k response latency 
T F c 
HPmax- H P c 
the relative change in hot-plate response latency 
HP C 
with: 
TF = mean of maximum increased t a i l - f l i c k response latencies 
max 
TF = mean base-line t a i l - f l i c k response latencies 
HP_ = mean of maximum Increased hot-plate response latencies 
max 
HP = mean base-line hot-plate response latencies. 
"Analgesia" is defined in these tests as an increase of response laten­
cies, whereas "hyperalgesia" presents as a decrease of response latencies. 
In each group the base-line response latencies served as a control for a 
change. 
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с. S t a t i s t i c a l analysis of the experimental data * 
To allow s t a t i s t i c a l analysis of the experimental data, the area under 
the curve (AUC), composed of the l i n e drawn through the points representing 
the observed ef fect and a l i n e representing the mean base-line response 
latencies of the group of animals subjected to the tests used (the hot-plate 
t e s t and the t a i l - f l i c k r e f l e x ) , was calculated f o r each individual animal. 
The AUC's were compared with the standard parametric t e s t s , i . e . : the t - t e s t 
f o r one sample, the t - t e s t f o r two samples, or the one-way analysis of 
variance (ANOVA) followed by ( i f appropriate) the S-method of m u l t i p l e 
comparisons (Armitage 1971). I f the maximum ef fect observed was not 
altogether beyond the empir ical ly i n s t i t u t e d cut-of f time (see above), the 
e f f e c t i t s e l f , or the e f f e c t compared to the e f f e c t observed in another 
group was evaluated by means of the t - t e s t f o r one sample or f o r two samples 
respectively. To study the e f f e c t in time, ANOVA f o r randomized block design 
was used. 
I t i s emphasized that the small amount of data makes i t hazardous to draw 
f i n n conclusions, and the experimental results are to be regarded as a mould 
f o r a working hypothesis. 
* 
The help of Jan Tijssen is g r a t e f u l l y appreciated. 
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CHAPTER I I 
Dose-Effect Relationships of Intrathecally Injected Morphine and 
Nlcomorphlne, and the Reversibility of Splnally-Mediated Opiate 
Effects by Naloxone In the Rat 
a. Introduction 
The presence of two i d e n t i f i e d elements of the endorphin system at a 
spinal l e v e l , the i d e n t i f i c a t i o n of local endorphin production and release, 
the occurrence of c e l l u l a r effects in Іаліпае I and I I af ter local admini­
s t r a t i o n of enkephalin or morphine indicate the existence of an intraspinal 
endorphin subsystem (see Chapter I , Section I ; Chapter I , Section I I ) . An 
Intimate functional relat ionship with a putative transmitter substance of 
the primary af férents, i . e . substance Ρ (see above), as well as data which 
provided evidence that high-intensity st imulat ion of the s c i a t i c nerve en­
hanced met-enkephalin-immunoreactivity i n the CSF of the spinal cord (Yaksh 
1981 1 ) , relate to the involvement of t h i s subsystem i n transmission of a 
nociceptive s ignal . 
Also, the effects of opiate-drugs relate to such a funct ion, as 
evidenced by: 
1 . the existence of a dose-related suppression of nociceptive 
spinal reflexes and operant behavior a f ter intrathecal 
appl icat ion of narcotics, due to a d i r e c t spinal action 
(Yaksh 1976 1 , Yaksh 1977 1 , Yaksh 1978 1 ) , an e f f e c t also 
occurring af ter the appl ication of enkephalin (Yaksh 1977 
2 ) , or ß-endorphin (Yaksh 1978 3) . Naloxone in t ra thecal ly or 
systemically antagonized these actions (Yaksh 1977 (1,2)) 
2 . the naloxone-reversi ble select ive depression of the noci-
ceptive C-f ibre ref lex af ter intraspinal micro- in ject ions of 
morphine and met-enkephalin in to the dorsal horn. The short-
latency polysynaptic ref lex i s not depressed, indicat ing the 
absence of effectiveness in sharp ( " f i r s t " ) pain (Bell 1980; 
see Chapter IV) 
3. the naloxone-reversible influence of intravenous morphine on 
spinal reflexes in spinalized animals (Krivoy 1973, Goldfarb 
1978) 
4 . the specif ic depression of central nociceptors wi th in the 
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spinal cord, located in laminae I , V.and V I I , a f ter i n t ra -
venous morphine (Iwata 1971, Besson 1973, Dostrovsky 1973, 
Kitahata 1974, LeBars 1975, LeBars 1976, Toyooka 1978) 
5. a specif ic morphine-induced inh ib i t i on of the impulse trans-
mission associated with act ivat ion of cutaneous afferent 
C-f ibres, to ascending axons (Grossman 1974, Jurna 1976, 
Bowsher 1978, Jurna 1979). 
These findings may relate to presynaptic modulation of the nociceptive 
signal by opiates (LaMotte 1976, Atweh 1977 (1 ,2) , Atweh 1978, M i l l e r 1978, 
MacDonald 1978). Although the effectuator mechanisms have not been f u l l y 
characterized, hyperpolarization, membrane s tab i l i za t ion and neuromodulation 
were proposed (North 1976 3, Sastry 1978, North 1980, Barker 1978; see 
Section I , Chapter I ) . In view of the fact that enkephalin-binding is 
highest in the substantia gelatinosa (LaMotte 1976, Atweh 1977 1) , i t is 
l i k e l y that endorphinomimetic interact ion is the resul t of terminals in 
these layers (Duggan 1976). Moreover, micro-electrophoretic in ject ions of 
morphine into the neuronal network of the substantia gelatinosa of the cat 
spinal cord produced a selective depression of responses of more deeply-
ly ing spinal neurons to noxious, but not to t a c t i l e st imul i (Duggan 1976, 
Duggan 1977). The i nh ib i t i on of ascending ac t i v i t y produced by intravenous 
morphine in spinal ra t is more pronounced in axons responding to st imulat ion 
of afferent C-f ibres, than in axons activated from afferent A ^ f i b r e s (Jurna 
1979, Jurna 1980). 
Most experimental results have been obtained with the "standard" opiate 
drug morphine. However, in the c l i n i c , we are acquainted with nicomorphine 
(the 3,6-dinicot inoyl ester of morphine (Pongratz 1957, Zinn 1959)), whereas 
morphine i s not frequently used by us. Therefore, the effectiveness of nico-
morphine was established by assessing i t s dose-effect re lat ionship, and th is 
was to be compared with that of morphine. To establish the spec i f i c i t y of 
i t s ef fect on nociceptive signal transmission, the reve rs i b i l i t y of the 
e f fec t of an analgetic dose was tested by co-administration with naloxone. 
b. Materials and methods 
White Wistar rats of 250-300 grams were chronical ly implanted with an 
intrathecal catheter. Tests to assess behavioral ly-def i ned anti nociception 
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Included the hot-plate test and the t a i l - f l i c k r e f l e x . In ject ion procedures 
employed a gear-driven microinjector (see Chapter I ) . 
The effectiveness and the time course of an e f f e c t a f ter intrathecal 
morphine hydrochoride or nicomorphine were evaluated in six groups of r a t s , 
and each group was composed of f i v e r a t s . Three groups of rats were injected 
in t rathecal ly with nicomorphine i n doses of З у д , б уд, and l O p g respective­
l y ; the other three groups were injected intrathecal ly with morphine in a 
dose of 1 \ig, 2 yg and 3 pg respectively (table 11-A). Each r a t was injected 
wi th 20 μΐ: 10 μΐ was the drug-containing solut ion and the other 10 μΐ was 
vehicle wash. Analgesic tests (hot-plate response and t a i l - f l i c k ref lex) 
were performed at 5, 15 and 30 minutes, and thereafter at half hourly 
in terva ls u n t i l the response latencies had returned to base-line response 
latencies. The response latencies i n each group are presented as means 
(standard deviat ion, s . d . , in brackets)(tabie I I - A ) . 
The naloxone-reversibi l i ty of the observed antinociceptive effects of 
the endorphinomimetics was tested by concomitant intrathecal i n j e c t i o n of 
the analgesic drugs and 10 y g naloxone hydrochloride (table I I - B ) . 
c. Results 
c . l . Dose-effect relat ionships of the endorphinomimetic drugs morphine and 
nicomorphine i n behaviorally-defined analgesia 
The groups of r a t s , the dosage of the endorphinomimetics, the t o t a l 
volume which was in jected into the subarachnoid space, the mean base-line 
response latencies, as well as the response latencies af ter intrathecal 
in ject ions are presented i n table I I-A. The time course of the ant inoci­
ceptive ef fect is envisualized i n f i g . I I - 4 and f i g . I I - 5 for nicomorphine 
and morphine respectively. The r e l a t i v e e f f e c t i v i t y of the endorphinomimetic 
drugs in increasing response latencies in the hot-plate and the t a i l - f l i c k 
ref lex are quantif ied i n the TF/HP index (table I I - A ) . 
S t a t i s t i c a l analysis of the effects employed the one-way ANOVA of the In 
AUC (natural logarithm of the area under curve) of each individual animal 
belonging to the groups l i s t e d in table I I-A. For the hot-plate t e s t , the 
p-value f o r nicomorphine was < 0.01, and for morphine < 0 . 0 2 . For the 
t a i l - f l i c k ref lex the p-value f o r morphine was < 0 . 0 1 . S t a t i s t i c a l analysis 
of the ef fect on t a i l - f l i c k response latencies of two d i f f e r e n t doses of 
Table II-A. Mean response latencies (seconds, s.d. In brackecs) after Intrathecal Injections of three different doses of nlcomorphlne and morphine.There were 5 rats In each group. 
The volume Injected was 20 yl: 10 yl drug-containing solution , and 10 μ 1 vehicle wash, n.d.- not determined; '-minutes. 
group 
mean preinjection 
response 
latencies (sec) 
HP TF 
drugs Injected 
intrathecally 15' 
Mean response latencies (seconds) after injection 
30' 60' 90' 120' 150' 180' 210' 240' 
HP TF HP TF HP TF HP TF HP TF HP TF HP TF HP TF HP TF HP TF 
TF/HP 
Index 
N6 
N10 
Ml 
M2 
M3 
( 3 . 4 ) 
15.6 
(7.4) 
18.2 
(4.0) 
21.4 
(6.4) 
17.4 
(6.6) 
17.1 
( 4 . 1 ) 
( 1 . 5 ) 
7.7 
(1.9) 
16.0 
(4.0) 
7.2 
( 1 . 4 ) 
6.8 
(1.2) 
6.8 
( 1 . 8 ) 
3 u g 
Nlcomorphlne 
6 yg 
Nlcomorphlne 
10 yg 
Morphine 
1 ug 
Morphine 
2 yg 
Morphine 
З у д 
( 8 . 9 ) 
31.9 
(16.3) 
41.0 
(20.7) 
16.0 
(6.0) 
27.9 
(18.0) 
54.4 
(12.5) 
( 3 . 0 ) 
9.2 
( 1 . 3 ) 
40.2 
(20.0) 
7.8 
( 0 . 2 ) 
8.7 
(1.4) 
22.1 
( 7 . 4 ) 
(14.5) 
36.3 
(18.4) 
54.0 
(13.4) 
17.0 
( 6 . 2 ) 
49.6 
(14.2) 
60-(-) 
( 4 . 5 ) 
9.4 
( 1 . 9 ) 
n.d. 
8.3 
( 1 . 3 ) 
10.3 
(2.4) 
27.0 
( 4 . 9 ) 
(10) 
48.1 
(13.6) 
56.0 
(8.9) 
27.3 
( 8 . 8 ) 
49.7 
(14.2) 
60-(-) 
( 4 . 4 ) 
8.5 
(1.6) 
n.d. 
8.1 
( 0 . 9 ) 
11.3 
( 2 . 3 ) 
28.2 
( 2 . 7 ) 
( 5 . 6 ) 
31.6 
(20.7) 
55.8 
(19.3) 
26.4 
( 8 . 5 ) 
45.7 
(21.8) 
60-(-) 
( 2 . 3 ) 
8.1 
(0.4) 
n.d. 
9.0 
( 0 . 8 ) 
8.6 
(2.8) 
24.7 
( 6 . 7 ) 
14.9 7.8 n.d. 
( 5 . 2 ) (0.6) 
52.6 n.d. 42.0 
(16.5) (20.6) 
24.0 7.9 17.2 
( 6 . 5 ) ( 1 . 1 ) (6.1) 
43.0 7.6 25.2 
(23.6) (1.3) (18.1) 
60- 22.2 52.0 
(-) ( 5 . 5 ) (12.5) 
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
n.d. 30.0 n.d. 24.7 n.d. n.d. n.d. n.d. n.d. 
(18.0) (1B.0) 
6.5 19.9 6.5 n.d. n.d. r.d. n.d. n.d. n.d. 
( 1 . 8 ) ( 5 . 9 ) ( 1 . 9 ) 
7.3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
( 1 . 9 ) 
20.6 53.0 19.8 45.8 17.3 35.0 13.0 20.9 6.2 
( 8 . 5 ) ( 9 . 1 ) ( 9 . 6 ) (15.4) ( 8 . 5 ) (12.2) ( 7 . 7 ) (18.4) (1.5) 
0.11 
1 ( ' ) 
0.97 
0.36 
0.95 
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Fig. ІІ-4. Mean hot-plate response latencies after intrathecal injections 
of nicomorphine 3 yg, 6 yg, and 10 μ g. 
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Fig. II-5. Mean hot-plate response latencies after intrathecal injections of 
morphine 1 yg, 2 \lg, and 3yg. 
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nicomorphine, 3 and 6 yg respectively, was done with Student's t - t e s t , and 
the p-value was > 0.05, indicat ing the absence of a s t a t i s t i c a l s i g n i f i c a n t 
difference for these two groups for the t a i l - f l i c k r e f l e x . Thus, a clear 
dose-dependent increase in hot-plate response latencies may be said to be 
present. To characterise dose-effect relat ionships, a log-dose response 
curve was made ( f i g . I I - 6 ) . In mi l l igrams, nicomorphine appeared to be less 
potent than morphine. However, the molecular weight of nicomorphine (550.01) 
i s substant ial ly higher than that of morphine hydrochloride (375.8), and 
thus, i n a molar dose the difference in potencies i s not much at variance. 
SEC 
60 
40-
20 
/ * 
1 2 3 6 10 μ β 
D 
Fig. II-6. Log dose-effect relationships of 
morphine (M) and nicomorphine (N) for the hot­
plate response. A common base-line (BL) was calcu­
lated as a mean of the base-line response laten­
cies of animals listed in table II-A. (D = dose: 
yG = micrograms; E = Effect: sec = seconds). 
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The dose-effect relat ionship in the t a i l - f l i c k ref lex was much less con­
stant. The ANOVA-proven difference between the three groups ( p < 0.001), i n ­
dicated a dose-related increase i n t a i l - f l i c k response latencies af ter i n t r a ­
thecal in ject ions of d i f f e r e n t doses of morphine. I t was not possible to c a l ­
culate adequate dose-effect relationships as was done f o r the hot-plate 
t e s t . Especially at the intermediate dose of ei ther morphine (2 yg) or nico-
morphine (6 vg), in t rathecal ly in jected, a d e f i n i t e dose-related further 
increase compared to the increase in response latencies a f t e r the lower dose 
was absent. Actual ly, nicomorphine 6 \ig may have been less e f f e c t i v e i f com­
pared to the e f f e c t i v i t y of nicomorphine З у д . However, s t a t i s t i c a l analysis 
did not indicate a s i g n i f i c a n t difference between these two groups 
(Student's t - t e s t , ρ > 0.05), which may be explained by the low number of 
rats i n each group. 
There was no change in behavioral character is t ics, pupil s ize, breathing 
r a t e , heart rate, or r i g h t i n g ref lex af ter intrathecal in ject ions of e i ther 
of the drugs used. 
C.2. Naloxone-reversibi l i ty of the antinociceptive effects of i n t r a t h e c a l l y -
injected morphine and nicomorphine 
To t e s t the naloxone-reversibi l i ty of the antinociceptive effects of 
morphine and nicomorphine, naloxone 10 yg was co-administered in t rathecal ly 
with morphine 5 ug or nicomorphine 10μ g. Morphine 5 yg and naloxone l O y g 
did not resul t in a s i g n i f i c a n t change of hot-plate or t a i l - f l i c k response 
latencies (table I I-B) (one sample t - t e s t of the AUC: p > 0.5). Co-achiinis-
t r a t i o n of naloxone 10 yg with nicomorphine 10 yg (table I I-B) resulted i n 
an increase in the hot-plate response latencies af ter 30 and 60 minutes, and 
the presence of an e f f e c t i n the hot-plate test is indicated by s t a t i s t i c a l 
analysis (one sample t - t e s t of the AUC: ρ < 0.02). No e f f e c t was present in 
the t a i l - f l i c k ref lex (one sample t - t e s t of the AUC: ρ = 1 ) . The calculated 
TF/HP index af ter the co-administration of nicomorphine 10 yg and l O y g 
naloxone was 0.21. 
Table II-B. Mean responee latencies (seconds, s.d. in brackets) vi two groups of rats (5 rats in each ¿roup) after intrathecal injection 
of an analgetic dose of nicomorphine 10 μ§ together with naloxone 10 yg (group I), or morphine 5pg together with naloxone 10μ g (group II) 
The volume injected was 20 μ 1; 10 μΐ the drug-containing solution and 10 μΐ vehicle wash. HP » hot-plate test, TF - tail-flick reflex. 
Group 
of 
rats 
I 
II 
Mear 
prei nj ее ti on 
response 
latencies 
HP 
21.5 
(4.4) 
18.0 
(6.5) 
TF 
7.5 
(0.9) 
8.0 
(1.1) 
5 
HP 
23.0 
(1.8) 
18.8 
(9.3) 
TF 
6.9 
(1.7) 
7.7 
(0.6) 
15 
HP 
18.7 
(4.8) 
19.3 
(9.4) 
TF 
6.7 
(0.8) 
7.4 
(0.6) 
Mean 
30 
HP 
29.5 
(14.1) 
15.0 
(3.3) 
responsi 
1 
TF 
8.2 
(1.9) 
7.5 
(1.1) 
' 1 atenei 
60 
HP 
31.0 
(10.7) 
22.0 
(6.6) 
es after inject 
' 
TF 
8.1 
(0.8) 
8.6 
(1.0) 
90' 
HP 
23.6 
(8.1) 
19.3 
(5.4) 
on 
TF 
7.8 
(0.7) 
8.0 
(1.0) 
120 
HP 
21.5 
(5.8) 
23.4 
(4.5) 
TF 
7.5 
(1.0) 
8.2 
(0.8) 
150 
HP 
21.5 
(6.6) 
21.2 
(5.9) 
TF 
7.5 
(1.2) 
7.0 
(1.5) 
180' 
HP TF 
22.0 7.9 
(5.3) (0.9 
20.3 8.2 
(7.2) (1.0) 
4ί 
Г*. 
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d. Discussion 
Several endorphinomimetics, i . e . fentanyl , morphine, 1-methadone and 
meperidine, have been found to be e f f e c t i v e i n producing behaviorally-
defined analgesia i n rats af ter intrathecal i n j e c t i o n ; yet other compounds, 
i . e . cyclazocine, l-a-acetylmethadol, pentazocine, d-methadone, nalorphine 
and naloxone, f a i l e d to show an e f f e c t (Yaksh 1977 1 ) . The analgetic action 
proved to be dose-dependent and somatotopically l imi ted with cord dermatoma 
regions (Yaksh 1977 1 ) . My f indings are in accordance with these e a r l i e r 
observations (table I I - A ) . S i g n i f i c a n t l y , the return of the increased 
response latencies to control values, the absence of motor problems, and the 
f a i l u r e to af fect the r ight ing ref lex r e f l e c t the absence of local toxic 
ef fects af ter intrathecal i n j e c t i o n of the drugs. The absence of local 
t o x i c i t y had e a r l i e r been assessed i n a study involving examination of 
spinal tissues af ter m u l t i p l e applications of endorphinomimetic drugs, and 
i n shock t i t r a t i o n experiments (Yaksh 1978 1 , Yaksh 1981 4 ) . 
As indicated above (Chapter I . B . b . 3 . ) , 'analgesia' presents i t s e l f as an 
increase i n response latencies compared to base-line response latencies. How­
ever, protracted exposure to the nociceptive stimulus w i l l cause t issue 
damage and t issue damage interferes with exact assessment of a change. There­
f o r e , an empirical ly established c u t - o f f time (see Chapter I .B.b.3.) was 
f i x e d . This implies that an increase of response latencies beyond c u t - o f f 
time does not inform us as to the actual e f f e c t . Therefore, maximum doses of 
3 μ g morphine hydrochloride and 10 y g nicomorphine were employed to obtain 
the maximum assessable increase of response latencies. The lowest dose of 
morphine and of nicomorphine (1 yg and 3 y g , respectively) increased hot­
plate response latencies j u s t beyond the signal-noise r a t i o . 
The time course of e f f e c t a f t e r intrathecal morphine exhibited a plateau-
phase, indicat ing d i f f e r e n t k inet ics of morphine i n the el iminat ion phase 
compared to nicomorphine. Morphine is known to be present i n the central 
nervous system mainly i n the ionized form (Finck 1977 3 ) . This would hinder 
passage through biological membranes, including the blood-brain b a r r i e r , and 
thus extend i t s residence i n the CSF as well as the duration of i t s e f f e c t 
(see Chapter IV). The time course of the observed antinociceptive e f f e c t was 
presented i n f i g . 11-4 and f i g . 11-5, and both the e f f e c t and the duration 
of e f f e c t were dose-dependent. The time course of the lower dose of morphine 
(1 y g ; see f i g . I I - 4 ) was at variance with the time course at a higher dose. 
An i n i t i a l reduction i n hot-plate response latencies was observed, followed 
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by an Increase i n response latencies. A dual action of morphine was shown to 
be present in the vas deferens (Jacquet 1980), and i t was proposed that the 
inh ib i to ry ef fect of morphine can mask the exci tatory. A l te rnat ive ly , the 
d i f f e ren t i a l endorphin receptor configurations or (sub)types at a spinal l e -
vel (Fields 1980; see Section I , Chapter I ) may mediate these excitatory and 
inh ib i to ry ef fects . However, morphine i s known to increase the threshold to 
st imulat ion of C-fibres (Carstens 1979); the transmission of nociceptive s ig -
nals was shown to implicate single rather than mult ip le receptor configura-
t ions (Pasternak 1980, Yaksh 1977 1) ; and excitatory effects of morphine are 
thought to involve non-nociceptive neurons, and these excitatory effects 
were proposed to act synergis t ica l ly with a depressant action on nociceptive 
neurons (Belcher 1978 2) . Whatever the mechanism involved, both endorphins 
and endorphinomimetics are known to have biphasic effects in the various en-
dorphin subsystems (Section I , Chapter I I I ) , such as: central respiratory 
control (Florez 1980), behavioral effects (Bloom 1976, Browne 1979), e lectro-
encephalographic ac t i v i t y (Tor te l la 1978, Frenk 1978 2) , and c i rcu la tory ef-
fects (Lemaire 1978 1 ; Section I , Chapter I I I ) . The absence of a biphasic ef-
fec t of nicomorphine af ter i t s intrathecal in ject ions may re late to the do-
ses used. A l ternat ive ly , nicomorphine and morphine may d i f f e r i n the i r 
act ions. 
Nicomorphine i t s e l f was shown to have no s ign i f icant binding to opiate 
receptors in ra t brain membranes (Lobbezoo 1982), and i t s effects may be ex-
plained by hydrolysation of nicomorphine to i t s active phenolic hydrolysis 
products 6-mononicotinoyl morphine and morphine (Lobbezoo 1982). The 6-mono-
nicot inoyl product may be transformed to morphine as well (Lindner 1981 ( 1 , 
2 ) ) . Such transformations were considered not to explain the favourable 
c l i n i c a l p ro f i l e of nicomorphine (Lobbezoo 1982), and i t f a i l s to explain 
the presence of a non-naloxone reversible component (at 30 and 60 min. af ter 
intrathecal in ject ion) in nicomorphine-associated antinociceptive e f fec t ive-
ness (table I I - B ) . As n icot in ic acid is formed by hydrolyt ic cleavage of 
nicomorphine, the dif ference may be thought to relate to the presence of 
n ico t in ic acid, although i t fa i led to interact at the level of receptor 
binding (Lobbezoo 1982). 
The presence of spinally-mediated parasympathetic side-effects of i n t ra -
thecal ly or epidural ly injected endorphinomimetics (Dlrksen 1980 3, Dirksen 
1982) and some of the considerations described above made us investigate 
whether cholinergic mechanisms are involved in nociceptive signal trans-
mission at a spinal level (Yaksh and Dirksen submitted; Chapter I I I ) . 
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CHAPTER I I I 
Cholinergic Transmission at a Spinal Level and Nociceptive 
Signal Transmission in the Rat and the Cat; I t s Relevance to 
Opiate Effectiveness In the Rat 
A. Cholinergic transmission at a spinal level and nociceptive signal 
transmission in the ra t and the cat 
a. Introduction 
Acetylcholine i s a transmitter substance in the spinal cord, as i s 
Indicated by the local presence of acetylchol ine, choline acetyl transferase 
and acetylcholinesterase (Macintosh 1941, Feldberg 1948, Roessmann 1967, 
Kasa 1970, Si lver 1970, Odutola 1972). The spinal cholinergic mechanisms 
iden t i f i ed include n icot in ic and muscarinic exc i ta t ion , as well as mus-
car in ic i nh ib i t i on (Mylinsky 1977, Krnjevic 1974). An increase of cho l in-
ergic tone at a cerebral level is associated with anti nociception involving 
muscarinic mechanisms (Redigo 1975). Moreover, a muscarinic in t racor t l ca l 
inh ib i to ry system has been proposed (see discussion). 
Recently muscarinic receptor si tes were shown to be present in a l l 
phases of spinal cord physiology and the absence of an apparent change of 
3 
receptor number or a f f i n i t y for H-QBN (quinucl idinylbenzi late) below a 
transsection of the spinal cord fur ther indicated a local cholinergic system 
(Kayaalp 1980). Degeneration of primary afférents is not associated with 
loss of choline acetyl transferase, indicat ing that acetylcholine 1s not 
involved in transmission at the primary afférents (Jessell 1979). 
The effects of the cholinomimetic drugs carbachol and acetylcholine 
together with physostigmine on nociceptive signal transmission at a spinal 
level w i l l be presented below. 
b. Materials and methods 
b . l . Animals for intrathecal in jec t ion 
To administer the drugs in t ra theca l ly , a specially-prepared polyethylene 
catheter (PE-10) was inserted into the lumbar subarachnoid space through an 
opening in the cisterna magna. The catheters were permanently f ixed in an 
78 
a r t i f i c i a l pocket between the superf ic ia l neck muscles and the o c c i p i t a l 
bone by closure of the skin over the in dental acry l ic cement concealed knot 
of the PE-10 catheter or by st i tches around enthickened parts of the 
catheter in the cat. In the cat, the catheter extended 30 cm down the spinal 
cord, a lenght determined to correspond approximately with L/L vertebrae 
5 б 
i n the cat (Yaksh 1978 1 ) . Two cats were catheterized t h i s way. Other 
deta i ls of the implantation are described elsewhere (Yaksh 1976 2; see 
Chapter I ) . A l l animals were allowed to recover 7-10 d^ys p r i o r to 
i n i t i a t i n g these experiments. Animals were used only once. 
b.2. Measurement of nociception 
To measure the nociceptive thresholds in r a t s , the hot-plate (maintained 
at 52.5°C) and the t a i l - f l i c k (a project ion bulb focused through a s l i t over 
which the t a i l was placed) tests were employed. The end point in the hot­
plate test was generally taken to be the l i c k i n g of ei ther hind paw although 
occasionally some rats were observed to jump. In t h i s case, the jump was 
taken as the end point . To prevent t issue damage, the c u t - o f f times for 
these experiments were 60 and 6 seconds (sec) for the hot-plate and t a i l -
f l i c k t e s t s , respectively. In the cat experiments, a thermal probe having a 
heated surface of 1 cm2maintained at 70°C was placed l i g h t l y for a maximum 
of 12 sec on several previously depilated body areas. This strong stimulus 
produced a local skin twi tch followed rapidly by a vigorous escape response 
(Yaksh 1978 1 ) . 
b.3. Drug in ject ions 
Drugs injected i n t r a t h e c a l l y in the r a t were dissolved such that the 
f i n a l dose was administered in a volume of 10 - 20 μΐ of isotonic sal ine. 
Each intrathecal drug i n j e c t i o n was followed immediately by an i n j e c t i o n of 
10 μΐ of vehicle to clear the catheter (catheter volume is 6 - 8 y l ) . I n t r a ­
thecal in ject ions in the cat were made i n a volume of 0.3 ml followed by 0.1 
ml of the vehicle. Drugs injected included: acetyl chol ine, physostigmine 
s a l i c y l a t e , carbachol, naloxone hydrochloride, P icrotoxin, strychnine, 
methysergide, phentol ami ne and atropine sulphate. A l l drug-containing 
solutions were freshly prepared pr ior to i n j e c t i o n . 
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Results 
c l . Intrathecal acetylcholine and acetylcholine in combination with 
phy sosti gmi ne and behav i oral ly-defined analgesia. 
Intrathecal in ject ions of acetylcholine i n a dose up to 150 pg (con­
tained in 10 u l vehicle) did not change base-line hot-plate or t a i l - f l i c k 
response latencies af ter 5 minutes. The effects observed included a short 
period of sal ivat ion and squeaking immediately af ter the i n j e c t i o n . I n ­
j e c t i o n of physostigmine (10 vg contained i n 10 μΐ) at a spinal level tended 
t o increase the hot-plate response latencies. No change in t a i l - f l i c k 
response latencies was observed ( f i g . I I - 7 , table II-C) and the calculated 
TF/HP index was -0.15. Combination of physostigmine 10 μ g with acetylcholine 
10 ug ( t o t a l amount of injected volume 20 y l : 10 yl drug-containing solut ion 
and 10 y l vehicle wash) tended to further increase the hot-plate response 
latencies (mean 46.4 s e c ; s.d. 19.4 sec), but f a i l e d to increase the t a i l -
60' 
HOT ПАТЕ 
• ESrONSE 
IA1ENCT 
30 
TAIL 
FLICK 
«FLEX 
Fig. II-7. Graphic 
representation of mean 
hot-plate and tail-
flick response laten­
cies (seconds) and 
standard deviations 
after intrathecal (ith) 
injections of drug-
containing solutions. 
The arrow indicates the 
moment of intrathecal 
injection. 
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Table II-C. Mean hot-plate (HP) and tail-flick (TF) response latencies (in seconds; s.d. in brackets) prior to 
and at 5, 15, 25 and 45 minutes after intrathecal injections of physostigmine 10 yg, physostigmine 10 y g + 
acetylcholine 50 pg, and physostigmine 10 yg + acetylcholine 150 yg. The total injected volume for each rat was 
20 yl (5 in each group). The relative effpctivity of the drug injected in increasing the hot-plate (HP) and 
tail-flick (TF) response latencies is quantified in the calculated TF/HP index (n.d. - not determined). 
physostigmine 10 yg 
physostigmine 10 yg + 
acetylcholine 50 yg 
physostigmine 10 yg + 
acetylcholine 150 yg 
preinjection values 
HP TF 
22.2 1.7 
(5.5) (0.3) 
23.2 1.9 
(7.6) (0.3) 
21.9 1.7 
(5.5) (0.2) 
5' 15' 25' 45' 
HP TF HP TF HP TF HP TF 
31.3 1.6 29.4 1.4 25.5 1.6 n.d. n.d. 
(12.6) (0.2) (16.9) (0.2) (10.4) (0.3) 
46.4 1.6 45.4 1.5 24.3 1.8 n.d. n.d. 
(19.4) (0.3) (19.3) (0.2) (14.4) (0.3) 
60 4.9 58.0 3.8 45.5 1.8 18.7 n.d. 
(-) (1.7) (4.5) (1.7) (21.6) (0.4) (10.3) 
TF/HP 
index 
-0.15 
-0.21 
1.08 
о 
oo 
81 
f l i c k r e f l e x . I t was observed that the analget ic 'ef fect of the combination 
of physostigmine and acetylcholine was present or not present at a l l , i n ­
dicat ing the existence of a "threshold". The calculated TF/HP index was 
-0.21 (table I I - C ) . A higher dose of acetylcholine (150 yg) again i n combi­
nation with physostigmine 10 yg ( t o t a l amount of injected volume 20 y l ) s i g ­
n i f i c a n t l y increased both the hot-plate and the t a i l - f l i c k response laten­
cies (TF/HP index 1.08), indicat ing a dose-dependent effectiveness of acetyl­
chol ine. 
S t a t i s t i c a l analysis by a one-way ANOVA of the AUC of the t a i l - f l i c k 
ref lex or the hot-plate t e s t f o r each animal in ei ther of the groups l i s t e d 
i n table I I -C, or those receiving 150yg acetylcholine i n t r a t h e c a l l y , gave a 
p-value of < 0.01 f o r e i ther analgesic test used. 
с 2. Intrathecal carbachol induced behavioral ly-def i ned analgesia. 
E a r l i e r studies of YakSh had indicated that intrathecal I n j e c t i o n of 15 
yg carbachol contained in 10 yl saline resulted i n an increase of hot-plate 
Fig. II-8. Hot-plate 
and tail-flick response 
latencies (seconds) af­
ter intrathecal (ith.) 
injection of carbachol 
15 yg (first arrow). Sa­
line failed to affect 
the antinociceptive 
effects of carbachol, 
however, atropine 15 yg 
ith. (second arrow) re­
versed the carbachol-
induced increases in 
hot-plate and tail-
flick response laten­
cies, as indicated by a 
return to base-line 
response latencies. 
Atropine 15 yg or 
saline intrathecally 
s 
й
 2 
t t were without effect. 
9 0 TIMEimm) 
• • CARBACHOL + SALINE 
• « CARBACHOL + AIROPINE 
* — » ATROPINE 
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and t a i l - f l i c k response latencies w i t h i n 5 minutes (table I I - D , f i g . I I - 8 ) 
{Yaksh and Dirksen submitted). In t h i s study, i t was also found, that 
•atropine 15 pg i n 10 y l , but not curare, reversed the antinociceptive 
ef fects of intrathecal carbachol, as indicated by a return of response 
latencies to base-line values ( f i g . I I - 8 ; f i g . I I - 9 ) . 
Early effects of intrathecal carbachol i n j e c t i o n included squeaking and 
occasionally a v i s i b l e increase of s a l i v a t i o n . No changes in motor c o n t r o l , 
r i g h t i n g r e f l e x , behavior, or postural control were observed in any animal. 
c . 3 . Intrathecal carbachol induced behaviorally-defined analgesia and 
interact ion with other transmitter systems 
To evaluate interact ions with a few transmitter systems known to be 
present at a spinal l e v e l , naloxone hydrochloride 15 y g , Picrotoxin 2 y g , 
strychnine 4 ug and a solut ion containing methysergide 30 y g and phentol-
amine 30 yg were in jected intrathecal ly 10 minutes af ter an intrathecal 
i n j e c t i o n of carbachol 15 yg (table I I - D ) . Naloxone, Picrotoxin, and methy-
Рг· С С Рг. С Ç Pr. С С Pr. С С Рг. С С Рг. С С Рг. с с 
Sal Nal Phmt Stry Piero Cur Atro 
«My 
Fig. II-9. Each bar represents the mean hot-plate response latencies 
after carbachol (C) 15 y g intrathecally or С in combination with naloxone 
15 y g (Nal), phentolamine 30 y g + methysergide 3 yg (Phent + Methy), 
strychnine 4 yg (Stry), Picrotoxin 2 y g (Piero), curare (Cur), or 
atropine 15 μ g (Atro), intrathecally. 
Table II-D. Mean hot-plate (HP) and tail-flick (TF) response latencies (seconds; s.d. in brackets) prior to and 10 minutes 
after intrathecal (ith.) injection of carbachol 15 yg. Thereafter, naloxone 15 Mg or phentolamine 30 yg + methysergide 30 yg 
or strychnine 4 μ g or Picrotoxin 2 yg was Injected intrathecally. Again, mean hot-plate and tail-flick response latencies 
were assessed for each group. There were 5 rats in each group. 
Group of rats 
Naloxone 
Phentolamine + 
Methysergide 
Strychnine 
P i c r o t o x i n 
p r e i n j e c t i o n response 
latencies 
HP TF 
17.6 1.6 
(4.8) (0.3) 
17.8 1.5 
(5.0) (0.2) 
14.8 1.8 
(4.8) (0.3) 
21.4 2.0 
(5.9) (0.4) 
10 min. a f t e r 15μ g 
carbachol i t h . 
HP TF 
51.5 3.4 
(18.9) (2.4) 
51.3 4.6 
(19.5) (1.6) 
60 3.7 
(-) (2.1) 
53.8 4.5 
(13.9) (2.0) 
Drug(s) i t h . 
i n j e c t e d 
Naloxone 15y g 
(20 μ ΐ ) 
Methysergide 30 μg 
+ phentolamine 30 μ g 
( 2 0 μ 1 ) 
Strychnine 4 μ g 
(20 μ ΐ ) 
P i c r o t o x i n 2 μ g 
( 2 0 μ 1 ) 
response latencies a f t e r 
the 2nd i t h . i n j e c t i o n 
15 minutes 25 minutes 
HP TF HP TF 
51.7 3.6 55 3.7 
(18.5) (2.3) (11.2) (2.2) 
51.2 4.8 51.0 4.3 
(19.5) (1.8) (20) (1.7) 
46.1 4.4 45.3 4.7 
(21.6) (1.6) (20.1) (1.9) 
46.7 4.4 37.1 4.3 
(20.4) (2.2) (21.3) (2.2) 
OS 
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sergi" de plus phentol ami ne a l l f a i l e d to af fect the carbachol -induced i n ­
crease in response latencies ( f i g . 11-9). Intrathecal i n j e c t i o n of strych­
nine 4 yg reduced both the hot-plate and t a i l - f l i c k response latencies in 
two out of f i v e animals ( table I I -D, f i g . I I - 9 ) . The l i m i t e d amount of data 
did not allow s t a t i s t i c a l analysis. 
с . 4 . 'Analgetic'actions of in t rathecal ly- in jected carbachol in cats 
One cat received carbachol 50 yg in 0,3 ml sal ine, and the other at one 
instance saline 0.3 ml , while l a t e r f i r s t atropine 50 ug in 0.3 ml followed 
by carbachol 50 yg in 0.3 ml . 
As shown i n f i g . 11-10, wi th in 5 min af ter the carbachol i n j e c t i o n , 
there was a clear elevation i n the skin twitch response latency. A s l i g h t 
l a té ra l i sa t i on was observed to the l e f t (L) side compared to the r ight (R) 
12 
;10 
8 
B L 0 HRS 
Fig. II-IO. Heat probe induced skin-
twitch response latencies (seconds) 
in cats after intrathecal injection 
of 50 y g carbachol (С), or 50 y g 
atropine (A), or saline (S), or the 
combination of С and A. The anti­
nociceptive effect was somatotopi-
cally-limited with cord dermatome 
regions. A slight lateralization of 
the antinociceptive effect to the 
left side (L) was observed (R » 
right side). Each point in the graph 
represents a mean of 5 tests. BL " 
base-line response latencies. 
OCarbachol 50y g (0.3 ml) ith. 
A=Atroplne 50 y g (0.3 ml) ith. 
S=Saline 0.3 ml ith. ·-· 
C+A *-*. 
Table II-E. Mean response latencies (seconds, s.d. in brackets) prior to and after intrathecal injection of isotonic NaCl or 
atropine 50 jig and a subsequent intrathecal injection of carbachol 50 \ig, for cats. A l ™ intrathecal isotonic saline, A2 = 
carbachol, В " intrathecal carbachol and atropine . 
P r e i n j e c t i o n value 
Al 
A2 
В 
4 
(0.7) 
3.6 
(1.5) 
2.3 
(0.8) 
Drug 
NaCl 0.3 ml 
" 
Atropine 50 μ g 
(0.3 ml) 
10' 
-
~ 
2.2 
(0.9) 
Carbachol 
no 
50 μ g* 
50 pg 
(0.3 ml) 
5' 
4.7 
(2.0) 
11.3 
(0.9) 
F 5.1 
(4.7) 
15' 
n.d. 
12 (-) 
1.8 
(1.1) 
30' 
3.6 
(1.5) 
12 
(-) 
2.5 
(0.8) 
60' 
n.d. 
#9.1 
(3.7) 
3.7 
(1.7) 
75' 
n.d. 
#8.6 
(3.4) 
n.d. 
120' 
n.d. 
4.1 
(2.7) 
1.9 
(0.7) 
* after 25 yg Carbachol (half of the eventual dose), salivation, defecation and urination occurred 
it right lateralized block 
F at the right side, a short-lasting Increase in response latency was observed 
n.d. not determined 
oo 
ел 
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side. Saline 0.9% 0.3 ml in jec t ion was not associated with any sign of 
ag i ta t ion or altered response to the 70 "C heat probe. Atropine 50 yg in 0.3 
ml saline 5 min. pr io r to the in jec t ion of carbachol 50 pg in 0.3 ml saline 
markedly reduced the 'analgesic' ef fect of carbachol (table I I - E ) . 
S ign i f icant ly the time course of the "analgesic ef fect" af ter the i n t ra -
thecal in jec t ion revealed an ef fect somatotopically-Hmlted with cord derma-
toma regions. Other signs observed to occur af ter the in jec t ion included 
sa l i va t ion , defecation and ur inat ion. There was no change in behavioral 
character is t ics , pupil s ize, breathing rate or heart rate. The r ight ing 
ref lex remained in tac t . 
d. Discussion 
Acetylcholine in a dose up to 150 ug fa i led to change base-line hot-
plate or t a i l - f l i c k response latencies 5 minutes af ter intrathecal in jec t ion 
i n the rat ( c . l . ) . However, intrathecal acetylcholine together with physo-
stigmine tended to increase the hot-plate response latencies ( table I I -C , 
f i g . 11-7), and at a su f f i c ien t dose both the hot-plate and t a i l - f l i c k 
response latencies were increased (table I I -C , f i g . I I - 7 ) . Thus, i t may be 
presumed that a rapid breakdown of acetylcholine alone by spinal ly- located 
enzymes (see Introduction) and enzymes in the CSF (Haber 1980), l imi ted the 
effectiveness of acetylchol ine. Carbachol had been shown to bring about 
behaviorally-defined analgesia af ter intrathecal in jec t ion ( f i g . I I - 8 ; Yaksh 
submitted). As carbachol i s a quarternary ammonium compound and as the blood-
brain barr ier is two-way e f fec t i ve , a local spinal action may be presumed, 
which i s fur ther indicated by the segmental'analgesiaObserved in the cat 
( c . 4 . ) . Furthermore, the s i te of action i s not sheltered by biological bar-
r i e r s , as had been indicated by: electormicroscopic studies which revealed, 
that the ext racel lu lar space of the central nervous system is open to the 
subarachnoid space (Dermietzel 1976), and the presence of free exchange of 
substances, determined by the concentration gradient (Rail 1962, Dermietzel 
1976). 
The se lec t i v i t y of the action was indicated by the reve rs i b i l i t y of 
carbachol-induced 'analgesia' by atropine ( f i g . I I - 8 , f i g . I I - 9 , f i g . 11-10; 
Yaksh submitted) and the absence of changes in motor cont ro l , postural con-
t r o l , and behavior. The atropi ne- revers ib i l i t y may be regarded as an i n -
d icat ion of muscarinic transmission involved. Another ef fect observed af ter 
87 
intrathecal in jec t ion of e i ther cholinomimetic compound was sa l i va t ion . As 
the data indicated that th is ef fect of the cholinomimetic compounds was 
mediated at a spinal level as we l l , th is observation may be interpreted as 
an indicat ion that an ascending t rac t with intraspinal cholinergic synapsis 
terminating in supraspinally-located central nervous system centres involved 
i n innervation of the sal ivary gland, i s present. 
The involvement of central acetyl cholinergic mechanisms in nociceptive 
signal transmission has been known for a long time. A dose-dependent an t i -
nociceptive ef fect involving muscarinic mechanisms was observed fol lowing 
in t ravent r icu lar in jec t ion of acetylcholine (Redigo 1975, Dewey 1976). 
However, the spinal and supraspinal mechanisms in mediating behaviorally-
defined analgesia are not i den t i ca l . An increase of the acetylcholinergic 
ac t i v i t y i n the brain by systemical ly- injected physostigmine or systemic 
nicot ine (Risch 1980, Karras 1980) was shown to be associated with the 
release of Cor t i so l , and the involvement of the hypothalanic-hypophysary 
endorphin system was proposed (Risch 1980, Karras 1980). Furthermore, physo-
stigmine int raper i toneal ly ( i . p . ) in jec ted, l i k e morphine, was shown to 
increase the 5-hydroxytryptamine output i n the brain, and in a dose of 250 
yg/kg i . p . , a 'Straub t a i l ' response was reported to occur (Aiello-Malmberg 
1979). However, methysergide plus phentolamine, or naloxone, in t ra theca l ly -
injected did not af fect intrathecal carbachol-induced anti nociception ( f i g . 
I I - 9 ) . This indicates that neither changes in serotonergic output, nor an 
ef fect involving the noradrenergic inh ib i to ry pathways, nor endorphinergic 
mechanisms account for the observed antinociceptive e f fec t . 
An al ternat ive explanation of the antinociceptive ef fect associated with 
an increase in cholinergic tone may be found in an act ivat ion of inh ib i to ry 
interneurones (Weight 1966). There i s strong evidence that GABA (Otsuka 
1973, Ryall 1975) and glycine (Aprison 1965) act as inh ib i to ry transmitters 
in the spinal cord. D i f fe ren t ia l blocking actions of strychnine on glycine 
and Picrotoxin on GABA have been shown to occur (Gal indo 1969, Ten 
Bruggencate 1969, Obata 1970, Curtis 1967, Curtis 1971). We observed an 
in teract ion of strychnine on carbachol-induced anti nociception in two out of 
f i v e animals ( f i g . I I - 9 , table I I - D ) . This may indicate, that th is in te r -
action at a spinal level is s imi lar to the interactions observed in the 
muscarinic in t racor t i ca l cholinergic inh ib i tory system (Bhargava 1969, 
Jordan 1972, Vazquez 1969, P h i l l i s 1968). Thus, i t was found that g lyc ine, 
an important inh ib i to ry transmitter (Werman 1968), may play a role in the 
ant i nociception induced by an increase in cholinergic tone. A l te rnat ive ly , 
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strychnine may have affected the membrane permeability changes (Pollen 1966) 
induced by the cholinomimetic in teract ions. As Picrotoxin proved to be wi th-
out an observable e f fec t , GABA-ergic transmission does not seem to be invo l -
ved. 
Whereas the hot-plate response latencies were increased dose-dependently 
a f te r intrathecal In ject ions of cholinomimetic drugs, t a i l - f l i c k response 
latencies were not invariably increased. The re la t ive contr ibut ion to each 
of the analgesic tests was presented in the calculated TF/HP index ( t a i l -
f l i c k / hot-plate index) and physostigmine or physostigmine together with 
acetylcholine 50 ug f a i l e d , a f ter intrathecal i n jec t ion , to increase t a i l -
f l i c k response latencies. 
A select ive increase in hot-plate response latencies, thus without a 
concomitant increase in t a i l - f l i c k response latencies, was found in 4-amino-
pyridine-potentiated morphine analgesia af ter intraperi toneal in jec t ion of 
the drugs (Tung 1981). However, the mode of action of 4-aminopyridine is 
d i f fe ren t from those of physostigmine, as 4-aminopyridine was shown to 
increase both evoked and spontaneous release of acetylchol ine, rather than 
i n h i b i t acetylcholinesterase (Harvey 1977), and as the effects of 4-amino-
pyr idine are thought to resul t from n icot in ic rather than muscarinic actions 
(Stoyanov 1976, Johns 1976, Harvey 1977). Furthermore, 4-aininopyridine may 
cause norepinephrine release (Leander 1977). As central n ico t in ic action 
(Phan 1973) as well as noradrenergic effects (Satoh 1970 (1 ,2) , Yaksh 1979 
2) resulted in antinociceptive e f fec ts , these actions of 4-aminopyridine may 
prove to be involved in i t s actions. However, the atropi ne-reversi b i l i ty of 
the cholinomimetic-induced spinally-mediated anti nociception ( f i g . I I - 8 , 
f i g . 11-9), which indicates an interact ion with the intraspinal muscarinic 
chol inergic system (Kayaalp 1980), as well as the fa i l u re of phentol ami ne to 
af fect carbachol-induced analgesia ( f i g . I I - 9 ) , seem to argue against such a 
mechanism. 
The observation that a d i f f e ren t i a l effectiveness in increasing hot-
plate and t a i l - f l i c k response latencies presented i t s e l f af ter in jec t ion of 
physostigmine or physostigmine together wi th 50 yg of acetylcholine but not 
a f te r physostigmine together with 150 ug acetylcholine could argue in favour 
of k inet ic factors being involved. However, the dissociat ion of effects at 
intermediate (but not at low) doses of endorphinomimetics argues against 
k ine t ic factors, and, a l te rna t ive ly , a f a c i l i t a t o r y ef fect in the neuro-
physiological substrate of the t a i l - f l i c k ref lex as a consequence of an 
exci tatory (acetylchol inergic) in te rac t ion , which is overruled by an i n -
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h i b i t o r y ef fect at a higher dose may prove to be present. I f so, t h i s 
sequence may be regarded as an expression of a depolarizing block. 
I t may be noticed, that such a dissociat ion of effects in the hot-plate 
t e s t and the t a i l - f l i c k r e f l e x , which, as was indicated above, was also 
observed for the endorphinomimetics at intermediate doses (nicomorphine 6 
y g , morphine 2 w. Chapter I I ) , occurred af ter intrathecal i n j e c t i o n of the 
endorphinomimetics plus physostigmine as w e l l . The simultaneous intrathecal 
i n j e c t i o n of physostigmine and 3 ]ig nicomorphine actually shortened the t a i l -
f l i c k response latencies, while increasing the hot-plate response latencies 
(Dirksen 1982, Dirksen to be published; see below). The r e l a t i v e c o n t r i ­
bution to each of the analgesic tests i s presented i n the scatter p l o t of 
f i g . 11-11, and in the calculated TF/HP index (see Chapter I ; see tables 
I I-A to I I - E ) . 
Δ 
300 
200 
100 
0 
-50 
Fig. 11-11. Scatter plot of the maximum relative 
change (Δ%) In hot-plate and tail-flick response 
latencies after intrathecal injection of endor-
phinomimetic drugs, cholinomimetic drugs or the 
combination of these two, as well as the combina­
tion of endorphinomimetic drug and the choliner­
gic blocking agent atropine. All drugs were in­
jected intrathecally (M = morphine: 1 - 1 yg, 2 
= 2 pg, and 3 = 3 \ig; N • nicomorphine: 3 = 3 
yg, 6 = 6 yg; Ρ = physostigmine 15 pg; Ach = 
acetylcholine: 50 » 50 yg, 150 = 150μ g; A -
atropine 15 yg. 
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В. The relevance of cholinergic transmisson at a spinal level to opiate 
effectiveness in the rat 
a. Introduction 
As endorphins, endorphinomimetics and acetylcholinergic transmission are 
known to induce changes i n each others a c t i v i t y at a cerebral level (see Dis­
cussion), such possible interact ions were subject of our subsequent study 
(Dirksen 1982, Dirksen to be published, Dirksen submitted f o r publ icat ion). 
b. Materials and methods 
To administer the drugs i n t r a t h e c a l l y , a specially-prepared polyethylene 
catheter (PE-10) was inserted i n t o the lumbar subarachnoid space through an 
opening i n the cisterna magna. Drugs were injected 7 - 1 0 days af ter com­
p l e t i n g the implantation and the i n j e c t i o n of a drug employed a gear-driven 
microin jector. To measure the nociceptive threshold in r a t , the hot-plate 
(maintained at 52.5°C) and the t a i l - f l i c k (a project ion lamp focused through 
a s l i t over which the t a i l was placed) tests were employed. Other deta i ls of 
the methods and materials are presented elsewhere (Yaksh 1976 2, see Chapter 
I ) . Drugs in jected included: physostigmine s a l i c y l a t e , atropine sulphate, 
3,6-d1nicotinoyl morphine (nicomorphine),and morphine hydrochloride. A l l 
drug-containing solutions were freshly prepared p r i o r to i n j e c t i o n . 
c. Results 
Intrathecal i n j e c t i o n of 3 y g nicomorphine or 1 pg morphine resulted in 
a comparable increase i n the hot-plate response latencies (table 11-A and 
I I - F ) . Intrathecal i n j e c t i o n of 3 yg nicomorphine together with physostig-
mine 15 μ g was not associated with a s i g n i f i c a n t fur ther increase i n the 
hot-plate response latencies, i f compared to the increase i n hot-plate 
response latencies a f t e r the intrathecal i n j e c t i o n of 3 pg nicomorphine (two 
sample t - t e s t of the AUC's: p> 0.2)(table I I - F ; f i g . 11-12). The e f f e c t of 
nicomorphine 3 yg in increasing the t a i l - f l i c k response latencies (table 
I I -A, and I I-F) proved to be abolished by the co-administration of physostig-
mine (two sample t - t e s t , ρ < 0 . 0 1 ) . The TF/HP index was -0.24, indicat ing 
TABLE II-F. Mean response latencies (seconds; s.d. in brackets) after Intrathecal Injections of nicomorphlne (N) Ъ\%, nlcomorphine (N) 
3 yg together with physostlgmine (Ph) 15 \ig, morphine (M) 1 yg, and morphine (M) 1 pg together with physostigmine (Ph) 15Wg. There were 
5 rats in each group. The volume injected was 20 μΐ; 10 μΐ the drug-containing solution and 10 HI vehicle wash. 
Group 
of rats 
N3 
N3 + PhlS 
Ml 
Ml + Phl5 
Mean 
preinjection 
response 
latencies 
HP TF 
15.0 7.6 
(3.4) (1.5) 
15.8 7.9 
(5.9) (1.0) 
21.4 7.2 
(6.4) (1.4) 
19.0 7.4 
(5.6) (0.6) 
5 
HP 
19.5 
(8.9) 
37.6 
(17.7) 
16.0 
(6.0) 
42.7 
(15.2) 
1 
TF 
12.0 
(3.0) 
7.8 
(3.4) 
7.8 
(0.2) 
10.6 
(3.8) 
15 
HP 
30.2 
(14.5) 
40.4 
(14.0) 
17.0 
(6.2) 
43.2 
(15.6) 
• 
TF 
15.5 
(4.5) 
4.9 
(0.7) 
8.3 
(1.3) 
9.1 
(2.3) 
Mean response latencies after injection 
30' 
HP 
24.9 
(10) 
32.9 
(17.2) 
27.3 
(8.8) 
58.6 
(3.1) 
TF 
14.1 
(4.4) 
5.9 
(1.1) 
8.1 
(0.9) 
9.5 
(2.3) 
60 
HP 
19.4 
(5.6) 
23.4 
(20.9) 
26.4 
(8.5) 
51.1 
(13.4) 
1 
TF 
9.3 
(2.3) 
7.1 
(0.8) 
9.0 
(0.8) 
9.5 
(1.1) 
90 
HP 
n.d. 
22.8 
(9.3) 
24.0 
(6.5) 
44.7 
(21.1) 
1 
TF 
n.d. 
6.6 
(1.1) 
7.9 
(1.1) 
7.8 
(0.8) 
120' 
HP 
n.d. 
12.6 
(4.9) 
17.2 
(6.1) 
22.8 
(0.9) 
TF 
n.d. 
7.0 
(1.0) 
6.5 
(1.8) 
7.6 
(1.7) 
150' 
HP 
n.d. 
16.6 
(3.0) 
19.9 
(5.9) 
n.d. 
TF 
n.d. 
7.1 
(1.3) 
6.5 
(1.9) 
n.d. 
TF/HP 
i ndex 
1.02 
-0.24 
0.97 
0.21 
to 
TABLE II-G. Mean response lateiicies (seconds; s.d. in brackets) after intrathecal injections of nicomorphine (N) SlJg, nicomorphine (N) 
6 yg together with atropine (A) 15pg, morphine (M) 3ng, and morphine (M) 3pg together with atropine (A) 15yg. There were 5 rats in 
each group. The volume injected was 20 111, 10 Ul was drug-containing solution and 10μ 1 vehicle wash. HP = hot-plate test, 
TF » tail-fliclt reflex. 
Group 
of rats 
N6 
N6 + A15 
M3 
M3 + A15 
Mean 
prelnjection 
response 
latencies 
HP TF 
15.6 7.7 
(7.4) (1.9) 
13.3 7.4 
(3.3) (1.1) 
17.1 6.8 
(4.1) (1.8) 
16.9 7.2 
(4.0) (0.8) 
5' 
HP TF 
31.9 9.2 
(16.3) (1.3) 
19.6 8.2 
(17.2) (0.7) 
54.4 22.1 
(12.5) (7.4) 
46.7 12.3 
(16.3) (4.5) 
15 
HP 
36.3 
(18.4) 
20.5 
(9.5) 
60 
(-) 
46.1 
(16.4) 
1 
TF 
9.4 
(1.9) 
7.8 
(1.6) 
27.0 
(4.9) 
15.0 
(8.4) 
30 
HP 
48.1 
(13.6) 
19.2 
(11.0) 
60 
(-) 
45.2 
(20.3) 
Mean response latencies after injection 
60' 90' 180' 
TF 
8.5 
(1.6) 
6.5 
(1.5) 
28.2 
(2.7) 
14.7 
(8.7) 
HP 
31.6 
(20.7) 
13.4 
(3.7) 
60 
(-) 
39.7 
(21.6) 
TF 
8.1 
(0.4) 
5.7 
(1.3) 
24.7 
(6.7) 
12.8 
(9.6) 
HP 
14.9 
(5.2) 
15.4 
(4.7) 
60 
(-) 
26.9 
(20.8) 
TF 
7.8 
(0.6) 
7.0 
(1.1) 
22.2 
(5.5) 
8.5 
(2.8) 
HP 
n.d. 
n.d. 
45.8 
(15.4) 
n.d. 
TF 
n.d. 
n.d. 
17.3 
(8.5) 
n.d. 
240' 
HP 
n.d. 
n.d. 
20.9 
(18.4) 
n.d. 
TF 
n.d. 
n.d. 
6.2 
(1.5) 
n.d. 
TF/HP 
Index 
0.11 
0.21 
0.95 
0.61 
σι 
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the dissociation of e f f e c t in these two tests. The increase in hot-plate 
response latencies observed af ter intrathecal i n j e c t i o n of l p g morphine, 
was further increased by the co-administration of 15 yg physostigmine 
(tables II-A and I I - F ; see f i g , 11-12) (two sample t - t e s t , ρ < 0.001). 
However, no s i g n i f i c a n t change was present in the t a i l - f l i c k response 
latencies (two sample t - t e s t , n . s . j . Thus, co-administration of morphine 1 
vg and physostigmine 15 pg caused a s i g n i f i c a n t further increase of the hot­
plate response latencies, whereas the e f f e c t of co-administration was not 
apparent i n the t a i l - f l i c k ref lex and a dissociat ion i n the e f f e c t of 
morphine together with physostigmine i n the two analgesic tests i f f u r t h e r 
indicated by the TF/HP index of 0.21. 
Intrathecal i n j e c t i o n of 15 yg atropine attenuated the effectiveness of 
both morphine З у д (two sample t - t e s t , ρ < 0.001 for ei ther analgesic test) 
and nicomorphine 6 yg (two sample t - t e s t , ρ <0.01)( tab le I I -A, I I -G; f i g . 
11-13). None of the drugs, e i ther alone or in combination, caused any change 
i n behavior, postural tone, r ight ing r e f l e x , or motor problems. 
Fig. 11-12. The effects of physo­
stigmine in endorphinomimetic in­
duced behaviorally-defined anal­
gesia at a spinal level (C = pre-
injection response latencies; N3 
= nicomorphine 3 yg ith.; Ml • 
morphine 1 y g ith.; Ρ " physo­
stigmine 15 y g ith.; ith.: intra-
thecally injected). 
N3 NP С Ml MP 
94 
60 
u 
ш (Л 
2 
ш 
й зо-
ζ 
о 
Q. (Л 
Ш 
ОС 
α. 
I 
0 
τ 
- Ι ­
ο 
"^" 
;^; 
1 
• I I I M 3 M A 
Γ" 
С 
-
N6 
Ш I I NA 
Fig. 11-13. The effects of 
atropine on endorphinomime-
tic-induced behaviorally-
defined analgesia at a spinal 
level. The quantitative 
change may not be evaluated, 
as 60 seconds represents the 
cut-off time (C = pre-
injection response latencies; 
M3 = morphine 3 yg ith.; N6 " 
nicomorphine 6 y g ith.; A = 
atropine 15 \ig ith.; ith. = 
intrathecally injected). 
Discussion. 
At a cerebral level endorphins, endorphinomimetics and acetyl Chol inergi с 
transmission are known to induce changes in each others activity. Opiates 
(Schmidt 1978, Zsilla 1976, Jhamandas 1976) and endorphins (Moroni 1977) re­
duced the turnover rate of acetylcholine after intraventricular injection, 
and this may be thought to be the result of a reduced neuronal impulse flow 
of the cholinergic system. Physostigmine, in addition to analgesic proper­
ties of itself, was shown to potentiate morphine analgesia (Harris 1969, 
Howes 1969, Dewey 1970, Ireson 1970, Calcutt 1971, Pleuvry 1971, Tulunay 
1976), and cholinergic blockade by atropine inhibited the analgesic actions 
of morphine (Tulunay 1976). At a spinal level, similar interactions prove to 
be present. Thus, physostigmine obviously potentiated morphine"analgesia" 
(table 1I-F, fig. 11-12), and atropine reduced it (table 1I-G, fig. 11-13). 
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Although simi lar effects were observed af ter m'comorphine and physostigmine 
or atropine, the quant i tat ive change was at variance. Thus, physostigmine 
was less ef fect ive in potentiat ing nicomorphine-induced spinally-mediated 
behaviorally-defined analgesia, whereas atropine abolished i t s e f f e c t i v i t y 
( table I I - F , and I I -G ; f i g . 11-12, f i g . 11-13). Whether th is simply re-
presents a d i f fe rent point at the dose-response curve is to be determined. 
Another aspect of intrathecal nicomorphine-induced behavi oral ly-def ined anal-
gesia which was at variance with the ef fect of morphine was the naloxone-
r e v e r s i b i l i t y . Naloxone inh ib i ted the antinociceptive ef fect of both endor-
phinomimetic drugs, but the i nh ib i t i on of nicomorphine-induced ant inoci-
ception was incomplete (table I I - B ) . 
The differences in respect to the in teract ion of m'comorphine with physo-
stigmine, the abolishment of ef fect of m'comorphine af ter cholinergic block-
ade with atropine, the TF/HP index ( f i g . 11-11; Chapter I I I . A . d . ) , and a non-
naloxone reversible component in the antinociceptive ef fect of m'comorphine 
af ter intrathecal i n jec t i on , make i t tempting to speculate on a speci f ic 
cholinergic mechanism involved in nociception af ter intrathecal m'co-
morphine, as increased cholinergic tone at a spinal level is associated with 
behavi oral ly-def ined analgesia which is not attenuated by naloxone (Yaksh 
submitted; Chapter I I I - A ) . Whether nicomorphine has specif ic cholinomimetic 
ef fects or a high potency to af fect acetylcholine metabolism, a feature 
which i t may share with other endorphinomimetics and naloxone (Manner 1976), 
remains to be determined. 
The interact ions of cholinomimetic drugs and endorphinomimetic drugs i s 
not invariably associated with analgesia (Moroni 1978). Fac i l i ta to ry in te r -
actions have been found in some regions of the brain (Vallano 1980), and of 
special in terest are experimental results which indicate that physostigmine 
reduces the respiratory depressant action of opiates (Weinstock 1980). 
I t may prove advantageous to use these d i f fe ren t ia l actions with respect 
to the respiratory centres, and i f nicomorphine proves to have cholino-
mimetic effects of i t s e l f , i t may be thought to potentiate i t s endorphino-
mimetic actions at a spinal l eve l , whereas i t attenuates i t s respiratory 
depressant actions. 
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CHAPTER IV 
Epidural and Spinal Endorphinomimetlcs for Surgery and 
Postoperative Pain Relief 
A. The antinociceptive effectiveness and the side-effects of epidural ly and 
in t ra thecal ly injected endorphinotnimetics for surgery and postoperative 
pain r e l i e f 
a. Introduction 
As was discussed in chapter I , I I , and I I I , "analgesia" may be i n s t i -
tuted by modif ication of the transmission of the nociceptive signal by a 
select ive drug-induced functional change of the afferent neuronal c i r c u i t or 
the descending pathways. As to the afferent neuronal c i r c u i t , opiates proved 
to be ef fect ive and i t may be presumed that i t s effectiveness relates to the 
a b i l i t y of the opiates (endorphinonn'metics) to mimic the inh ib i to ry effects 
of endorphin on substance P-excitatory transmission (Chapter I ) . Further-
more, of the various poss ib i l i t i es to i n s t i t u t e at a spinal level such a 
select ive drug-induced antinociceptive e f fec t , especially opiate in jec t ion 
has found i t s c l i n i ca l appl icat ion. The main reasons and intentions to adapt 
such a method are: to l i m i t the presence of the drug to the locus of i t s 
effectiveness (see General Int roduct ion) , and to reset transmission of the 
nociceptive signal at i t s entrance to the central nervous system as to 
preserve sensory homeostasis. 
Pr ior to the c l i n i ca l t r i a l s on the use of the method of peridural or 
Intrathecal in ject ions of opiates for anti nociception during surgery and the 
postoperative period, the poss ib i l i t y of t ox i c i t y had to be considered. How-
ever, opiates do not exhib i t local or systemic t issue tox i c i t y af ter e i ther 
Intramuscular or intravenous administrations. Also, mul t ip le experimental 
intrathecal in ject ions had been shown not to resul t i n any toxic ef fect (see 
above). When i t was apparent that i n humans too, mul t ip le intrathecal i n -
jec t ions (Wang 1978, Wang 1979) or epidural in ject ions up to four days 
(Behar 1979) did not resul t i n any toxic e f fec t , we considered the method as 
applicable. Nevertheless, careful at tent ion has to be paid to ensure that 
no preservatives are present in the preparations used for intrathecal or 
peridural administrations, as these can cause serious complications (Mathews 
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1979, Thornson 1947). 
After a preliminary assessment of the dose (mg) and volume (ml) required 
for adequate "analgesia" (Dirksen 1980 2), the effectiveness of peridural 
and intrathecal endorphinomimetics was clinically evaluated (Dirksen 1980 
3). 
b. Patients, materials, and methods 
The patient population, surgical procedures, analgesic drugs, doses, 
mode of application and effectiveness are described in table II-H. During 
the pre-operative visit, all patients were fully informed and consent was 
obtained. Evening medication was Mogadon and, if requested, 10 mg 
diazepam. Premedication consisted of diazepam 10 mg orally two hours before 
coming to the theatre, and atropine 0.25 mg and droperidol 5 mg (n=56) intra-
muscularly half an hour before coming to the theatre. Nine patients only 
received 10 mg diazepam orally two hours before coming to the theatre. All 
patients were fasted. After arrival to the induction room, blood pressures 
(oscillotonometric measurement), pulse rates and pulse quality, breathing 
rates and breathing pattern, were noted for all patients (fig. 11-14). The 
skin was disinfected and anesthetized with one or two milliliters of a 1% 
Xylocaine solution. For epidural puncture an 18 gauge Tuohy needle from the 
D 
disposable Abbott tray was used (58 patients). During the insertion, all 
patients lay in the left lateral position. The epidural space was identified 
by using the hanging drop technique (Moore 1975). After identification, an 
epidural catheter was introduced approximately 3 cm cephalad. The site of 
puncture is reported in table II-H. The site of the catheter tip will be one 
segment higher than the actual puncture. After the epidural catheter was 
secured and the patient was instructed to turn and lie on the back, he/she 
was then moved to the operating theatre. All patients were connected to an 
ECG and pulse monitor (Siemens Sirecust 300 A). The blood pressures were 
measured again, pulse quality and pulse rates, breathing pattern and 
breathing rates were established, the expiratory carbon dioxide concentra-
tion was measured with a capnograph (Jaeger), and the pupil size was ob-
served. Bradycardia was defined as a heart rate of less that 50 b.p.m.. 
Respiratory depression was defined as an expiratory carbon dioxide concentra-
tion exceeding 6%, or a respiratory frequency of less than 10 (breath per 
minute). The endorphinomimetic drug, diluted in glucose 5% to a total volume 
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I PERIDURAL PUNCTURá 
IGENERAL ANAESTHESrAl 
Fig. 11-14. Flowchart of the procedures conducted. 
of 20 ml, was injected through the catheter. 
A similar procedure was followed for the intrathecal administration. Du-
ral puncture with a 22 gauge needle was performed at either L, - or Ц . 
in seven patients in the lateral position. A total volume of 3 - 5 ml 
glucose 5% containing 2 - 4 mg nicomorphine was injected into the subarach­
noid space. Four groups of patients can be distinguished in this study 
(table II-H): 
group I ¡received nicomorphine 2 - 4 mg intrathecally (n=7) 
group II rreceived nicomorphine 5 mg epidurally (n=ll) 
group III : received nicomorphine 10 mg epidurally (n=24) 
group IV :received piritramide 15 mg epidurally (n=23). 
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Table II-H. Patient population (four groups), analgesic drugs, dose, 
solution, mode of application, surgical procedures, and effectiveness. 
1 
11 
U l 
1 ^ 
ENDORPHINOMIMETIC 
NICOMORPHINE 
NIC0M0RPH1NE 
MCOMORPINE 
PIRITRAMIDE 
MG 
2 - 4 
5 
10 
15 
MODE/SOL/VOL 
¡NTRATHECALLY 
OLUCOSE 5% 
3 - 5 m l 
EPIDURALLY 
0LIC0SE 5% 
20 ml 
EPIDURALLY 
GLUCOSE 5% 
20 ml 
EPIDURALLY 
GLUCOSE 5% 
2C ml 
SJM3ER 
o( p ts 
7 
11 
24 
2 3 
ASA AGE 
I - I I 52 
І - Ц І иг 
I - I ! 
1-11 
49 
41 
SURGICAL PROCEDURE 
lower abaommal 
lower ubdommal 
orthopaedic 
репрпегш vascular 
lower abdominal 
upper abdominal 
penphera vascular 
ower abdominal 
upper a b d o m ' r a l 
DJRA'ION 
surg 
2 hrs 
2 h r s 
2 hrs 
2 hrs 
RECURRENCE OF 
NOCICEPTION after 
2 0 h r s ( 4 - 2 7 Г 
4 hrs I 1 - 91 
4 hrs ( 1 . 5 - β) 
5.75hrs 125-10) 
analysis o' variance group I different from group II I I I . IV. ρ < 0.01 
After the solut ion was in jected, a period of at least 30 minutes pre­
ceded induction of general anesthesia. During t h i s pre-induction period, a l l 
variables were re-examined every 2 to 3 minutes. Voluntary motor control was 
tested by requesting the patients to move and to raise t h e i r legs. 
ρ 
Anesthesia was induced with a sleep dose of thiopentone (Pentothal ) 
(as assessed by loss of eyel id r e f l e x ) , followed by 4 mg pancuronium i n t r a ­
venously to f a c i l i t a t e intubat ion, v e n t i l a t i o n and surgery. L ight hyperventi­
l a t i o n (expiratory carbon dioxide 4.6%) was used to prevent spontaneous 
breathing. Incremental doses of thiopentone, diazepam, or droperidol were 
given i f anesthesia was too l i g h t . No awareness occurred. I f the endo­
tracheal tube provoked react ion, fluothane 1/4 - \/2% was added to the 
inspiratory gases (nitrous oxide/oxygen: 6/3). When spontaneous breathing 
had resumed af ter surgery, expiratory carbon dioxide was measured. The 
qual i ty of analgesia was subjectively assessed by questioning the pat ient 
(eg. : 'Are you feel ing pain?'; i f yes: 'Are you bothered by t h i s p a i n ' , or : 
'Does i t h u r t ? ' ) . 
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с. Results 
As we established in our fonner study (Dirksen 1980 2 ) , the pinprick 
method can be used to establish the extent of blockade. Pinpricks in the 
anesthetized area feel ' d i f f e r e n t ' , due to the lack of "hurt ing pain" 
(Bowsher 1978, Hassler 1972). I n i t i a l spread is confined to regions l imi ted 
with cord dermatoma regions, s imi lar to conventional intrathecal or epidural 
anesthesia. In t h i s study the premedicated patient could not discriminate 
the difference accurately. As i n i t i a l spread did not seem to be related to 
the eventual extent nor to the incidence of supraspinally-mediated side-
e f f e c t s , no further e f f o r t s were made to establish the extent of the 
blockade. 
Invar iably, the f i r s t sign of blockade appeared i n 5 - 10 minutes and 
consisted of increased deflections of the Plethysmograph (see IV-B). Motor 
control was preserved i n a l l pat ients. Somatognosia was i n t a c t in a l l 
pat ients, necessitating general anesthesia to allow f o r surgery to take 
place. 
The mean duration of operation was 2 hours. I f the peritoneum was open­
ed, the intest ine was observed for p e r i s t a l t i c movements, which were pre­
served i n a l l pat ients. In a l l cases, operative conditions were sat is facto­
ry to the surgeon. Br ief changes (less than 5 seconds) i n heart rate asso­
ciated with reduced deflections of the Plethysmograph could be observed at 
peritoneal handling and any sudden increase of surgical trauma. No last ing 
vegetative reactions ( i . e . tachycardia, bradycardia, hypertension, sweating) 
were observed. At the end of the operation, those patients not l i s t e d in 
table I I - I (CNS depression; see Discussion, b. The side-effects of epidural-
l y or in t rathecal ly injected endorphinomimetics) were f u l l y awake and free 
of pain. During the postoperative period the patients were observed f o r side-
effects (table I I - I ) , duration of blocked nociception (table II-H) and 
changed motor c o n t r o l . 
c . l . Antinociceptive effectiveness 
The blockade of nociception during anesthesia was ref lected by the ab­
sence of vegetative reactions and a stable pat ient . Br ief changes (less than 
5 seconds) i n heart rate and reduced deflections of the Plethysmograph did 
occur occasionally at peritoneal handling and sudden increases of surgical 
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trauma. These changes did not pers is t . No additional intravenous analgesics 
were necessary. The blockade of nociception outlasted the surgical period 
and l e f t the patient with a blocked nociceptive signal transmission charac­
ter ized by the absence of "hurt ing pain". Intrathecal nicomorphine (group I ) 
resulted i n a s i g n i f i c a n t l y longer blockade of nociceptive signal transmis­
sion (analysis of variance: group I d i f f e r e n t from groups I I , I I I and IV; 
ρ < 0.01; table I I - H ) . I f droperidol had been omitted from the premedication 
(n = 9 ) , t h i s seemed to be associated with a less complete blockade of 
nociception. 
C.2. Side-effects 
The side-effects observed are presented i n table II-H and included post­
operative nausea (17%), postoperative sleepiness (CNS depression; 5%), brady­
cardia (3%), postoperative hypercapnia (12%), postoperative bradypnoea (5%), 
and postoperative urine retention (8%). Sleepiness, nausea, hypercapnia, and 
bradycardia were accompanied by a narrowing of pupil diameter. The incidence 
of side-effects was highest a f ter intrathecal application (86%). Also, epi­
dural i n j e c t i o n of the higher dose of nicomorphine was accompanied by a high 
incidence of side-effects (42%), of which urinary retention was prevalent 
and did not occur in the other groups. In two patients a hypertensive period 
(not caused by pain) occurred i n the l a t e postoperative period (see below). 
Table II-I. Side-effects observed after intrathecal or epidural administra­
tion of the endorphinomimetic drugs. 
j f O i P 
SICE E"ECTS 
DRUG 
1 
1 1 NICOMOnPHINE 
I I , MC0M0BPH1NE 
I I I 
IV 
M C O M W P H I N E 
PIRITHAMIOE 
TC 
Мб 
2-4 
S 
10 
19 
Τ». 
MODE 
Ol 
аэрііссіюп 
INTRATHECAL 
EPIDURAL 
EPIDURAL 
EPIDURAL 
Nuntoer 
ol 
p.s 
7 
11 
24 
23 
65 
NAUSEA 
3 
2 
4 
2 
11 
[4Э%| 
(1»%l 
[16%] 
[ 9%| 
ilT'/el 
CNS 
deprossion 
1 IU%I 
1 I 9%l 
1 I Oi l 
3 1 5%) 
BRADYCARDIA 
<50 
2 ' 9"/.l 
2 1 3%l 
R_ESPIRATO_R 
е к р C 0 2 
> 60·/. 
3 U3%> 
1 1 9%l 
3 [1Ζ7/Ί 
1 1 t%] 
8 l ' 2 * l 
DEPRESSION 
bradypneu 
1(101 
ІІ1И4) 
1 
JÎINARY SIDE E 
r«lenlion '
 0 i 
pis 
1 
1 1 L%l 9 I 21%) 
1 1 4%l ' 
31 5%l 5 1 B%] 
FFECTS 
% 
16 
11 
42 
13 
32 
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d . Discussion 
The data presently available on in t ra thecal ly or epidural ly injected 
endorphinominietics include observations in chronic pain treatment (Bapat 
1979, Behar 1979, Chayen 1980, Cousins 1979, Johnston 1980, Magora 1980 
(1 ,2 ) , Wang 1979, Howard 1981, Glynn 1981), postoperative pain treatment 
(Bapat 1979, Behar 1979, Chayen 1980, Cousins 1979, Davies 1980 1 , Ebert 
1980, Glynn 1979, Graham 1980, Magora 1980 1 , Nelson 1980, Samii 1979, Wolfe 
1980, Gebert 1980, McClure 1980, Glynn 1981, Barron 1981, Pinckaers 1981), 
obstetr ic analgesia (Bapat 1979, Booker 1980, Chayen 1980, Husemeyer 1979, 
Magora 1980 2, Perriss 1980, Scott 1980, Carrie 1981), perioperative 
analgesia (Dirksen 1980 (2,3) , Glynn 1979, Mathews 1980, Müller 1980, 
Christensen 1982), and experimental applications (Lesl ie 1979, Torda 1980). 
ß-endorphin (Oyama 1980) and d i f fe rent kinds of endorphinomimetics, i . e . 
morphine, methadone, pethidine, d i laud id , fentanyl , diamorphine, and nico-
morphine have been used. 
The epidural ly or in t ra thecal ly in jected endorphinomimetics nicomorphine 
and p i r i t ramide, supplemented with l i g h t general anesthesia, provided excel-
len t conditions for surgery. The course of anesthesia was characterized by 
s t a b i l i t y and the absence of autonomic ref lexes. These observations were 
recently substantiated by others (Müller 1980, Kaufman 1981). Short- last ing 
changes in heart rate (less than 5 seconds) could be observed during surgery 
and can be related to the l i g h t level of anesthesia, the presence of somato-
gnosy, or the i n a b i l i t y of opiates to af fect the short-latency polysynaptic 
ref lex and related transmisson (see Chapter I I ) . I t was at no time necessary 
to supplement anesthesia with intravenous analgesics. As the blockade of s ig-
nal transmission is confined to nociception and the other sensory modalit ies 
remain unchanged, general anesthesia can not be omitted i f th is technique is 
used for "analgesia" during surgery. Motor control was unchanged, and no 
muscular r i g i d i t y occurred. 
d . i . The antinociceptive effectiveness of epidural ly or in t rathecal ly 
injected endorphinomimetics 
Systemic neuroleptic drugs are known to potentiate narcotic analgesics. 
A s ign i f i cant decrease in ED50 was shown to occur as a consequence of the 
systemic administration of dopamine receptor blocking agents (Tulunay 1976). 
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This indicates that the dopaminergic system has a modulatory action on the 
antinociceptive ac t i v i t i es of endorphinomimetics. Evidence for a descending 
dopaminergic pathway to the spinal cord (Hökfelt 1979 2) and an independent 
dopaminergic system in the spinal cord (Karoum 1980) has recently been ob-
tained (see Chapter I ) . The simultaneous administration of droperidol and 
morphine int rathecal ly was more potent than morphine (Kim 1980). These obser-
vations substantiate our observation of an increased ef fect of per idural ly 
or in t rathecal ly injected endorphinomimetics, i f combined with premedication 
with droperidol. One patient in group I (nicomorphine in t rathecal ly) did not 
receive droperidol i n the premedication and analgesia lasted 4 hours (table 
I I - H ) . In 50% of the patients in group I I I (nicomorphine 10 mg) who did not 
receive droperidol (n = 8 ) , analgesia was considered f a i r , whereas in a l l 
other patients (with droperidol) analgesia was excel lent. 
Diazepam may have an influence on spinal signal transmission as w e l l . 
Spinally-located receptors for diazepam were shown to exist (Möhler 1977), 
binding to which might involve enhancement of stimulus-evoked presynaptic 
transmission (Curtis 1967, Möhler 1979). No data are presently available on 
the nature of th is re lat ionship. 
Nitrous oxide must have added to "analgesia" during the period of 
surgery. I t s ef fect on ce l l u la r ac t i v i t y under the influence of nociceptive 
signals (Kitahata 1971, Shimoji 1971 (1 ,2 ) , Pearl 1976, Spencer 1976), the 
naloxone-reversibi l i ty of nitrous oxide analgesia, and the tolerance to 
nitrous oxide analgesia associated with morphine tolerance (Berkowitz 1976), 
make i t tempting to speculate on a nitrous oxide-induced conformational 
change of the opiate receptor towards the agonist conf igurat ion. This too 
would resul t in an increased analgesic ef fect of spinal opiate. Since 
nitrous oxide obviously gains access to higher centres of the central 
nervous system, the analgesic ef fect resul t ing from th is must have added to 
the spinal analgesia. The exact nature of summation of these analgesic 
effects remains to be determined (Snyder 1977, Yaksh 1978 5) . 
The absence of "hur t ing" pain was character ist ic during the post-
operative period. The patient could feel the wound, but i t was not bother-
some. The duration of th is ef fect (4 - 20 hrs) depended on the drug used, 
and the mode of administrat ion. In contrast with these posi t ive f indings are 
observations of a high incidence of inef fect ive analgesia (Husemeyer 1979, 
Husemeyer 1980) or only moderate effectiveness (Bapat 1979, Magora 1980 2, 
Yu 1980, Perriss 1980, Writer 1980) in obstetr ic appl icat ions. The recent 
posi t ive results of intrathecal opiates (Scott 1980, Ahmad 1981) and high 
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dose epidural opiates (Härtung 1980) in labour may indicate an inadequate 
segmental l eve l . A l te rnat ive ly , an explanation can be found in the recently 
observed increased level of c i rcu la t ing 0-endorphin in obstetr ic patients 
(Csontos 1979, Fletcher 1980, Goland 1981). This increase can e i ther resul t 
from an increase of the release of hypophyseal endorphin or resul t from 
release of endorphin generated by the placenta (Odagiri 1979, Nakai 1978, 
Houck 1980). Competition fo r the available endorphin receptor si tes would 
reduce the ef fect of external ly-appl ied endorphinomimetic drugs. 
Whether access i s gained to the receptor s i tes , is determined by 
k ine t i cs . Some important considerations are: 
1 . The receptor s i tes mediating the analgetic effects are located in the 
spinal cord (see Chapter I ) . The spinal cord is much shorter than the 
vertebral column (lower level L . ) . Application of the endorphinomimetic 
drug should resul t i n a su f f i c ien t concentration at the receptor l eve l . 
The level of the blockade i s determined by the cord segment (Knell 1980) 
2 . The dose of the endorphinomimetic i s not related to body weight, but w i l l 
depend on the to ta l amount of binding si tes to be occupied (Bromage 1980) 
3. Spread of the opiate w i l l a f fect spinal segments, resul t ing in a blockade 
somatotopical ly-l imited with cord dermatoma regions (Bromage 1980, 
Dirksen 1980 2) 
4 . Spinal application of nicomorphine resulted in a prolonged effectiveness 
compared with epidural in ject ions (table I I - H ) . This observation i s in 
accordance with data on local anesthetics (Giasi 1979), not supporting 
the concept that a rapid vascular absorption from the subarachnoid space 
occurs (see below) 
5. Solutions in the epidural space are d i rec t ly exposed to a large vascular 
surface area that provides ideal conditions for rapid vascular uptake. 
The amount that w i l l be retained in the epidural space w i l l depend on the 
l i p i d - s o l u b i l i t y of the drug used (see below). 
The mode by which the epidural ly injected drug gains access to the 
receptor compartment i s presently not known. I t has generally been presumed, 
that the rapid appearance of high concentrations of endorphinomimetics in 
the CSF (see below), re f lec ts the a b i l i t y of these drugs to penetrate the 
meninges in humans (Cousins 1979). I f so, the amount of drug absorbed into 
the cerebrospinal f l u i d w i l l depend on the local concentration of the drug 
i n the epidural and subarachnoid spaces, the passage through the membrane 
separating the epidural space from the cerebrospinal f l u i d , sequestration 
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of the drug, and elimimation of the drug. After being absorbed into the CSF, 
the drug w i l l have to penetrate the neuraxis where the receptors are 
located. Such penetration does occur (Teschemacher 1973), but may require a 
long time. A l te rnat ive ly , the drugs may prove to be secondarily transported 
to the CSF, which would mean that the drug is absorbed by a segmentally 
organized blood flow supplying the neuraxis and del ivering the drug to i t s 
s i tes of act ion; secondarily to t h i s , the drug w i l l appear in the CSF. No 
data are presently available to exclude ei ther poss ib i l i t y . 
d.2. The side-effects of epidural ly or in t rathecal ly injected 
endorphi nomimetics 
Even though the intent ion as " to l i m i t the presence of a drug to i t s 
s i t e of effectiveness" i s good (see General Int roduct ion) , many w i l l be 
aware of the fact that the presence of a drug wich has been injected into 
the epidural or intrathecal space, is not l imi ted to the spinal structures. 
Various side-effects related to drug-action in specif ic parts of the central 
PSYCHOTROPIC EFFECTS 
RESPIRATORY DEPRESSION 
REDUCED SYMPATHETIC TONE — 
PUPILLARY CONSTRICTION 
CIRCULATORY DEPRESSION 
NAUSEA 
ANALGESIA 
URINARY RETENTION 
Fig. 11-15. Effect and eide-effects related to inter-
ference with receptor eites located in functional 
relationship with specific centres. 
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nervous system were observed (Table I I - I , f i g . 11-15), and these may be 
related to spi nal ly-medi ated mechanisms, but also to blood-borne e f fec ts , 
and/or to upward transport i n the l iquor (CSF). The l a t t e r two are charac-
ter ized by the occurrence of supra-spinally mediated ef fects . 
d , 2 . i . Spinally-mediated side-effects 
The occurrence of urinary retention i s thought to be the resul t of b in-
ding to opiate receptors local ized in the sacral segments. Such might i n f l u -
ence the parasympathetic preganglionic nerves (which have been shown to be 
associated with endorphin modulation (Glazer 1980)), thus ef fect ing para-
sympathetic i nh ib i t i on (Torda 1980). Due to t h i s , urinary retention may 
occur i f su f f i c ien t receptor s i tes have been occupied. Such Is indicated by 
the observation that especially the higher dose of nicomorphine epidural ly 
injected was associated with th is s ide-ef fect (21 %; table I I - I ) . As the 
course of th is s ide-ef fect was mi ld , urinary catheterizat ion was not re-
quired. Similar observations were reported by others (Torda 1982). In other 
respects (respiratory depression), the presence of cholinergic mechanisms 
may actually be beneficial (Oirksen 1982; Chapter I I ) . 
d . 2 . i i . Supraspinally-mediated side-effects of epidural ly or in t ra thecal ly 
injected endorphinomimetics 
Pupi l lary constr ic t ion i s related to opiate-receptor binding at a supra-
spinal level (Atweh 1977 2) , including the pretectal nuclei (Bird 1976), and 
associated with other supraspinally-mediated effects (see Results). S i g n i f i -
cant ly , th is may prove to be an early sign that endorphinomimetics are 
present at the v i c i n i t y of the receptor si tes of higher centres (Dirksen 
1980 (2 ,3 ) ) . Another, and potent ia l ly harmful 1 supraspinal ly-mediated ef fect 
i s respiratory depression (table I I - I ) . I t is thought to be the resul t of 
binding to receptor si tes in the respiratory centre, which may be located in 
the f loor of the fourth ventr ic le and the caudal aspect of the th i rd ven-
t r i c l e (Mitchell 1963, Florez 1980), and where a regulatory role of the 
endorphins has been suggested (Moss 1978). Delayed respiratory depression 
was reported fol lowing intrathecal in jec t ion of morphine (Glynn 1979, 
L io l ios 1979, Davies 1980 (1 ,2) , Gebert 1980, Baskoff 1980, Mok 1981), and 
peridural pethidine 100 mg in patients premedicated with dlamorphine (Scott 
1979), and possibly af ter diamorphine in t ra thecal ly (Barron 1981). As lower 
doses of morphine did not relate to respiratory depression (Torda 1980, 
Torda 1982, Rawal 1982), th i s ef fect may thought to be dose-dependent. 
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Coadmi ni s t r a t i on with systemic analgesics or local anesthetics may add 
to the r isk of occurrence of respiratory depression (Boas 1980, Barron 
1981). A recent report on delayed respiratory arrest af ter a local 
anesthetic (Holmboe 1982) may indicate that th is danger is not exclusively 
related to opiate administrat ion. In the patients studied by us, respiratory 
depression which required the administration of an antagonist, occurred, due 
to an accidental " to ta l opiate spinal" (Dirksen in prep.) . 
F ina l l y , c i rculatory depression may re f lec t penetration of vasomotor con-
t r o l centres (see Section I , Chapter I I I ) . Met-enkephalin has been shown to 
cause a naloxone-reversible reduction of blood pressures and heart rate when 
applied to the ventral surface areas of the brain stem (Florez 1977). I n t ra -
cisternal ly-administered endorphin induced an i n i t i a l t ransient increase in 
blood pressures and heart ra te, followed by delayed hypotension and brady-
cardia (Laubie 1977 1 , Feldberg 1978). Similar mechanisms may be involved in 
the c i rculatory changes observed af ter intrathecal morphine (Davies 1980 1 , 
Glynn 1979). 
d .2 . i 1 i . Mechanisms by which epidural ly or in t rathecal ly injected 
endorphinomimetics gain access to supraspinally located CNS si tes 
Blood-borne effects of in t rathecal ly or epidural ly injected endorphino-
mimetics 
Dependend on the amount of drug which has been taken up by the blood, 
blood-borne effects of epidural ly or in t ra thecal ly injected endorphino-
mimetics w i l l occur. Uptake from the subarachnoid space i s slower than from 
the epidural space (Chauvin 1982, Giasi 1979), which may explain the pro-
tracted ef fect of the drugs after intrathecal administration ( table I I - H ) . 
This difference may relate to the presence of excellent conditions for rapid 
vascular uptake from the epidural space, as th is is known to contain a dense 
venous plexus. The amount of drug-uptake w i l l also depend on the l i p i d -
so lub i l i t y of the drug in jected, as the r ich adipose tissue of the epidural 
space w i l l retard the absorption of l i p id -so lub le drugs (sequestration). 
I f blood-borne effects are important, these should be most obvious af ter 
epidural in jec t ions. However, as was indicated by data on k inet ics obtained 
i n c l i n i ca l studies, the importance of blood-borne effects of epidural ly-
in jected endorphinomimetics is l imi ted ( f i g . 11-16). Only i f conditions in 
which uptake-kinetics are markedly changed, p reva i l , than unexpected high 
blood levels and undesirable side-effects occur (Bullingham 1980). 
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Fig. 11-16. The human body consists of a number of subsystems with are in 
series and parallel to each other. The heart-lung-heart, H(s), is considered 
as the system that governs transport from the venous (ven.) pool to the 
aorta. The other tissues and organs of the body are grouped together in 
F(s). Once molecules pass F(s) they enter again in the venous pool (positive 
feedback). Fs(s) describes the transport from the aorta to the site of 
effect (transfer function), whereas the R(t) describes the transfer of drug 
concentration to response. D (β) input : after intravenous injection, 
the drug gains access to the*venous pool and H.(s) describes the transport 
from injection site into the venous pool. D (β) input : after peridural 
injection, part of the drug will directly gain'access to the receptor com­
partment (F (s)), while the rest of the drug will enter the venous pool; 
the relative contribution of the amount of drug which directly gains access 
to the site of action to effect may prove to be greater than the contri­
bution of the part which is diluted in H(s)(after Van Rossum, to be 
published). 
Thus, i t was found that : 
1 . Plasma levels of epidural ly injected fentanyl ( l i p i d - s o l u b l e ) 
were i n s i g n i f i c a n t , and did not contribute to analgesia (Wolfe 
1980) 
2. In ject ion of pethidine (water-soluble) in to the epidural space 
was associated with blood-concentrations of 0.2 - 0.7 yg/ml 
(Cousins 1979, Glynn 1981), and such concentrations are not 
considered to contr ibute to analgesia 
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3. The CSF levels of pethidine af ter peridural in jec t ion were sub-
s tan t ia l l y higher than plasma levels, and correlated with the 
occurrence of analgesia (Glynn 1981) 
4 . The analgetic effectiveness of per idural ly injected morphine was 
shown to be higher than and outlasted the effectiveness of a 
s imi lar dose intramuscularly (Lanz 1982, Rawal 1982) 
5. Analgesia af ter peridural ly injected morphine outlasted the 
presence of measurable plasma levels; although "analgesic" levels 
were reported to be present for two hours, analgesia lasted 28 
hours (Modig 1981, Rawal 1982) 
6. In ject ion of morphine in to the peridural space resulted in high 
morphine concentrations in the f l u i d of the lumbar subarachnoid 
space and low plasma levels (Engquist 1981) 
7. The peak concentration of morphine in the CSF, which was reached 
about 30 minutes af ter peridural i n jec t ion , was about 50 - 500 
times greater than the corresponding plasma levels (Max 1981) 
8. Persistent high l iquor concentrations were consistent with the 
prolonged effectiveness of epidural morphine (Gustafsson 1982). 
As was indicated above, the l ip id -so lub le drugs w i l l be sequestrated in 
the adipose tissue of the epidural space. In the same instant el imination by 
the venous plexus w i l l occur. These factors w i l l l i m i t the penetration of 
such a drug into the subarachnoid space (or uptake by segmental blood sup-
ply) and thus render them less e f fec t ive . Higher doses w i l l overcome t h i s . 
The rapid el imination of l ip id -so lub le drugs from the nervous t issue w i l l 
l i m i t the duration of the effect because of a sharp f a l l to below the 
ef fect ive concentration (Herz 1978). Infusion techniques w i l l extend the 
effectiveness (Bowen Wright 1980), but w i l l also cause a high blood concen-
t r a t i o n . The water-soluble drugs w i l l be sequestrated in the l iquor . This 
w i l l allow a larger amount of upward transport (see below), but w i l l also 
increase the duration of ef fect and the depth of penetration in to the spinal 
cord (Herz 1978). 
The volume of drug-containing solut ion is much larger for epidural i n -
jec t ion (10 - 20 ml) , than the volume for intrathecal in jec t ion (2 ml ) . This 
volume w i l l allow the drug to spread over a large area from which a gradual 
uptake occurs. The drug appearing in the CSF w i l l s imi lar ly be exposed to a 
large surface of central nervous system t issue. The amount of free drug 
available for upward transport w i l l thus be l im i ted , and therefore one would 
по 
expect the incidence of supraspinally-mediated side-effects to be much 
lower. In general, the incidence of supraspinally mediated side-effects 
proved to be lower af ter epidural than af ter intrathecal i n j e c t i o n (Table 
I I - H ; Dirksen 1980 3 ) . Yet, physicochemical properties of the drug w i l l have 
an additional inf luence, as i t influences k inet ics (see below). 
Respiratory depression was not found to be a predominant aspect in epidu­
ral i n j e c t i o n of nicomorphine (Pinckaers 1980). In contrast to a l a t e respi­
ratory depression af ter intrathecal i n j e c t i o n , only an early e f f e c t on ar­
t e r i a l Pc o (PaCQ ) was observed ( f i g . 11-17, f i g . 11-18), indicat ing 
that systemic uptake, or uptake and transport to the supraspinally-located 
central nervous system centres by the epidural veins, rather than upward 
transport may account f o r some e f f e c t on respirat ion. Yet, no s i g n i f i c a n t 
corre lat ion between serum levels of morphine and reduced vent i la tory respon­
se to CO« af ter peridural i n j e c t i o n of morphine 10 mg was found (Doblar 
1981), indicat ing that upward transport may account f o r supraspinal CSF 
concentrations associated with ( la te) respiratory depression by t h i s drug. 
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Fig. 11-18. In contrast with intrathecally injected nico-
morphine (see fig. 11-17), peridural injection of this drug 
is not associated with a significant rise in arterial 
P„„ (Pa„„ ,kPa) (from: Pinckaers 1980). 
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Upward transport and effectiveness of drugs present in the CSF 
Based on k inet ic data derived from in t ravent r icu lar appl icat ions, some 
predictions on the actual effectiveness and duration of ef fect of a drug 
present in the CSF can be made, as these seem to be associated with physico-
chemical properties of the drug administered (Kaufman 1975, Herz 1971). 
I ntrathecal ly- in jected water-soluble analgesics provide a deposit in the CSF 
associated with the a b i l i t y to penetrate deeply into the nervous t issue, 
preferent ia l ly the grey matter. As the blood-brain barr ier is two-way 
e f fec t i ve , el imination w i l l be slow for these substances. A combination of a 
slow onset and a long duration of action can thus be presumed (Bromage 
1980). From these considerations i t can be stated that a water-soluble 
analgesic in a dose su f f i c ien t for saturation of the binding si tes of the 
spinal segments to be blocked, w i l l contribute to a long-last ing e f fec t . 
Within the l im i t s of a minimum and a maximum ef fec t , a dose-dependent e f fect 
on nociceptive signal transmission w i l l occur (see Chapter I I ) . Epidural 
administration w i l l involve uptake k inet ics from the epidural space. This 
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w i l l render some opiates which are highly ef fect ive af ter intrathecal i n ­
j e c t i o n , less e f f e c t i v e , whereas a more favourable uptake from, and a sus­
tained deposit i n , the epidural space contributes to a higher ef f ic iency of 
others. A re lat ive overdose w i l l be associated with a higher incidence of 
s ide-ef fects, because of an upward transport of unbound molecules. Such w i l l 
not increase t h e i r spinally-mediated effectiveness, as indicated by the 
observation that the higher dose of m'comorphine epidural ly did not resul t 
i n a s i g n i f i c a n t prolongation of the desired ef fect (table I I - H ) . 
The average delay-time τ for reaching the d i s t r i b u t i o n area (a funct io­
nal un i t of the CSF compartment composed of the upper cervical canal, the 
basal cisterns and the epicort ical area (Palma 1978 (1,2) , Wüst 1980)) 
a f te r in jec t ion of a radioactive label led substance was 4.5 hrs (_+ 1.6 hrs) , 
which was explained by b id i rect ional d i f fus ion rather than "f low" (Partain 
1978). τ f o r observing supraspinally mediated side-effects af ter i n t r a ­
thecal nicomorphine, quanti f ied by measurement of the amount of respiratory 
depression ref lected by a r ise of Pa™ . proved to be 5 - 6 hours 
(Plnckaers 1980; see f i g . 11-17). Also, supraspinally-mediated side-effects 
of epidural morphine were reported to occur as soon as 6 hours af ter admini­
s t r a t i o n (Bromage 1982). This would indicate that in adjunct to τ for 
upward transport, a lag-time f o r penetration to the supraspinal centres must 
be accounted f o r . Yet, i n contrast with these data which indicate a τ f o r 
rostrad ascent of б hours, are observations on delayed respiratory depres­
sion af ter intrathecal i n j e c t i o n of morphine, which may occur as la te as 
8 - 1 2 hours p o s t i n j e c t i o n . However, morphine has physicochemical charac­
t e r i s t i c s which d i f f e r from the other opiates used, and these may explain 
the differences. 
Table 11-J shows the pK, and oi l-water p a r t i t i o n rat ios of a few 
a 
endorphinomimetics that have been used f o r ei ther epidural or intrathecal 
in ject ions (see above). Compared to the other endorphinomimetics, morphine 
i s the poorest l i p i d - s o l u b l e drug, and as was described above, i t may be 
expected to l inger i n the water phase of the CSF, to be carr ied by CSF 
"f low". Additional factors may prove to be of importance to a wide d i s t r i ­
but ion, and a marked increase i n ionizat ion of morphine in acidic mi l ieu was 
shown to ( fur ther) retard the el imination of t h i s drug from the brain 
(Nishitateno 1979). 
Pathological conditions may change the CSF kinet ics markedly. Hyper-
function of the d i s t r i b u t i o n area, which occurs In dynamic decompensation 
due to epicort ical obstruction to CSF c i r c u l a t i o n or which occurs during 
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table II-J. pK 's, oil-water distribution (D . ) and partition co­
efficients (Ρ) at various pH's of a few endorpninomimetic drugs. 
Drug 
•Morphine sulphate 
#Nicomorphine 
•Pethidine 
@Piri trami de 
PKa Do/w Р 7.4 Р 7 . 1 Р 7.3 
7.93 6.23 1.42 0.80 1.18 
6.59 34.67 30.15 26.44 29.01 
8.50 527.60 38.82 20.20 31.31 
7.56 5248.07 2146.06 1351.19 1861.22 
Data from, or calculated with data of: 
•Kaufman 1975 
#Nourypharma, Oss, the Netherlands 
@Janssen Pharmaceutica, Beerse, Belgium 
developing hydrocephalus (Palma 1978 1 ) , may be associated with turbulence 
of the CSF in the d i s t r i b u t i o n area. Due to t h i s a rapid passage of the CSF 
t o the spinal cord (and back up) can be present. Although no research has 
been directed to study the implications of changed CSF k i n e t i c s , i t may be 
expected that such pathological changes may put a patient at r isk i f i n ­
jected i n t r a t h e c a l l y , for instance with a water-soluble drug the k inet ics of 
which depend mainly on CSF k i n e t i c s . Previous subarachnoid or i n t r a v e n t r i ­
cular bleeding may prevent transport to the cranial cavity (Tamaki 1979), 
whereas ventr icular ref lux may occur i n pathological conditions (Palma 1978 
1 ) . The consequences for drug disposi t ion and side-effects are to be 
evaluated. 
d. 2. i i i . Other side-effects 
The s i t e and mecham'sm(s) of some side-effects has, thus f a r , not been 
i d e n t i f i e d . An example of such is i tch ing (Reiz 1980), which, although not 
observed i n the patients reported above, can be bothersome. The mechanism(s) 
(an "enkephalinergic ref lex" (Scott 1982)) is (are) unknown. 
Below, the cardiovascular effects of epidural ly or in t rathecal ly i n ­
jected endorphinomimetics w i l l be described ( IV.В.) . As was indicated above 
( b . 2 . ; see Section I , Chapter I I I ) , the higher neuronal central nervous 
system centres are involved in cardiovascular changes involving endorphin 
mechanisms. Also, the spinal system i t s e l f may prove to be involved. 
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В. The effects of epidural ly or in t rathecal ly injected endorphinomimetics on 
c i rcu latory variables: c l i n i c a l observations 
a. Introduction 
Interference with the functional i n t e g r i t y of the spinal cord, i . e . 
transsection, cold block, or local anesthetics, is known to resul t in 
changes i n c i rcu latory var iables. Transsection of the spinal cord at the C-, 
spinal segment resulted i n subsequent increase of cholinergic tone involving 
supraspinally-located central nervous system structures and induced hypo­
tension, which was attenuated by naloxone as well as methyl atropi ne (Holaday 
1980, Faden 1979, Faden 1980 ( 1 , 2 ) ) . Also, cold block of the cervical spinal 
segments caused such a hypotension (Dembowsky 1980). A r e l a t i v e hyperto-
n i c i t y of the supraspinal cholinergic system was shown to cause a disturbed 
balance of t h i s system, with sympathetic outflow involving descending t racts 
to spinal structures Innervating the sympathetic ganglia and the adrenals 
(Doba 1973, Doba 1974). The r e l a t i v e contr ibut ion of the cholinergic and 
catechol ami nergic system i n t h i s balance proved to be species-dependent 
(Faden 1980 2 ) . The importance of the contr ibut ion of the sympathetic system 
to homeostatic control i n humans is indicated by the cardiovascular effects 
associated with reduced sympathetic outflow af ter intrathecal or epidural i n ­
j e c t i o n of local anesthetics. Suppression of sympathetic outflow i n humans 
depends on the extent of blockade of spinal segments. A marked reduction in 
plasma levels of norepinephrine and epinephrine has been measured in 
patients with a local anesthetic-induced segmental blockade up to level Т 6 , 
whereas no change could be measured i f the blockade was l i m i t e d to T« or 
below (Pflug 1981). These changes in plasma levels of c i r c u l a t i n g catechol­
amines closely para l le l changes in the mean a r t e r i a l blood pressure (Pflug 
1981). Thus, I t seems reasonable to propose that i n humans the spinal inner­
vat ion of the adrenal medulla and the sympathetic ganglia or ig inat ing at the 
levels Tg - L2 (Bonica 1968, Chusid 1973), which w i l l involve the splanch­
nic nerve (Gootman 1971), bears a functional r e l a t i o n to regulation of the 
blood pressures; furthermore, sympathetic innervation or ig inat ing at s t i l l 
higher levels (T, - T«) was shown to be involved i n innervation of the 
heart (Norn's 1974, Norn's 1977). 
Our data on c i r c u l a t o r y changes a f t e r epidural or intrathecal i n j e c t i o n 
of opiates indicate that at a spinal l e v e l , endorphinergic mechanisms are 
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involved in the modulation of innervation of sympathetic tone. 
b. Patients, materials, and methods 
For f u l l detai ls on pat ients, mater ials, and methods, the reader is 
referred to part A of t h i s chapter. There are four groups of patients i n 
t h i s study (table I I - H ) : 
group I : received nicomorphine 2 - 4 mg intrathecal ly (n=7) 
group I I : received nicomorphine 5 mg epidural ly (n= l l ) 
group I I I : received nicomorphine 10 mg epidurally (n=24) 
group IV : received pir i t ramide 15 mg epidural ly (n=23). 
A l l patients were connected to an ECG and a pulse monitor (Siemens 
Sirecust 300 A). Pr ior to epidural or intrathecal puncture, blood pressures 
(oscil lotonometric measurement), pulse rates, and pulse qual i ty were noted 
f o r a l l pat ients. After puncture, blood pressures, pulse rates, and pulse 
qual i ty were measured again, and af ter i n j e c t i o n of the drug-containing 
s o l u t i o n , a l l of these variables were recorded every 2 to 3 minutes u n t i l 
the induction of general anesthesia. 
с Results 
The cardiovascular variables d i a s t o l i c blood pressure, systol ic blood 
pressure, and heart rate, before and af ter i n j e c t i o n of the endorphinomime-
t i c drugs, are presented in the scatter plots of f i g s . 11-19 to 11-26. A l l 
data were obtained p r i o r to induction of general anesthesia (see Chapter 
IV.Α.). 
An early marked increase of deflections of the Plethysmograph attached 
to one of the f ingers of the l e f t hand preceded observable changes in blood 
pressures and heart rate. The moment at which these changes occurred synchro­
nized with early signs of changed nociception (5 minutes af ter i n j e c t i o n ) . 
I n not one patient were measures to cope with c i rculatory changes necessary. 
Stat ical analysis of the data (table I I - M indicated a s i g n i f i c a n t reduc­
t i o n in the systol ic blood pressures in groups I , I I I , and IV. The higher 
dose of nicomorphine (nicomorphine 10 mg epidural ly in jected; group I I I ) re­
duced systol ic blood pressures s i g n i f i c a n t l y more than the lower dose (nico­
morphine 5 mg epidural ly in jected; group I I ) ( a n a l y s i s of variance: group I I I 
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Fig. 11-22. Heart rates before and after the epidural 
injection of 5 rag nicomorphine (n = 11). 
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Fig. 11-24. Heart rates (HR) before and after the 
epidural injection of 10 mg nicoinorpULne (n = 24). 
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Flg. 11-26. Heart rates (HR) before and after the 
epidural injection of 15 mg piritramide (n - 23). 
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significantly different from group II, p< 0.05). Diastolic blood pressures 
were significantly reduced in groups I, III, and IV, and heart rates were 
significantly reduced in groups III and IV. Changes in blood pressures and 
heart rates were observed in group II as well, however, statistical analysis 
did not show a significant reduction. The statistical data of mean changes 
and the standard deviation of the mean change (in brackets) are presented in 
table II-K. 
Table II-K. Mean changes in blood pressures ( Δ mmHg) and heart rates 
(Δ beats per minute)(s.d. in brackets) after intrathecal or epidural 
injections of the endorphinomimetics, in groups I, II, III, and IV. 
SBP 
DBP 
HR 
I 
- 7 ( i 8 ) * 
- 9 l i 9 ) * 
0(±10) 
11 
№(.8) 
- 7 ( i 6 ) 
-ól i lO) 
I I I 
issisi* 
- 8 ( i 9 ) * 
-101*12)* 
IV 
- 9 ( ± 8 ) * 
- 8 ( i 9)* 
- 4 ( 1 9 ) * 
* ρ < 0.05 
** ρ <0.01 
Ο III different from II (ANOVA: ρ < 0.05) 
SBP » systolic blood pressure; DBP = diastolic blood pressure; HR = 
heart rate (from Dirksen 1980 3). 
In two patients a postoperative period of hypertension not caused by 
pain occurred, indicating that the effects observed may include late rebound 
phenomena. 
d. Discussion 
Epidural i n j e c t i o n of the endorphinomimetics nicomorphine and 
p i r i t ramide was associated with a reduction i n both d i a s t o l i c and systol ic 
blood pressures ( f i g s . 11-19 to 11-26; table I I - K ) . The dose-dependency of 
t h i s e f f e c t is indicated by the observation that nicomorphine 10 mg epi-
dural ly injected caused a s i g n i f i c a n t l y greater reduction in systol ic blood 
pressure than nicomorphine 5 mg epidural ly injected d i d . The reduction in 
heart rate was s i m i l a r l y af fected, as again the higher dose of nicomorphine 
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was more e f fec t ive . Nicomorphine in t ra thecal ly injected caused a reduction 
i n blood pressures as we l l . This indicates that a local spinal action is 
involved in mediating the e f fec t , however, in addition effects of the drug 
af ter systemic uptake may be thought to contr ibute to the e f fec t , especially 
a f ter an epidural i n jec t ion . At no instance were therapeutic measures to com-
pensate for the reduction in either heart rates or blood pressures neces-
sary; however, the tendency towards collapse in po l i c l i n i ca l applications of 
th is technique (Ni jhuis 1980) indicated that the reduction in blood pres-
sures is associated with a reduced a b i l i t y to compensate for postural 
changes. 
The neurophysiological substrate for the effects on cardiovascular v a r i -
ables is not f u l l y known. Endorphins and endorphinomimetics are known to 
cause hypotension and bradycardia i f injected in t rac i sternal ly (Laubie 1977 
(1 ,2 ) , Feldberg 1978). However, the early occurrence of the c i rcu latory 
changes as well as the absence of signs of supraspinally-mediated effects 
( i . e . pupi l lary const r ic t ion , reduced respiratory rate, r ise in expiratory 
carbon dioxide, psychomimetic signs, or nausea), at the instant at which the 
c i rcu la tory changes began, are strong indications for a spinally-mediated 
e f fec t ; moreover, supraspinally-mediated effects af ter in t ra thecal ly i n -
jected endorphinomimetics have a lag-time of several hours (see above; 
Pinckaers 1980). 
I n accordance with our f indings, c i rcu latory changes due to change in 
sympathetic tone (Deveaux 1981), change in afferent sympathetic response 
(Lesl ie 1979), and s ign i f i cant changes i n skin blood f low, together with a 
reduction in blood pressures (Glynn 1981), have been observed. However, 
others fa i led to observe any change in blood pressure or sympathetic tone 
(Bapat 1979, Behar 1979, Cousins 1979, Perriss 1980, Samii 1979). The reason 
fo r th is controversy remains to be resolved. The effects on c i rcu la tory 
variables are not special effects of nicomorphine, as we observed s imi lar 
effects af ter peridural in jec t ion of pi r i trami de ( f i g . 11-25, f i g . 11-26), 
and as s imi lar effects were reported af ter peridural in jec t ion of meperidine 
i n postoperative patients (Glynn 1981). The extent of the blockade may prove 
to be of more relevance, as we injected 20 ml of drug-containing solut ion 
epidural ly , whereas others used only 10 ml . Thus, in analogy to the 
e f f e c t i v i t y of local anesthetics in af fect ing cardiovascular variables (see 
Int roduct ion) , i t may prove to be essential that the T5 - Lo spinal 
segments or even higher spinal segments are involved in drug action before 
an observable c i rculatory change preva i ls . The observations on c i rcu latory 
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changes induced by morphine and pethidine per idural ly injected at a thoracic 
level i n a volume of 10 ml (Torda 1982), are in accordance with such an 
explanation. 
At th is level (T5 - L 2 ) , excitatory (Kerr 1962, I l l e r t 1972, Gebber 
1974, Coote 1974 1 , Barman 1978) and inh ib i to ry ( I l l e r t 1969, Gootman 1971, 
I l l e r t 1972, Coote 1974 (1 ,2) , Coote 1975, Kirchner 1975, Barman 1978, 
Gilbey 1981) projections of supraspinal o r ig in and pathways or ig inat ing from 
spinal afférents (Wyszogrodski 1973, McCall 1977) converge onto sympathetic 
preganglionic neurons, the somas of which were shown to be mainly located in 
the intermedi d a t e r a i ce l l column of the spinal cord (Chung 1975). The i n -
h ib i to ry descending control of sympathetic ac t i v i t y is thought to resul t in 
act ivat ion of the baroreceptor afférents (Foreman 1973, Gebber 1974, Coote 
1974 2, I l l e r t 1969), and thus may be thought to Involve the nucleus tractus 
sol i t a r i us (see Section I , Chapter I I I ) . In addition to th is descending i n -
h ib i to ry cont ro l , a tonic noradrenergic inh ib i to ry system not or ig inat ing in 
th i s cardiovascular control centre (Dembowsky 1980), as well as an i n t ra -
spinal inh ib i tory (interneuron) system in which the inh ib i to ry synapse 
proved to be on the sympathetic neuron (or might be presynaptic) (Kirchner 
1975, I l l e r t 1972), were shown to be present. A presynaptic location was 
fur ther indicated by a blood pressure-increasing e f fec t , associated with an 
increase in sympathetic output upon intraspinal st imulat ion in laminae 
I I - VII ( I l l e r t 1972). 
The neurotransmitter substances involved in th is inh ib i to ry control are 
s imi lar to those held responsible for descending inh ib i t i on of nociceptive 
signal transmission at a spinal l eve l , i . e . : serotonin (Hare 1972, Coote 
1974 1 , Gilbey 1981, Godefroy 1981) and noradrenaline (Dembowsky 1980) (see 
Chapter I ; and see Yaksh 1981 3) . 
Acetylcholine fa i led to af fect preganglionic sympathetic neurons (Coote 
1981), thus a change in cholinergic tone may prove not to account for the 
c i rcu la tory effects of endorphinomimetic drugs at a spinal level (see Chap-
te r I I I ) . 
The s i te of action of the endorphinomimetic drugs may be thought to be 
w i th in the intraspinal enkephal inergi с system (see Section I ; Section I I , 
Chapter I ) . Enkephalins were shown to be present in the dorsal as well as in 
the ventral horn (Cesseliη 1980). Furthermore, the sympathetic preganglionic 
neurons are thought to be involved in enkephalinergic transmission 
(Schultzberg 1978 2 ) , and various opiates ( i . e . morphine, fentanyl , methado­
ne, and pethidine) were recently shown to cause a rapid, consistent dose-
123 
dependent, stereospecif ic, naloxone-reversible depression of preganglionic 
sympathetic discharges evoked by st imulat ion of descending intraspinal 
excitatory pathways and spinal ref lex pathways in spinalized cat (Franz 
1982). Whether the endorphin receptor s i tes involved prove to be auto-
receptors on descending excitatory pathways which co-release endorphin and 
an excitatory t ransmit ter, or rather enkephal inergi с interneurons (or both) 
i s presently unknown. The role of other putative transmitter and/or 
modulator substances (see Chapter I) remains to be elucidated. 
C. The overlap of endorphinergic mechanisms i n cardiovascular and sensory 
homeostasis. 
As was presented above (IV.A. and IV.В.) , the spinal ly-located endorphin 
subsystem proved to be involved in nociceptive signal transmission and 
cardiovascular control mechanisms. However, the spinal subsystem is part of 
larger subsystems which are characterized by t h e i r funct ion: cardiovascular 
homeostasis and sensory homeostasis (Section I , Chapter I I I ) . Reconsidering 
the organization of these functional subsystems, i t w i l l be apparent that 
the par t ic ipat ion of the spinal endorphin subsystem in both these homeo-
s t a t i c mechanisms represents an overlap which is not an exception, but 
conform the organization i n other parts of the central nervous system. Thus, 
the nucleus arcuatus, the locus coeruleus, the periaqueductal grey, the 
nucleus r e t i c u l a r i s g i g a n t o c e l l u l a r i s , and the nucleus raphe had been 
implicated i n cardiovascular and sensory mechanisms (Section I , Chapter 
I I I ) . 
The global overlap of functioning of these structures may serve as to 
explain why various drugs which are known to change nociceptive signal trans­
mission, i . e . endorphins, endorphinomimetics, and monoaminergic substances, 
also change cardiovascular variables (and vice versa). Moreover, patho­
physiological conditions such as hypertension, are known to be associated 
with an altered responsiveness to noxious st imulation (increased threshold) 
(Zamir 1979, Zamir 1980 1 ) , and t h i s altered responsiveness proved to be 
naloxone-reversible and associated with a re lat ive change i n endorphin-
a v a i l a M l i t y (Zamir 1980 ( 1 , 2 ) , Hutchinson 1981). F i n a l l y , ICV B-endorphin 
or systemic endorphinomimetics were shown to lower, in a naloxone-reversible 
fashion, the blood pressures of spontaneous hypertensive rats to a much 
greater extent than those of normotensive rats (Petty 1981, Hutchinson 
1981). More s p e c i f i c , st imulat ion of central nervous system structures which 
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are participating in tne overlap, i.e. the locus coeruleus and the peri­
aqueductal grey, was shown to be associated with analgesia and increased 
blood pressures (Segal 1977, Ward 1976, Galosy 1981). Part of such a related 
effect can be contributed to secondary mechanisms, thus, the locus coeruleus 
has, in addition to projections to the spinal cord and the nucleus raphe 
magnus, projections to the nucleus solitarii and the dorsal vagal nucleus 
(Westlund 1979, Westlund 1980). Further details on the endorphinomimetic 
involvement of the various structures to aspects of cardiovascular and 
sensory homeostasis have been described (Section I, Chapter III), and to 
illustrate the concept of the overlap in endorphinergic mechanisms, a 
schanatic representation was made (fig. 11-27). 
Fig. 11-27. Schematic representation of the overlap of endorphinergic 
mechanisms in cardiovascular and sensory homeostasis. 
a. Endorphinergic mechanisms of cardiovascular homeostasis. 
Baroreceptor input (BR) to the nucleus tractus solitarius (NTS) employs 
1-glutamate (1-glut) or substance Ρ (SP) in the primary neuron, and somato­
statin (SST) or enkephalin (ENK) modulates this transfer. Noradrenergic (ne) 
projections from the A 9 group of neurons, which is located in the dorso-
medial medulla around the nucleus of the solitary tract and dorsal motor 
nucleus of the vagus, may stimulate &-endorphin (ß-END) release from projec-
tions originating in the infundibular nucleus (nucleus arcuatus = N.ARC), 
and ß-endorphin release from these projections is stimulated by vasopressin 
(VP). The resulting inhibition of an inhibitory neuron (de-inhibition) will 
facilitate the inhibitory input to fibres projecting to the lateral 
reticular nucleus (LRN), from which fibres project to the dorsal vagal 
nucleus (DVN) and the nucleus ambiguus (N.AMB), and both nuclei are involved 
in efferent control. Descending tracts to the spinal cord originating in the 
NTS (dorsolateral funiculus) are noradrenergic excitatory to output to sympa-
thetic ganglia, the adrenals, or the heart (SYMP). Additional connections 
involve the nucleus reticularis gigantocellularis (NRGC), which relays on 
the nucleus raphe (NR), as do projections from the periaqueductal grey (PAG) 
and the locus coeruleus (LC). Some of these projections are inhibitory (-) 
at a spinal level, while others are noradrenergic stimulatory (+). Enkephali-
nergic interneurones (ENK), as well as ^-endorphinergic projections to the 
NTS, LC and PAG, are intimately related to these structures which are only a 
part of the total system. 
b. Endorphinergic mechanisms of sensory homeostasis. 
Endorphin modulation is present at various levels of nociceptive signal 
transmission. After arrival in the spinal cord (C- and A¿-fibres), the 
signal is elaborated by various transmitters and/or modulators, including 
enkephalin (ENK). Activation of feedback loops will change this process. 
Loop systems involve the locus coeruleus (LC), the periaqueductal and peri-
ventricular grey (PAG-PVG), and the reticular formation. An important relay 
for descending tracts proved to be the nucleus raphe magnus (Nucl. Raphe 
M.)· In each of these cell groups involved in the feedback loop systems, 
enkephalin transmission, or modulation, is thought to be involved, and 
favours the activation of descending inhibitory pathways (I = inhibitory 
neuron). The nucleus arcuatus is thought to provide ^-endorphin. 
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Smranary and Conclusion 
In Section I i t was discussed that recent research had indicated the 
involvement of the endorphin system in opiate act ion. Most probably, such an 
opiate interact ion results from the a b i l i t y of opiates to mimic the effects 
of the natural ligands (the endorphins) by effectuat ing receptor-effectuator 
coupling. Although such endorphinomimetic actions approach the physiological 
sequence of events, t ime-related events at a receptor l e v e l , may prove to be 
d i f f e r e n t , especially i n the transmitter systems. 
The kind of ef fect of an opiate was proposed to re late to the s i t e of 
action (and the system l inked to effectuator mechanisms), as i t may be 
thought to relate to the receptor (sub)type (configuration) involved in 
agonist act ion. As to nociceptive signal transmission, the μ-receptor (sub-) 
type has been shown to be pr imari ly involved. Selective p-agonists have been 
synthetized, but s t i l l the induction of a selective (antinociceptive) e f f e c t 
i s , as y e t , not possible. A l ternat ive ly , a selective antinociceptive e f f e c t 
may be i n s t i t u t e d by administration of an agonist i n an anatomically 
d i s t i n c t subsystem engaged i n a specif ic function (nociceptive signal trans­
mission). Therefore, the organization of the ( f u n c t i o n a l l y - d i s t i n c t ) endor­
phin subsystem involved in nociceptive signal transmission was taken into 
consideration, as i t informs on the presence of (an) accessible p a r t ( s ) , the 
relationships of such part(s) to the t o t a l system, and the presence of 
putative overlaps with other functional subsystems. 
The spinal ly-located structures involved i n nociceptive signal trans­
mission, which were described as part of the afferent neuronal c i r c u i t or as 
part of the descending Inh ib i tory pathways, are accessible to drug admini­
s t r a t i o n with the c l i n i c a l l y well known techniques of intrathecal or p e r i ­
dural athii ni s t r a t i ons. Moreover, the spinal structures const i tute the en­
trance f o r nociceptive signals to the central nervous system. The involve­
ment of the spinal ly-located elements of the endorphin system i n nociceptive 
signal transmission was confirmed by the experimental results presented i n 
t h i s thesis. In the r a t , intrathecal in ject ions of morphine were associated 
with a dose-dependent increase in hot-plate and t a i l - f l i c k response laten­
c i e s . The absence of motor problems, of changes In behavior, of postural 
c o n t r o l , and the r ight ing r e f l e x , as well as the absence of an e f f e c t in the 
presence of an antagonist (naloxone), indicated the s p e c i f i c i t y and 
s e l e c t i v i t y of t h i s e f f e c t . 
The experiments were extended to include intrathecal nicomorphine 
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administrat ion, so as to evaluate the dose-effect relat ionships of th is 
( c l i n i c a l l y well known) drug. Nicomorphine, thought to be active because of 
i t s metabolic breakdown products, also increased dose-dependently the hot-
plate and t a i l - f H c k response latencies. However, naloxone, in a su f f i c ien t 
dose, only pa r t i a l l y prevented the antinociceptive effects at 30 and 60 
minutes af ter intrathecal coadministration with nicomorphine. 
The presence of a spinal ly- located muscarinic cholinergic system invo l -
ved in nociceptive signal transmission was defined in the ra t and the cat . 
Cholinomimetic drugs, i . e . carbachol and physostigmine plus acetylchol ine, 
induced a select ive (atropine-revers ib le) , dose-dependent increase in hot-
plate and t a i l - f l i c k response latencies. These effects did not resul t from 
changed ac t i v i t y of the noradrenergic or serotonergic project ions, nor from 
an ef fect involving the spinal ly- located endorphin subsystem. Yet, th is 
spinal ly- located muscarinic cholinergic system proved to be of relevance to 
opiate effectiveness, as the effectiveness of in t rathecal ly administered 
morphine was reduced by the presence of atropine, whereas physostigmine 
markedly potentiated i t s effectiveness. These interactions were quant i ta t ive-
l y d i f fe rent for morphine and nicomorphine. In the presence of atropine the 
effectiveness of nicomorphine was markedly reduced, whereas physostigmine 
fa i l ed to cause a s ign i f i can t fur ther increase in response latencies to 
noxious st imulat ion. These observations, together with a non-naloxone rever-
s ib le component in nicomorphine anti nociception, non-naloxone reve rs ib i l i t y 
of cholinomimetic-induced anti nociception, d i f fe ren t ia l effectiveness in the 
hot-plate test and t a i l - f l i c k ref lex at par t icu lar doses of cholinomimetics 
or nicomorphine, led to the proposit ion of a cholinergic component in 
nlcomorphine-associated anti nociception. 
The objective of the c l i n i ca l study was to evaluate whether In t rathecal -
l y or epidural ly opiates would, by a spinally-medlated effectiveness, modify 
nociceptive spinal transmission (as was iden t i f ied In animai experiments and 
ea r l i e r c l i n i ca l evaluation fo r pain treatment) to such an extent, as to 
allow i t s Introduction as a method of providing perioperative analgesia. 
The results of the c l i n i ca l t r i a l s indicate that epidural ly or In t ra -
thecal ly injected endorphinomimetics produce excellent antinociception. 
During surgery» a stable course of v i t a l variables was observed and 
addit ional Intravenous analgesics were not necessary. The presence of somato-
gnosia necessitated l i g h t general anesthesia. The postoperative period was 
characterized by the absence of 'hurt ing pa in ' . S ign i f i can t ly , the ef fect 
had been observed to be somatotopically l im i ted with cord dermatome regions. 
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The presence of other (mild) "s ide-ef fects" indicated the existence of 
functional overlaps at a spinal level as well as the occurrence of transport 
of the drug to supraspinally-located central nervous system structures. 
Spinally-mediated side-effects included urinary retention and changes in 
cardiovascular variables to which the spinally-mediated opiate effects were 
thought to contribute (reduced "sympathetic tone"). Either of these side-
effects exhibited a mild course, not necessitating therapeutic measures. The 
involvement of endorphinergic mechanisms in severe cardiovascular d is tur -
bance had been established. However, the hypothalamic-pituitary endorphin 
subsystems, which were considered to influence the incoming signal of the 
cardiovascular homeostatic system, proved to be pr imari ly involved. The 
coexistence of analgesic and cardiovascular effects were related to a 
putat ive functional overlap at a spinal l eve l . The d i f fe ren t ia l e f fec t ive-
ness, i . e . profound antinociceptive effectiveness and mild cardiovascular 
e f fec ts , can be explained by assuming that ' input modulation' by endorphins 
(at a spinal level of the nociceptive signal) i ns t i tu tes more profound 
changes than 'output modulation' (of the "sympathetic tone"). This does not 
mean that the l a t t e r bears no c l i n i ca l relevance, as af ter epidural admini-
s t ra t ion of opiate drugs the tendency towards collapse in the early post-
operative period has been reported. 
For a f ina l conclusion on the safety and use of the method of peridural 
or intrathecal administration of opiate drugs, the incidence and severity of 
side-effects has to be considered. In the patients reported above, serious 
side-effects were absent. Spec i f i ca l ly , the dangerous la te respiratory 
depression was not observed. I t may be proposed, that the (hypothetical) 
cholinomimetic properties of nicomorphine may have contributed to t h i s , as 
th i s was shown to potentiate i t s spinal actions, whereas i t had been shown 
to reverse the respiratory depressant actions of opiates. Such a disso-
c ia t ion of effects at a spinal and supraspinal level m y^ eventually 
contr ibute to a further refinement and increased safety of the method used. 
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Conclusion 
The spinal ly- located endorphin receptors are readily accessible, by 
means of the c l i n i c a l l y well known techniques of intrathecal or peridural 
i n j ec t i on , for the i n s t i t u t i o n of an endorphinomimetic-induced receptor-
mediated e f fec t , which is associated with excellent anti nociception. This 
allows the introduct ion of these techniques into anesthesiological practice 
fo r the purpose of inducing perioperative analgesia. 
131 
Samenvatting en Conclusie 
In het theoretische overzicht werd benadrukt dat de recente gegevens van 
onderzoeken aangeven dat opiaat effekten to t stand komen door in te r fe ren t ie 
met het endorfine systeem. Alhoewel nog veel onbekend i s , l i j k t het waar-
s c h i j n l i j k dat deze in te r fe ren t ie plaatsvindt, omdat de opiaten de effekten 
van de natuur l i jke agonisten (de endorfines) nabootsen door een in te rak t ie 
met de receptoren van het endorfin systeem. Geheel fysiologisch is de in te r -
akt ie n ie t , want alhoewel een zeer du ide l i jke overeenkomst in de dr ie -
dimensionale struktuur van opiaten en endorfines in de l i t e ra tuu r is aange-
toond en alhoewel de opiaten evenals de endorfines een receptor-effectuator 
koppeling bewerkstelligen, zal de t i j d s r e l a t i e van de in terak t ie van opiaten 
en de receptoren waarschi jn l i jk afwijken van d ie, welke met name in de trans-
mi t te r systemen van het endorfine systeem bestaan. Het soort ef fekt van een 
opiaat werd geduid als zi jnde secondair aan de plaats van het ef fekt (en het 
aan het locale systeem gekoppelde functionele systeem), als mogelijk ook aan 
de soort receptor (receptor (sub)type of receptor conf igurat ie) welke het 
meest b i j de agonist- interakt ie betrokken i s . 
Ten aanzien van anti noci cepti eve effekten wordt i n de l i t e ra tuu r aangege-
ven dat de u-receptor belangrijk i s . Alhoewel min of meer specifieke y-ago-
nisten reeds ontwikkeld z i j n , is de mate waarin het gewenste (antinocicep-
t ieve) ef fekt en de overige "b i j -e f fek ten" gescheiden z i j n , vooralsnog be-
perkt . Als a l ternat ie f werd aangevoerd, dat door een opiaat toe te dienen in 
een anatomische eenheid (een subsysteem) welke betrokken i s b i j een speci-
f ieke funkt ie (noci cepti eve signaal ge le id ing) , eveneens geprobeerd kan wor-
den effekten te scheiden. Hiertoe werd het functionele subsysteem betrokken 
b i j nociceptieve signaal geleiding gedefinieerd. Zulk een omschrijving in fo r -
meert over de pos i t ie van een toegankelijke struktuur, de re la t i e t o t het 
functionele systeem, als ook over het bestaan van functionele overlappingen. 
Het deel van het spinale systeem dat betrokken is b i j nociceptieve s ig -
naal geleiding, werd omschreven als bestaande u i t een afferent c i r c u i t en de 
descenderende inhiberende banen. Het is toegankelijk voor locale toediening 
van farmaca met de in de anesthesie veel gebruikte methodieken van i n t r a -
thecal e of peridurale i n jec t i es . Bovendien z i j n de spinale structuren dus-
danig gepositioneerd, dat z i j als "toegangspoort" van het centrale zenuw-
stelsel voor de nociceptieve signalen fungeren. De betrokkenheid van de 
spinaal gelocaliseerde elementen van het endorfine systeem b i j nociceptieve 
signaal geleiding werd bevestigd in de experimentele resultaten welke in d i t 
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proefschr i f t gepresenteerd werden. Intrathecaal toegediend morphine bleek, 
dosis-afhankel i jk , een verlenging van de reak t ie t i j d op een nociceptieve 
stimulus te bewerkstelligen in rat ten. De s p e c i f i c i t e i t van d i t e f fekt werd 
bevestigd in observaties t . a . v . de s e l e k t i v i t e i t van ef fekt (de motorische 
componenten en het gedrag van het dier waren onveranderd), en u i t de antago-
neerbaarheid van ef fekt met naloxone (een antagonist). 
De experimenten werden uitgebreid om de dosis-effekt re la t ies van het 
k l in isch veel gebruikte nicomorphine vast te s te l len . Na intrathecale toe-
diening van deze stof b i j rat ten werd, door effekten welke waarschi jn l i jk 
t o t stand komen via aktieve metabolieten, eveneens een verlenging van de 
reak t i e t i j d op toediening van een nociceptieve stimulus waargenomen. A fw i j -
kend bleek de e f f e k t i v i t e i t van naloxone, want met die dosis naloxone die de 
effekten van een vergel i jkbare en "antinociceptieve" dosis morfine voorkwa-
men, bleek nicomorfine nog ef fekt te hebben 30 en 60 minuten na toediening. 
Het intraspinale cholinerge systeem was in z i j n re la t i e to t nociceptieve 
signaal geleiding gekarakteriseerd in rat ten en katten als zi jnde muscari-
nerg, daar cholinomimetica (carbachol, of acetylcholine met physostigmine) 
een atropine-antagoneerbare dosis-bepaalde verlenging van de reak t i e t i j d op 
een nociceptieve stimulus bewerkstelligden. Deze e f f e k t i v i t e i t kon niet ver-
klaard worden door een veranderde a k t i v i t e i t van de noradrenerge of seroto-
nerge descenderende banen, noch door een veranderde a k t i v i t e i t van het deel 
van het afferent c i r c u i t gevormd door het spinale endorfine subsysteem. De 
betrokkenheid van d i t cholinerge systeem b i j de effekten van opiaten kwam 
to t uitdrukking in de verminderde e f f e k t i v i t e i t van morfine na intrathecale 
toediening tesamen met atropine, en door de sterke potenti ering van de 
e f f e k t i v i t e i t van morfine door physostigmine. Deze opiaat-cholinerge in te r -
akties waren kwant i tat ief verschil lend voor morfine en nicomorfine. De 
e f f e k t i v i t e i t van intrathecaal toegediend nicomorfine werd bi jna vol ledig te -
n ie t gedaan door het aanwezige atropine, t e rw i j l physostigmine de e f f e k t i v i -
t e i t r e l a t i e f minder deed toenemen. Deze bevindingen, de observaties dat de 
chol i nomi me t i sehe effekten t . a . v . nociceptieve signaalgeleiding op spinaal 
niveau niet naloxone-antagoneerbaar waren gebleken, als ook de bevinding dat 
de e f f e k t i v i t e i t t . a . v . de twee antinociceptieve testen (de staart- terugtrek 
ref lex en de hete-plaat test ) verschilden b i j bepaalde dosering cholinomime-
t i c a en nicomorfine, gaven aanleiding t o t de hypothese als zou nicomorfine 
mogelijk eigen chol 1nomimet1 sehe effekten kunnen hebben. 
De kl in ische studie had t o t doel te evalueren of opiaten na intrathecale 
of epidurale toediening, en door een ef fekt teweeg te brengen in het spinale 
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systeem, een dusdanige verandering van de nociceptieve signaalgeleiding t o t 
stand brengen (zoals gedefinieerd in dierexperimenten, en k l in ische p i j n be-
handeling elders), dat een adequate perioperatieve "analgesie" t o t stand kon 
worden gebracht. U i t de kl in ische resultaten bleek, dat na epidurale of 
intrathecal e toediening van opiaten een excellente blokkade van nocicepsis 
t o t stand kwam. Tijdens de operatie bleken de patiënten geen intraveneuse 
analgetica nodig te hebben, t e rw i j l het verloop van de v i t a l e parameters 
"s tab ie l " was. Door de aanwezigheid van somatognosie was l i ch te algemene 
anesthesie noodzakelijk. De patiënten waren postoperatief v r i j van p i j n "die 
zeer doet". Dat d i t ef fekt spinaal t o t stand kwam, was ondermeer gebleken 
u i t het segmentale karakter van de analgesie. Er werd echter geconstateerd 
dat niet alleen antinociceptieve effekten, maar eveneens andere effekten aan-
wezig waren. Deze werden gerubriseerd als zi jnde t o t stand gekomen op 
spinaal niveau (functionele overlapping), of als zi jnde het gevolg van pene-
t r a t i e naar supraspinale centra. Tot spinaal t o t stand gekomen effekten wer-
den gerekend: de stoornissen in urine passage, en (ten dele) de cardiovascu-
l a i r e veranderingen. Urine retent ie i s mogelijk secondair aan de cholinerge 
(parasympatische preganglionaire) beïnvloeding. De spinale cardiovasculaire 
effekten z i j n mogelijk gerelateerd aan beïnvloeding van de "sympathische 
tonus". Deze spinaal t o t stand gekomen effekten waren mi ld . Cardiovasculaire 
effekten ten gevolge van een verandering in het endorfine systeem kunnen ech-
te r zeer ernst ig z i j n . In de algemene in le id ing z i j n deze cardiovasculaire 
effekten verklaart door beïnvloeding van met name het hypothalame-hypofy-
salre systeem, welke gekoppeld l i j k t te z i j n aan de "toegangspoort" van 
cardiovasculaire stuursignalen. De sterke anti nociceptieve e f f e k t i v i t e i t en 
de geringe cardiovasculaire veranderingen duiden er op, dat alhoewel een 
overlapping van de funk t i one! e subsystemen op spinaal niveau aanwezig l i j k t 
te z i j n , endorphinomimetisehe modulatie van het ingangssignaal (op spinaal 
niveau de nociceptieve stimulus) meer consequenties heeft als modulatie van 
het uitgangssignaal (op spinaal niveau mogelijk de sympathische e f fe ren t ) . 
Geheel zonder betekenis is deze laatste waarschi jn l i jk echter n ie t , daar 
beschreven i s dat de mogelijkheid t o t cardiovasculaire compensatie M j 
houdingsverandering verminderd i s . 
Ook de "supraspinale" effekten dienen b i j de evaluatie van de bruikbaar-
heid van de methodiek van intrathecal e of epidural e opiaat toediening betrok-
ken te worden. Alhoewel deze effekten met nane na intrathecal e toediening 
aanwezig z i j n , waren deze b i j -e f fek ten n iet storend. Met name de desastreuze 
la te ademdepressie welke in de l i t e ra tuu r vermeld is na toediening van water-
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oplosbare analgetica, trad niet op. Hierbi j kan een rol spelen, dat 
cholinerge b i je f fekten van het nicomorfine op spinaal niveau een 
potent ier ing, maar t . a . v . de respi rat ie een antagonisme zul len veroorzaken. 
Mogelijk zal door gebruik te maken van een dergel i jke divergentie van 
spinale en supraspinale mechanismen, de beschreven methode kunnen worden 
ve r f i j nd en zal daarmee de ve i l ighe id ervan toenemen. 
Conclusie 
De spinaal gelocaliseerde endorfine receptoren z i j n met de conventionele 
technieken van epidurale of intrathecale toediening voldoend select ie f 
toegankelijk voor het bewerkstelligen van een endorfinomimeticum-geinduceerd 
e f fek t , hetwelk gepaard gaat met een excellente antinocicepsis. 
Dientengevolge z i j n deze methodieken toepasbaar in de anesthesiologie ten 
behoeve van het t o t stand brengen van peri operati eve "analgesie". 
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Sten i rigen 
1 . Morphine, whether epidural ly or in t ra thecal ly in jected, carr ies a pro-
h i b i t i v e high potential for serious s ide-ef fects, and as the la te i n -
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of v i t a l signs for the f i r s t 16 hours af ter such in jec t ions , i t s 
c l i n i c a l use by epidural or intrathecal route should be abandoned. 
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i s not tenable, because: endorphinomimetics i n s t i t u t e af ter i n t ra -
thecal or epidural in jec t ion an ef fect somatotopically l im i ted with 
cord dermatoma regions; i t denies the existence of a neuronal network 
at a spinal level which includes enkephalinergic transmission; and, i t 
f a i l s to take into account the available data on k inet ic behavior of 
the drug related to i t s e f fec t . 
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